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Abstract
Eight X-ray crystallographic studies of modified insulins are described, and,
where possible, the resulting models are compared with relevant native insulin struc-
tures or other modified insulin structures.
Three of the structures, namely B13 Clu-e Gln insulin, B9 Ser-e-His insulin a.nd
Zn2+ ---+Co2+ insulin, are isomorphous with 4Zn native insulin. The conformation of
all three, however, is determined as T3R3! (the first three residues of the B chains
in the R3 trimer extended instead of helical) rather than the T3R3 conformation as
described for the native structure. The metal binding of these three modified rhom-
bohedral insulins is different from that of the native structure, which has two axial
and three off-axial zinc sites with a total occupancy of 2.67. B13 Glu-s Gln insulin
lacks the axial zinc in the R3! trimer. B9 Set-s-His insulin contains additional zinc
sites, coordinated by the extra histidines in combination with B5 and BlO hist.idines.
Zn2+ ---+Co2+ insulin has two axial cobalt ions only, octahedrally coordinated in the
T3 trimer and tetrahedrally coordinated in the R3! trimer. It also contains two
phenol molecules in the phenol pocket which is usually seen to contain only one.
Another crystal form of B9 Ser---+His insulin, and the structure of
B8 Gly-+Ser/B13 Glu-+Gln/B30 Thr-amide insulin, are isomorphous with mono-
clinic native insulin. In B9 Ser-e-His insulin in this crystal form, like in the rhombo-
hedral form of the mutant, additional zinc sites are created with the extra histiclines.
The B9 Ser---+Asp/B27 Thr-e Glu insulin structure is isomorphous with or-
thorhombic native insulin. Although the B9 Ser -eAsp mutation is seen to produce
a very stable monomer in solution, the charge repulsion is overcome in the crystal,
resulting in dimers in the structure.
The A21 Asn-e Gly /B9 Ser---+Glu/B10 His-s Clu insulin structure is orthorhom-
bic and not isomorphous with any known insulin structure. The conformations of
the C-termini of the B chains in the asymmetric climer have changed to allow for
the different, denser, packing.
The structure of A4 Glu---+Gln/B25 Phe-e-Tyrj'des B30 single chain insulin is
presumably isomorphous with the structures of rat insulin II and insulin from the
snake Zaocys dhumnades dhumnades Cantor. Evidence is presented to support the
validity of the mutant structure, but the resolution of the data is insufficient to allow
detailed analysis.
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Chapter 1
Discovering insulin
1.1 Introduction
The disease Diabetes Mellitus was first described in an Egyptian papyrus, discovered
by Ebers in the tomb of Thebes in Egypt in 1862, which is said to have been written
between 3000 and 1500 BC. The first use of the term 'Diabetes Mellitus' is accredited
to Aretaeus of Cappadocia and Apolonius of Memphis in the second century AD.
'Diabetes' stems from the Greek word for 'pipe-like' because nutrients begin to pass
through the system rather than being utilised. 'Mellitus' is Latin for 'honey' or
'sweet', to distinguish the disease from 'Diabetes Insipidus', which is a pituitary
disorder in which large volumes of sugar-free urine are passed.
In the middle of the nineteenth century, evidence from autopsies started to
suggest a link between the pancreas and Diabetes Mellitus. Diabetics were some-
times seen to have pancreas damage, and patients with damaged pancreases almost
always had diabetes. In 1869 Langerhans discovered the existence of two systems
of cells in the pancreas: the acinar cells, secreting the pancreatic juice into the
digestive system, and islets floating between the acini, with some as yet unknown
function. In 1889 Minkowski and Von Mering depancreatised a dog, causing a state
of polyuria indistinguishable from diabetes. This was the first direct evidence of
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the link between diabetes and the pancreas. They also showed that it was not the
absence of the pancreatic juice that caused diabetes by studying the effect of ligating
the pancreatic ducts rather than removing the whole pancreas. In most cases this
caused minor digestive problems, but never diabetes.
The Frenchman Hedon proved in 1893 that a total pancreatectomy was nec-
essary to cause Diabetes Mellitus. He blocked the flow of pancreatic juice, removed
most of the pancreas, and grafted the small pancreatic remains just under the skin
of his test subjects, for easy removal at a later stage of the experiment. The blood
supply to this piece was left as normal as possible. At this stage no diabetes was
established. After removing the graft, Diabetes Mellitus could be diagnosed imme-
diately.
During the 1890s it was discovered that several diseases could be treated by
feeding patients extracts of thyroid. In analogy, it was tried extensively, probably
by more that 400 researchers worldwide (Bliss, 1982), to treat diabetic patients
by feeding them pancreatic extracts, without success. Mildly positive effects could
never be reproduced by others. Usually the toxic side-effects were far worse than
the positive effects, although sometimes the side-effects were seen as positive, e.g.
kidney failure could change the urine in such a way that diabetes was no longer
diagnosed.
In 1901 Opie showed a direct link between Diabetes Mellitus and damage to
the islets of Langerhans, generating a wide belief in an internal secretion in the islets,
responsible for the prevention of diabetes. In view of the failed pancreas therapy
experiments, scientists suggested that the exocrine pancreatic secretion might de-
stroy the active component of the internal secretion. Two distinct types of pancreas
seemed obvious choices for attempts to create pure internal secretion: that from
foetuses, in which islets develop before acinar cells, and that from certain types of
fish, which have anatomically distinct islet and acinar parts. There are no records
to prove the first was tried in the early years, the second was tried between 1902
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and 1904, but was not promising. Several scientists all over the world attempted to
isolate and purify substances from the pancreas that were supposed to cure Diabetes
Mellitus. Meanwhile, several diabetologists kept believing that a diet was the only
good way to treat diabetics.
1.2 Earliest treatment of Diabetes Mellitus
Until the 1910s opium was the only widely used medicine in the treatment of Dia-
betes Mellitus. However, this could only dull the patients' despair, but did nothing
to cure or treat. Further treatment consisted of more or less trendy diets. In the late
1850s Piorry advised the use of extra sugar, to compensate for the loss of sugar into
the urine. This 'eating a lot to compensate' was practised until the early 1900s. In
Paris under German siege, in 1870, Bouchardat noticed that rationing of food caused
the disappearance of glycosuria in diabetic patients, while exercise also seemed to
have a positive effect. The idea settled that maybe the body should be put under
as little metabolic strain as possible by limited eating.
At the time of the earliest tests of pancreatic extracts in the treatment of
Diabetes Mellitus, America had two leading diabetologists who did not believe in
pancreas therapy. They were Allen and Joslin. They both practised 'starvation
treatment' where the patients are undernourished for a certain amount of time.
They argued that apart from the carbohydrate metabolism the protein and fat
metabolisms in diabetic patients were also affected. By cutting down on food until
the patient's body was relieved of all metabolic strain, and then slowly building up
again until a reasonably healthy diet was achieved, many diabetics could live years
longer. Some patients, however, did not even tolerate the minimum amount of food
(the 'living diet '), and succumbed quickly.
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1.3 Towards reliable pancreas therapy
As early as the 1890s Paulesco, a Romanian scientist in Paris, developed an interest
in the internal secretion of the pancreas. He regained his interest in 1916, when
he did his first experiments with extracts in Bucharest. The First World War and
Austrian occupation prevented serious experiments until 1919, and he published
some successes with his 'pancreine' in 1920 and 1921.
In the early 1900s Zuelzer, in Berlin, developed a pancreatic extract he named
'acomatol' with which he managed to bring back a 50 year old patient from a coma
in 1906. This extract, produced for the Schering company, was probably very con-
taminated and produced many side-effects. It was tested in Minkowski's clinic in
1909, where it was concluded that the positive and negative effects were due to the
same component. This caused Zuelzer's funding to be withdrawn, and he stopped
publishing. He persisted with his experiments, however, and produced a new extract
for Hoffman-La Roche, for which he never published the extraction methods. With
hindsight, this extract was probably much better than the first, if the convulsions
that were reported were hypoglycaemic reactions (signs of a low blood-sugar level).
Many other researchers worked on the extraction of the internal secretion of the
pancreas, both in Great Britain and the United States of America. Some, like Dewitt
and Scott, used pancreatic duct-ligation to atrophy the acinar cells. This would
remove the juice that would, as they believed, have destroyed the internal secretion.
Others used alcohol (like Zuelzer) to remove the pancreatic juice. Among these
were Knowlton and Starling, and Murlin and Kramer. Most of their results were
irreproducible. Two Americans, Kleiner and Meltzer, did produce promising results
of a decline in blood-sugar in depancreatised dogs, caused by administering extract
of the dogs' own pancreases. Most of the control experiments were satisfactory. This
work stopped abruptly in 1919 because Kleiner left the laboratory (Bliss, 1982).
There were several meetings among those scientists to discuss the prospects of
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the research. Especially the intervention of a Scotsman, Macleod, who worked in
Ohio, and who had been in contact with the researchers in Britain and seen their
disappointing r~~ults, caused some of the above to stop their experiments.
On October 31, 1920, a fairly inexperienced general surgeon in London near
Toronto (Canada), Banting, read an article on pancreatic duct-blockage. This gave
him the idea of duct-ligation in order to isolate the internal secretion of the pancreas.
This, as seen above, had been tried before, but the article did not mention it and
Banting did not know. This is what he wrote in his note-book (Bliss, 1982):
"Diabetus
Ligate pancreatic ducts of dog. Keep dogs alive till acini degener-
ate leaving Islets.
Try to isolate the internal secretion of these to relieve glycosurea"
On November 8 he managed to arrange a meeting with Macleod, who worked
in Toronto at that time. Although Macleod had discouraged several scientists in the
field of pancreatic extracts, Banting's enthusiasm caused him to offer a laboratory
and some animals over the next summer holiday period, and the help of a student,
Best, as research assistant. In March 1921 Banting decided to take Macleod up
on his offer, after which the first dogs were depancreatised on May 17. Macleod
had advised to use Hedorr's method of pancreatectomy leaving a small piece grafted
under the skin to be removed later.
The first pancreatic extract was prepared and tested on July 30, with tempo-
rary success. The dog died a day later. The pancreas used had been removed seven
weeks previously and left to degenerate. Another dog, brought back from a coma,
also died within a day. In order to speed up, a full pancreatectomy was tried sue-
cessfullyon August 3, after which Hedorr's procedure was not used again. Banting
and Best named their preparation 'Isletin' in notes on the experiments on the dog
that had the first total pancreatectomy.
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Testing urine was sometimes difficult, because the volume of it decreased after
injections of extract; in some cases urination ceased altogether. But during the
second decade of the twentieth century methods of blood-sugar testing had been
developed and improved, which were much more accurate than urine sampling.
These tests made diabetes research more efficient and reliable.
Another time-saving idea was tried on August 17: extract of fresh, non-
degenerated pancreas. Banting and Best failed to recognise the positive results
and persisted with their faulty hypothesis that degeneration of the pancreas was
necessary to obtain pure internal secretion. Boiling extract rendered it inactive,
exhausting the pancreas' external secretion with secretin was too effective. Extracts
prepared with secretin lowered blood-sugar quickly but caused profound shock. More
and more control experiments were carried out, e.g. in vitro sugar-burning capac-
ity and checking the activity of mixtures with trypsin. Macleod recognised it was
this thorough testing that needed to be extended in order to make it impossible for
critics and pessimists to deny the positive effects. The experiments would involve
pre-injection blood tests, more frequent blood sampling after injection so as not to
miss the effect, and establishing that it was a real blood-sugar lowering effect rather
than dilution phenomena caused by the injections of reasonably large amounts of
extracts.
In the first half of September 1921 different ways of injecting were tested.
Rectal injections had no effect, while subsequent intravenous injection did prove
effective. On September 17 injections were given subcutaneously for the first time,
but the results were not satisfactory, and Banting and Best decided it was not worth
trying again until they had trypsin-free extracts. By the end of September two more
respected Toronto doctors/scientists, Starr and Henderson, had become involved in
attempts to keep the promising research going by providing lab space and money.
Some time between October and December 1921 Best read a publication by
Paulesco from July 1921. The blood-sugar data quoted by Paulesco were so different
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from the generally accepted values for hyperglycaemia (probably due to different
techniques used by Paulesco), that Best was not impressed and chose to ignore the
information in the article.
In their first paper, describing work done up to November If), which was pub-
lished in February 1922 (Banting and Best, 1922), Banting and Best concluded
that, although they had" always observed a distinct improvement ill the clinical
condition of diabetic clogs after administration of extract of degenerated pancre-as".
it was still too early for clinical trials. By then, they had started a so-called longevity
experiment, keeping a pancreatectomised dog alive for as long as possible.
A visiting biochemist, Collip, became actively involved in designing better
experiments. Banting discovered information about foetal pancreases, from which
active extracts could be prepared without ligation or degeneration because of the
relatively low content of acinar tissue; this meant that extract could now easily be
produced in abundance from fresh, whole foetal pancreas. Time had come to try
to capture "the active principle". New bacterial filtering methods produced more
sterile extracts. Subcutaneous injections became possible, spreading action over
a longer period, thus preventing shock. A new blood-sugar test was introduced,
probably by Collip.
On November 23, Banting was injected subcutaneously with I 1/2 cc of Berke-
Ield filtered extract. The group had become impatient, wanted to get into clinical
testing. This extract did not seem to have any harmful effect, but blood-sugar was
not mea.sured.
One longevity experiment ended on December 2; the dog died after convulsions.
due to anaphylactic shock. In retrospect, it could have been hypoglycaemic shock,
since more extract seemed to make it worse. The next longevity experiment started
four days later, in which the extraction was performed with alcohol instead of aquo-
ous saline, which was easier to evaporate in order to concentrate the extract. This
lead to the idea that the active principle could be extracted from adult pancreases
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with alcohol too. Adult pancreases were available more cheaply than foct.al pall-
creas. Although Banting and Best had started using alcohol and ad ult pancreases
before Collip joined them, his experience and expertise were much needed assets in
the group. He started using rabbits, and discovered that even healthy animals had
a blood-sugar lowering response to extract. lie also found that the residue and not
the filtrate of a final filtering step contained the really powerful active principle. On
December 20, 1921, Joe Gilchrist received tested, potent extract by mouth. with
no benefit after a day. At that time it still was not firmly cst.ablishr-d that only
injections would work.
Apart from testing urine and blood for sugar, Collip started testing t.hr: urine
for ketones and measuring the liver's glycogen, which show whether live-r func-tiou
could be restored with the extracts. He also discovered hypoglycaemic shork. il st atc'
of apparent toxic reaction which could be relieved by administering glucose solution.
Because Collip was a much more self-sufficient, experienced and thorough re-
searcher, his results were much better received than those produced by Banting awl
Best. Also, more and more people became involved in the experiments. This mad«
Banting feel he had been overtaken, and that his idea had been taken out of his
hands. Relationships within the group deteriorated quickly, and C'VC'1! \)('('(1111(' vio-
lent at times. Because of this animosity, Banting and Best decidc'cI t.o have' il firs!
official clinical test on January 11, 1922, on Leonard Thompson. TII(' timing was
wrong. It was still too early, and the extract did not perform as well as expected.
Meanwhile, Collip discovered the active principle could be purified to a. c('rtain
extent by gradually precipitating other protein with increasing amounts of alcohol.
Only at around 90% alcohol the active principle would precipitate leaving it (>tlrc'
enough not to cause abscesses at injection sites. His extract underwent Cl firxt, cl iJlica.!
test on January 23, also on Leonard Thompson. Two days later tilt' grollp sigJlc'd
an agreement to work together as a group again rather than trying to compete with
each other.
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During February more clinical tests were carried out, all with favourable re-
sults. At the same time, Paulesco started clinical trials, independently and with-
out knowledge of the work in Toronto. In April, the Latin-rooted name 'insulin'
was proposed. The name 'insuline' had been suggested for the hypothetical inter-
nal pancreatic secretion twice before, in 1909 (de Meyer, 1909) and again in 191G
(Sharpey-Schafer, 1916), by two independent scientists, and unknown to the Toronto
group.
On May 3, 1922, the discovery of insulin was officially announced to the medical
world by Macleod.
1.4 The insulin molecule
After the actual isolation of insulin in 1922, it took another six years for Winter-
steiner to establish that insulin is a protein (Wintersteiner el al., 1928). And it was
not until 1955 that the primary structure of insulin was elucidated by Sanger anrl
co-workers. An account of this process can be found in the transcription of Sanger's
Nobel Prize lecture (Sanger, 1959).
1.4.1 Finding the primary structure
Based on the knowledge of protein chemistry in general and the composition of in-
sulin in particular, by 1943 Sanger started investigating the sequence of amino acids
of insulin. Chibnall and his colleagues (Chibnall, 1942) had shown a high content
of free a-amino groups, i.e. a relatively high number of N-terminal residues, one of
which had been determined by Jensen and Evans (1935) to be phenylalanine. (in-
til 19.52 Sanger believed the molecular weight of insulin to be 12,000. In that ycar,
Harfcnist and Craig showed it to be around 6,000, using the method of partial substi-
tution by 1-fluoro-2,4-dinitrobenzene (FDNB), separation of the reaction products
and colorimetric analysis of the monosubstituted derivative for the dinitrophcnyl
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group.
For further study of the N-termini, Sanger developed tho ])\,P-ITlf'thoc!
(Sanger, 1945), which was later also used for many other proteins. 'lhc result was
the discovery of two phenylalanine and two glycine termini, along with 1l011-t c-rminal
E-DNP-Iysine. The assumed four polypeptide chains were thought. to 1)(' linked by
disulfide bridges due to the relati ve abundance of cystei nes (d u Vignr-aud (I al., 1!):l9 ).
By oxidation with performic acid (Sanger, 1949a)' the crosslinks wore lirokr-n , re-
suIting in two fractions, A and B. Fortuitously, the two types of amino ilCids thed
could have confounded this experiment by reacting with pcrforrnic acid, IlW! Irion-
ine and tryptophan, are not present in insulin. Fraction 1\ contained t.hr- sm alk-r
number (around 20) of residues, only 12 unique ones, of which 11(1)(' wcrr: hasir.
Four of them were cysteine. Fraction B had 30 residues, two of which we're' cystcin«.
It seemed there was only one type of glycine chain and 011(' type' of phouylalaninc-
chain, which was confirmed in 1949 (Sanger, 1919b). Mild acid hydrolysis of t.ln-
DNP-derivatives of the fractions made it possible to study the N-tcrtllillal S('<lII('I)(,(,S.
resulting in Phe-Val-Asp-Glu (fraction B) and Gly-I1e-Val-Glu-Glu (frart.ion A).
This meant there were only two types of chain, and not. four difr('J"{'nt OI)(,S,
so the 12,000 molecular weight insulin was built up of two identical halves. Or, al-
ternatively, the actual molecular weight was 6,000. During 19.10 Satl,!!;C'1" and 'I'uPPY
managed to sequence the whole of fraction B (Sanger and TlIPPY, I !):) Iii). Sep-
aration of the complex partial hydrolyzate by various means resulted ill simpler
mixtures of which direct analysis was possible. They ended up with Cl plIzzlc' of
about 45 peptides of varying lengths from which .5 sequences could 1)(' dr-durr-d:
Phe-Val-Asp-Glu-His-Leu-CyS03H-Gly (N-terminal sequence] (1)
Gly-Glu-Arg-Gly (2)
Thr-Pro-Lys-Ala (:q
Tyr-Leu- Val-CyS03H-GIy (1)
Ser-His-Leu- Val-GIu-Ala (!))
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Four amino acids were still missing, and it was impossible to establish how
the sequences would be joined together. The use of proteolytic enzymes (pepsin,
trypsin and chymotrypsin) (Sanger and Tuppy, 1951b) as hydrolytic agents instead
of acid, solved this problem by producing different peptides, which also included the
missing residues. Determination of the sequence of fraction A was completed by 1953
(Sanger and Thompson, 1953). This was more difficult because of the specific amino
acid content and the lower susceptibility to enzymatic hydrolysis. Ionophoresis at
around pH 3 was needed to separate the problematic cysteic acid peptides.
By that time, it was firmly established that the molecular weight of insulin
was, in fact, 6,000. So the only remaining question, that of the number and nature
of the disulfide bridges, was reduced to finding two between chains A and B, and one
intrachain bridge in chain A. In order to do this, unoxidised insulin was subjected to
hydrolysis to isolate peptides with intact cystines. Acid hydrolysis was not suitable
because of disulfide rearrangement reactions, but enzymatic, neutral and alkaline
hydrolysis all proved useful. Thus the complete sequence of insulin was deduced
(see figure 1.1).
Ala.Lys.Pro. Thr. Tyr .Phe.Phe.Gly .
Arg
NHlNHl Glu
I I .
Phe.Val.Asp.Glu.His.Leu.Cys.Gly.Ser.His.Leu.Val.Glu.AIa.Leu.Tyr.Leu.Val.Cys.Gly
I \
S S
I \
NHl S NH2 NHl S NH2
I I I I \ I
Gly.lle.Val.Glu.Glu.Cys.Cys.Ala.Ser.VaI.Cys.Ser.Leu.Tyr.Glu.Leu.Glu.Asp.Tyr.Cys.Asp
Ls-s_j
Figure 1.1: Sequence of insulin. Sanger used bovine insulin in his
studies. Note the specific way of depicting amides. During strong acid
hydrolysis the amide groups of some glutamines and asparagines are
also hydrolysed. The real identity of these residues could be more ap-
propriately determined by enzymatic hydrolysis (Sanger et al., 1955).
Human insulin differs from bovine insulin at positions A8, AlO and B30, where
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it has threonine, isoleucine and threonine, respectively. The molecular weight of
human insulin is 5,808 (Hansen and Brange, 1987). The net charge of insulin is
zero at pH 5.5, in good agreement with the isoelectric pH of 5.3-5.35 as originally
determined by Wintersteiner and Abramson in 1933.
1.4.2 The three-dimensional structure of insulin
Insulin had been crystallised for the first time by Abel (1926). Over the years,
the crystallisation method for these rhombohedral crystals was standardised. The
discovery of Scott (1934) of the need for zinc in the crystals, was a big step forward
in this. In 1935 Crowfoot received a first sample of finely crystalline insulin. She
recrystallised the material according to Scott's method and took the first X-ray
photographs, which were published in the same year (Crowfoot, 1935). They were
not the first X-ray photographs of protein crystals ever, for pepsin had been used
before (Bernal and Crowfoot, 1934). The first crystallisations were approached as
an organic chemist would, so the crystals were dried with alcohol. Soon, however, the
positive influence of mother liquor was an established fact, and X-ray measurements
of wet insulin crystals were published (Crowfoot and Riley, 1939).
The interpretation of the X-ray patterns had started with the use of Patterson's
ideas on the determination of the components of interatomic distances in crystals
(Patterson, 1935). With the simplifications introduced by calculating Harker sec-
tions only (Harker, 1936), the maps showed, in the case of insulin, strong features
at 10 and 22 A interatomic distances. When the first amino acid crystal struc-
ture, glycine, was solved in 1939 through the application of the Patterson synthe-
sis (Albrecht and Corey, 1939), solving protein structures with the same methods
still seemed "madness", according to Patterson himself, as mentioned by Crowfoot
Hodgkin in 1968 (Hodgkin and Riley, 1968). The idea of replacing zinc isornor-
phously with heavier ions had taken root almost as soon as the first photos had
been taken. However, the intensity changes introduced by cadmium were too small
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to be of any help. Iodination experiments were not followed through, probably
partly because of the war, and because of the lack of experience with protein struc-
ture analysis in general. Until around 1950 most of the interpretation consisted in
building models, almost by guessing and then checking whether they could produce
the diffraction patterns observed. All the proposed models exhibited the correct
symmetry, namely 32 (Hodgkin and Riley, 1968), but nobody recognised the pos-
sibility of calculating the correct size of the insulin molecule and the contents of the
asymmetric unit then. The idea of utilising multiple crystal forms in structure de-
termination was described by Crowfoot in 1938. Unfortunately, the many different
shapes of crystals observed all turned out to be the same crystal form.
It was not until the primary structure of insulin became available m 1955
(Sanger et al., 1955) that Hodgkin's group in Oxford started devoting most of their
time to the problem of solving the three-dimensional structure of insulin.
Schlichtkrull's methods of crystallisation (Schlichtkrull, 1958) and his investiga-
tions into the exact amount of zinc in those crystals, along with earlier experiments
with cadmium insulin crystallisation according to Scott, paved the way for the pro-
duction of lead insulin. It proved possible to remove zinc by soaking in EDTA and
then replace the zinc with lead. X-ray measurements were taken of the isomorphous
series of zinc-free, zinc, cadmium and lead insulin (Hodgkin and Riley, 1968). Es-
pecially the differences between metal-free insulin and lead insulin were large, but
the feasibility of solving the structure with those alone, was still in doubt at that
time.
However, it was not long at all until enough isomorphous heavy atom deriva-
tives were found to solve the structure to a resolution of 2.S.A. Five derivatives were
used for the phase determination:
• zinc-free insulin acetate, 0.01 M lead
• zinc insulin acetate, 0.1 M lead
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• zinc insulin citrate, 0.02 M uranyl fluoride
• zinc insulin acetate, 0.01 M uranyl acetate
• zinc insulin citrate, mercuribenzaldehyde, saturated solution
Anomalous dispersion measurements were also taken. So late on Sunday night,
August 3, 1969, insulin was solved (for a facsimile of the original note announcing
the solution of the insulin structure, see Dodson, Glusker and Sayre (1981)), and
the structure of rhombohedral 2-zinc insulin to a resolution of 2.8;\ was published
on November 1, 1969 (Adams et al., 1969). The peptide chain, the disulfides and
the aromatic residues were well defined. A few regions, especially on the outside of
the molecule, were not completely clear.
After the determination of the primary structure of insulin by Sanger et al. in
1955, several groups in China started the chemical synthesis of insulin in 1958. They
succeeded in 1965 (Kung et al., 1965), after which some pressure was applied to de-
termine the three-dimensional structure. The Cultural Revolution delayed the start
until the beginning of 1967 (Tang, 1981). The structure of insulin to 2.5;\ resolu-
tion was published in 1971 (Peking Insulin Structure Group, 1971). In 1972, when
the Oxford group had extended their calculations to include data to 1.9A resolution,
Hodgkin visited China and it was decided the two groups would carry out further re-
finement separately and simultaneously. This resulted in publications by the Beijing
group of the structure at 1.8;\ resolution (Peking Insulin Structure Group, 1974)
and at 1.2A (Chang et al., 1986), and at 1.5A resolution by the Oxford group
(Baker et al., 1988). Meanwhile, both groups started studying different insulin
species, for example insulin shortened at the B chain C-terminus
(Peking Insulin Structure Group, 1976), 4-zinc insulin (Bentley et al., 1976), in-
sulin crystallised in cubic form (Dodson et al., 1978) and insulin from hagfish
(Cutfield et al., 1979).
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1.4.3 Biosynthesis of insulin
The biosynthesis of insulin starts in the nucleus of the B-cells of the pancreas. Most
species have only a single insulin gene (Bell et al., 1980). The DNA contains two
intervening sequences, one in the 5' part of the mRNA that remains untranslated,
and one almost in the middle of the sequence for the C-peptide region of proinsulin,
179 and 786 base pairs respectively. After transcription the mRNA ends up in the
cytoplasm of the cell. It is thought (Steiner, 1983) that translation of the mRNA
into the 110 amino acid preproinsulin (species: rat) starts while the ribosome is free
in the cytosol. The signal sequence of the preproinsulin anchors the ribosome to
the membrane of the rough endoplasmic reticulum (RER), after which the protein
is translocated into the ER lumen. The 59 "extra" amino acids in the preproinsulin
appear to contain all the information for accurate processing and secretion of the
mature hormone. The prepeptide has many hydrophobic side chains and is exactly
long enough to span the RER membrane so that the prohormone can start folding as
soon as its N-terminus enters the ER lumen. There is evidence that this anchoring
function of the prepcptidc enhances the efficiency of protein folding. However, the
prepeptide will be cleaved off by signal peptidase on the inner surface of the mem-
brane before the whole of the peptide chain has entered the lumen. This is necessary
for the correct bridging of the last two cysteines, one of which is the last-but-one in
the nascent chain.
The length and not the amino acid content of the connecting peptide in proin-
sulin (26-35 residues of greatly varying sequence for all known species) appears its
most important feature. Its function in folding and disulfide formation, i. e. main-
taining the correct spatial separation of B30 and AI, could just as easily be exerted
by a much shorter peptide. The reason for its excessive length may be that the
prohormone chain needs to span the distance from the interface between the small
and large ribosomal subunits (where translation takes place) to the inside of the ER,
which is longer than 51 amino acids plus the necessary distance between B30 and
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Al in the mature hormone (Steiner, 1983). This is an example of the 'minimum
length hypothesis' (Steiner, 1981). After folding and disulfide bridging, proinsulin
is transferred to the Golgi apparatus. There the proteolysis of the prohormone starts
and the mature hormone is concentrated, sorted and packed into secretory granules,
ready for extracellular release.
1.4.4 Insulin function
The actions of insulin have been known for quite some time (Steiner, 1977):
• membrane transport of glucose, amino acids and certain ions;
• increased storage of glycogen;
• formation of triglycerides;
• stimulation of DNA, RNA and protein synthesis.
Three other peptide hormones are produced in the islets of Langerhans in the
pancreas:
1. glucagon, consisting of 29 amino acids, in the A cells;
2. somatostatin, a cyclic 14 amino acid polypeptide, in the D cells;
3. pancreatic polypeptide, 36 amino acids with an amide C terminus, in the pp
cells.
Glucagon antagonises most of insulin's actions, while stimulating insulin secretion.
Somatostatin inhibits the three other islet hormones and a range of hormones from
different origins. Pancreatic polypeptide inhibits pancreatic secretion altogether
(Johnston et al., 1988).
Once in the blood, insulin controls glucose homeostasis by stimulating the
uptake of glucose into skeletal muscle and, to a lesser extent, into liver and adi-
pose tissue. In muscle and adipocytes this uptake is mediated by the so-called
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insulin-sensitive glucose transporter GLUT -4, a process that is not yet understood.
Other processes in the regulation of glucose homeostasis are: alterations in glyco-
gen metabolism in muscle and liver and decreased gluconeogenesis in the liver.
The enzymes involved in the insulin-regulated processes of glucose metabolism ap-
pear to be regulated by (de )phosphorylation of serine and/or threonine residues
(Lee and Pilch, 1994).
All known actions of insulin are initiated at the plasma membrane by insulin
receptors responding to ligand binding. A schematic view of the insulin receptor
can be seen in figure 1.2.
<;
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Figure 1.2: Schematic view of the insulin receptor. Reproduced from
Lee and Pilch (1994)
The a-subunit of 723 amino acids contains the site or sites for insulin binding.
The 620 amino acid ,a-subunit is built up of three regions: the extracellular, trans-
membrane and cytosolic domains. Both subunits are glycosylated, resulting in ap-
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proximate molecular masses of 130 kDa and 95kDa respectively
(Lee and Pilch, 1994). The insulin holoreceptor is composed of two a-subunits and
two ,B-subunits covalently linked by disulfide bridges to form a functional dimeric
protein complex. The receptor gene is translated into a single aiJ-product of which
two are linked together via disulfide bridges before being processed into separate
0'- and ,B-subunits. The covalent linkage of the two aiJ-heterodirners is unusual
among the receptor/tyrosine kinase family of which the insulin receptor is a mem-
ber. The insulin holoreceptor can, however, under mild conditions be reduced to
a,B-heterodimers which are functional monomeric receptor species with a lower lig-
and binding affinity than the holoreceptor. The exact position of the disulfide bridges
both between 0'- and ,B-subunits and between a,B-heterodimers are not, known; dif-
ferent studies are contradictory (Lee and Pilch, 1994).
Ligand-receptor contact occurs within the a-subunit. The exact regions of
contact remain incompletely defined despite a lot of research effort. Various trun-
cated versions ofthe receptor have been studied for insulin binding and it seems that
only those with an intact a-subunit are capable of binding the ligand, leading to
the conclusion that the entire a-subunit is important in some way for insulin bind-
ing. At physiologically relevant hormone levels there seems to be a stoichiometry of
one insulin molecule per holoreceptor, with negative cooperativity for binding of a
second ligand (Lee and Pilch, 1994). Thus insulin somehow breaks the symmetry
of the receptor upon binding. Lee and Pilch propose a model for insulin binding
to the receptor (see figure 1.3a) where at physiological concentrations insulin makes
contact with two partial binding sites on separate halves of the receptor, resulting
in high-affinity binding. It can be seen from the model that at high concentrations a
second insulin molecule could potentially make contact with only one of the partial
binding sites, resulting in low-affinity binding (figure 1.3b).
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b)
Figure 1.3: Schematic view of insulin binding as proposed by Lee and
Pilch.
a) One insulin molecule per holoreceptor at physiological concentra-
tions;
b) A second insulin molecule may bind, less strongly, at high concen-
trations.
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In essence, the model proposed by Lee and Pilch is the same as that proposed
by Schaffer (1994), with high-affinity binding of the first insulin molecule to two
different partial binding sites on the two a-subunits of the receptor, after which
low-affinity binding of a second molecule is possible to only one partial binding site.
Schaffer implicates specific insulin residues in the binding to both partial binding
sites. The dimer-forrning surface of insulin (mainly residues B24, B25, A21 and B12,
and potentially some residues which are buried beneath the B chain C-terminus),
named the 'classical binding site', is best re-named 'binding site 1', and binds to
receptor binding site 1. It appears that the opposite side of the insulin molecule,
known to be involved in hexamer formation, forms 'binding site 2'. The two most
important residues in this site are leucines A13 and B17.
Following binding of the ligand, the receptor is rapidly autophosphorylated
on some or all of seven tyrosine residues in the cytosolic domain of the .a-subunit.
Exactly how the signal for autophosphorylation is propagated from the site of lig-
and binding on the a-subunit to the intracellular autophosphorylation sites on the
,B-subunit is unclear. The most likely explanation seems a series of conformational
changes, first between the a-a-subunits, then the transmembrane domains of the
,B-subunits, followed by the ,B-,B-subunits, after which ATP-binding and autophos-
phorylation can take place (Lee and Pilch, 1994).
The insulin receptor family primarily regulates nutritional metabolic path-
ways, whereas all other receptor/tyrosine kinases mainly regulate cell growth and
differentiation. The same subdivision exists in that the insulin receptor family has
covalent links between the a,B- heterodimers, and again in that these receptors do
not form direct complexes with substrates and/or effector molecules after autophos-
phorylation. Instead, the insulin receptor, upon autophosphorylation of at least the
tri-tyrosine subdomain, acquires exogenous kinase activity, phosphorylating its prin-
cipal substrate: insulin receptor substrate 1 (IRS1). IRS1, in turn, binds effector
molecules which are responsible for the actual processes of glucose transport and
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metabolism.
1.5 Research into modern treatment of Diabetes
Mellitus with insulin
Since 1922, a lot of research bas gone into the improvement of insulin therapy, both
in terms of improved insulin preparations and case of usc.
Achieving purity was the first challenge. Abel discovered insulin could be crys-
tallised (Abel, 1926), which became standard procedure in insulin purification only
after Scott (19;14) established that zinc was needed in order to crystallise insu lin ill
rhombohedral form, a discovery inspired by his observation of zinc in the pancreas.
Another crystallisation step reduced allergic reactions (.Jorpes, 1949). Chromato-
graphic techniques started to playa role in the 1960s, leading to the first chromate-
graphically purified insulin, Monocornponent insulin (Schlichtkrull cl al., 1970).
The search for new insulin preparations with various desired properties was
approached in many different ways. At first it was thought the number of injections
needed every day could be reduced by using insulins with a retarded uptake from the
injection site, which could be achieved by introducing basic additives as in prol.a.rninc
and isophane insulin (Hagedorn et al., 1936, Krayenbiihl and Rosenberg, 1946). Ad-
dit.ion of compounds like surfen or globin to acid insulin solutions, which produce
heavily insoluble complexes upon neutralisation in tissue fluids, and complex for-
mation of zinc with neutral insulin suspensions, had the same effect. IIO\\'c\'C'r, tile
need for strict metabolic control in prevention of long-term complications called for
the reinstatement of multiple injections, along with the development of rapid-acting
insulins for the relief of the glucose-surge just after meal times, and mixtures of
rapid-acting and intermediate-to-Iong-acting insulins. Developments in this field
include Rapitard and Act rapid (Schlichtkrull, 1959, Schlicht.krull cl al., 19(1).
The duration of action could also be influenced by the physical state and
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size of the insulin particles. Ultralente (Hallas-Moller, 1956) is an example of a
long-acting crystalline insulin preparation. Initially, only bovine insulin was used
for crystalline preparations, having a slightly longer action than porcine insulin in
crystalline form. Gradually, longer acting porcine preparations became available.
Then, in 1979, recombinant DNA techniques made it possible to produce human
insulin in Escherichia coli (Goeddel et al., 1979). Amazingly, this was clone with-
out knowledge of the nucleotide sequence of the human insulin gene. Crea cl al.
(1978) had chemically synthesised two separate genes for chain A and B (77 and
104 base pairs for 21 and 30 amino acids, respectively, plus start and stop coclons
and restriction site bases) following nucleotide sequences that had \)('('11 dcsigllcd
from the amino acid sequences. By designing the nucleotide S<'ql[('I1C('St.hr- Wily t.hoy
did, there was no need to produce every possible trinucleotide separately. They pro-
duced 29 oligonucleotides, made from carefully chosen di-, tri- and tdralllickotide
building blocks. Goeddel et al. (1979) describe the actual assembly of t.h« g('Il('S, t.hr-
subsequent construction of the plasmid, and the expression ami chara.ctcrisatioll of
the product. They show that the amino acid content of the product is indist.inguish-
able from that of porcine insulin. It took another year before the artual lIucleotide
sequence of the human insulin gene was published by Hell and co-workers (I !)~O).
Only 21 out of 51 of the codons used by Crea et al. turned out to \H' the SiUIl<'in
the correct DNA-sequence.
Production of human insulin could also be achieved by conversion of porrinr-
insulin (Markussen, 1982) or biosynthesis in Saccluirouujccs ctrc.nisia: rill ln-r t hall
E. coli (Markussen et al., 1986). Over the years, the production of many t.ln-rapc-u-
tic insulins has involved chemical alteration of the molecule. Nowadays, modified
insulins can be synthesised by mutation of the genes used ill V coli or ,";. ('( /'( I'/S/O(,
thus facilitating structural and functional studies. But apart. from t.hr-sci(·ltI.ific pos-
sibilities opened up by the availability of recombinant insulin, t.hr-rr-was it pressing
need for a new source of the protein, because the demand for insulin for therapy
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was outgrowing the supply of slaughter pancreases for the isolation of insulin. Even
now (Kott, 1996) the major insulin manufacturers are not able to provide insulin
for every area of the world, and cheaper beef and pork insulin is still produced,
especially for third world countries.
Because of the varying needs of diabetic patients, insulin has to be available
in multidose quantities. This requires the addition of antimicrobial preservatives.
Banting and Best used tricresol to that effect, and to this day phenol and deriva-
tives like m-cresol and methylparaben are used throughout the range of therapeutic
agents. Other additives include sodium chloride or glycerol as isotonic agents, and
certain buffers (Brange, 1987).
Alongside research into better and purer preparations, came the develop-
ment of techniques of administering them. At the time of Banting and Best it
was already established that oral therapy did not have any desired effect, and
that subcutaneous or intravenous injections were the only option. Many other
routes of absorption were tested, including rectal administration and absorption
by mucosae. Success was limited. Even with more modern technology of aerosol
powder (Wigley et al., 1971), surfactants (Hirai et al., 1981), liposome-enclosure
(Dapergolas and Gregoriadis, 1976) or polymer-crosslinking (Saffran et al., 1986)
the desired efficiency and bioreactivity has not been achieved. The subcutaneous im-
plantationofvinyl-ethylenecopolymerpellets (Creque et al., 1980, Brown et al., 1986)
or biodegradable insulin-albumin microbeads (Goosen et al., 1983), releasing in-
sulin slowly and constantly over a longer period of time, seems more promising.
Most recently, reports have appeared on glucose-responsive insulin release from
certain polymeric systems (Shiino et al., 1995, Valuev, 1995). However, the only
techniques in actual clinical use are based on injections. Hospitals operate systems
of continuous infusion, either according to continuously measured glucose concen-
trations (Albisser et al., 1974, Pfeiffer et al., 1974) or a pre-programmed schedule
(Slama et al., 1974). These insulin pumps are not yet available to the general public,
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although additional research is done on implantable pumps (Buchwald et al., 1981).
Today's most patient-friendly portable insulin delivery is the NovoPen, which has
reduced injections to just pressing a button. Most diabetics seem to prefer this to
other available options (Jefferson et al., 1985, Walters et al., 1985).
1.6 Classification of Diabetes Mellitus
In 1979, the National Diabetes Data Group formally classified Diabetes Mellitus
and other categories of glucose intolerance as follows:
• Type I, insulin-dependent Diabetes Mellitus. Since this type usually occurs
in juveniles, it was previously called juvenile diabetes. It can, however, start
at any age. Patients usually present with easily recognisable symptoms, so
diagnosis is not difficult. Genetic determinants seem important for the onset
in most patients, with environmental factors a close second. Abnormal immune
responses (e.g. in normal childhood diseases like mumps) and autoimmunity
(see Bottazzo, 1993) are also thought to play an aetiologic role .
• Type II, noninsulin-dependent Diabetes Mellitus. This type can become recog-
nisable at any age, although it can be asymptomatic for years and thus usually
presents in patients over 40 years of age. Often only the complications seen
after years of having diabetes, like neuropathy and cataracts, cause a diagnosis
to be made. Occasionally people are diagnosed as a direct result of population
studies, e.g. Mooy et al., 1995 and Beks et al., 1995, a study in Boom, The
Netherlands. This research into the prevalence of NIDDM and predictors for
the development of the disease resulted in 106 newly diagnosed diabetics out
of 2,484 participants between age 50 and 74. Not only age is an important
factor in NIDDM. The genetic basis of NIDDM seems even stronger than that
of IDDM, and it is aggravated by environmental factors. Moreover, 60 to 90%
of all NIDDM patients in the Western world are obese, which should be seen
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as an indicator for subclassification of the type II diabetic. Symptoms are
usually (at least partly) alleviated by weight loss .
• Other types of diabetes. Diabetes forms part of certain other conditions and
syndromes, whether obviously aetiologically related or not. This class can be
subdivided according to known or suspected aetiological relationships, where
diabetes may be secondary to
1. Pancreatic disease (neonatal or later on in life);
2. Hormonal abnormalities which may have either hypoinsulinaemia or hy-
perinsulinaemia as a consequence;
3. The administration of certain hormones, drugs and chemical agents, of
which oral contraceptives, tricyclic antidepressants and marijuana are but
a few;
4. Insulin receptor abnormalities, either in the number of receptors or their
affinity for insulin, or even because of the presence of antibodies to re-
ceptors (with or without associated immune disorders);
5. Certain genetic syndromes, e.g. metabolism disorders, insulin resistance,
hereditary muscle disorders and cytogenic disorders like Down's syn-
drome;
6. Other types, of which diabetes associated with malnourished populations
is the most prominent example .
• Gestational Diabetes Mellitus. There are two ways in which Diabetes Mel-
litus and pregnancy can occur simultaneously. One is where a previously
diagnosed diabetic woman becomes pregnant, which involves certain risks for
both mother and child. The other is in Gestational Diabetes, when a preg-
nant women becomes diabetic at some stage during pregnancy, because of the
pregnancy and most commonly only for the duration of the pregnancy. It is
easy to see the origin of problems in both cases, if one considers the fact that
even in a normal pregnancy the third trimester is a permanent state of mild
hypoglycaemia because all organs have to work harder than normal, some up
to 50%. Sometimes the pancreas functions sub-optimally. This means that
the pregnant woman does not produce enough insulin herself, and the foetus
will start to produce insulin to attain an acceptable maternal insulin level.
This means the production of more foetal urine into the amniotic fluid. At
the same time the level of growth hormone in the foetus rises along with the
foetal insulin level (Remmers,1994). This causes macrosomia (birthweight >
4,000 grams), which may cause problems at birth. A Glucose Tolerance Test
usually points out the need for diet or insulin therapy. Oral hypoglycaemic
treatment can not be used by a pregnant diabetic (Drury, 1988). Even after
insulin treatment for GDM, most pregnant women return to normal glucose
tolerance after delivery. If this is not the case, they have acquired clinical dia-
betes. From the previously gestational diabetics, 40% acquire overt Diabetes
Mellitus within 20 years (Coustan, 1993) so they should be kept under some
sort of observation .
• Impaired Glucose Tolerance. For the diagnosis of IGT an oral glucose toler-
ance test is essential. The criteria for this classification lie between those for
normal subjects and diabetics. Consequently, the seriousness of the disorder
is intermediate between normal and diabetic, with some clinical complications
being completely absent while others, especially cardiovascular abnormalities,
commonly present. Thus, IGT may have prognostic implications that should
not be overlooked, especially in seemingly healthy individuals. Like overt di-
abetes, IGT can be linked to numerous disorders and obesity. Patients with
IGT do not necessarily proceed to develop clinical diabetes; many return to
normal glucose tolerance for no apparent reason while others stay in the IGT
class for many years.
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Apart from the clinical classes mentioned above, there are two so-called sta-
tistical risk classes (NDDG, 1979):
1. Previous Abnormality of Glucose Tolerance. This class is restricted to those
persons who have normal glucose tolerance but have previously demonstrated
diabetic hyperglycaemia or IGT either spontaneously or in response to an
identifiable stimulus. Re-classification of gestational diabetics, former obese
diabetics who have normal glucose tolerance after weight loss, and temporarily
hyperglycaemic patients (due to trauma or injury) into this class is a useful
tool for facilitation of follow-up of such patients. The likelihood of such persons
developing clinical diabetes (again) should be considered to be increased.
2. Potential Abnormality of Glucose Tolerance. Persons who have never exhibited
abnormal glucose tolerance but who are at substantially increased risk for
the development of diabetes should be classified as PotAGT. Certain risks
for development of IDDM and NIDDM are well established, such as being a
relative of an IDDM or NIDDM diabetic or belonging to certain ethnic or
racial groups, although the degree of risk for any of the specific circumstances
is much less clear.
1.7 Studying the three-dimensional structure of
insulin
As described above, human insulin consists of 51 amino acids, divided into two
chains, commonly labelled A and B, with 21 and 30 amino acids respectively. The
chains are linked by three disulfide bridges, two forming interchain cystines at A7-B7
and A20-B19, and one forming an intrachain cystine at A6-Al1. A piece of antipar-
allel ,B-sheet is formed upon dimerisation: residues B23 to B28 of one monomer lie
anti parallel to the same stretch in the other monomer. There are two very small
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a-helices in the A chain, and a three turn a-helix running from residues B9 to BIg
is found in every insulin structure known so far.
Although insulin is only a small protein hormone with a characteristic three-
dimensional structure, the sequence varieties in nature and the biological activities
of these different forms in vitro, are quite diverse. This diversity provides a tool
for research into more effective and efficient insulins for the treatment of Diabetes
Mellitus. Solving modified insulin structures will help understand the differences
in structure-function relations of all these insulins. It is also thought that under-
standing properties (e.g. conformational changes) in a small protein like insulin will
contribute to the understanding of proteins in general.
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Chapter 2
Protein crystallographic methods
2.1 Introduction to protein crystallography
A crystal is a solid with regular three-dimensional ordering. The regular repeat of the
unique unit (unit cell) in a crystal can be represented by a regular repeat of points,
the lattice, with the same geometry as the original unit cells. The symmetry of the
lattice should reflect the symmetry of the crystal. This means that the symmetry
most representative of the crystal does not always give rise to a primitive cell. A
primitive unit cell can be described by a single representative point, commonly
chosen to be the origin (0,0,0), from which the crystal can be built up by generating
points with unit translations along the unit cell edges. Non-primitive lattices would
have additional representative points translated 1/2 along appropriate cell edges.
The lattice, or lattice function l( r), can be seen as a three-dimensional array of
D-functions corresponding to the lattice points. The unit cell function u( r) describes
the detailed information of the structure of the molecule( s) in the unit cell. The
crystal structure function c( il) is the convolution of the lattice function with the
unit cell function (Sherwood, 1976):
c(il) = l( r)®u( r)
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(2.1 )
The unit cell contains one or more molecules built up of atoms. In a classical
description, the charged particles in the atoms, namely the protons and electrons, in-
teract with electromagnetic radiation like X-rays, producing the diffraction pattern
observed when a crystal is put in an X-ray beam. The particles start to oscillate,
becoming a source of radiation themselves, thus scattering the incoming wave. Be-
cause the intensity of scattered radiation is inversely proportional to the square
of the mass of the scattering particle, electrons scatter X-rays around one million
times more effectively than protons. It is therefore the electron cloud of atoms that
is responsible for the abovementioned diffraction pattern. The scattering from the
electron cloud is proportional to that of a free electron, assuming the electrons os-
cillate in phase. In other words, the scattering of a volume element dr at position
r is proportional to the electron density p(rj at r. The use of the term electron
"cloud" implies a finite size to the space the electrons around an atom may occupy.
The approximation of an atom by a point-atom, useful though it may be in other
cases, would in an X-ray experiment for a single atom give rise to equal scattering
in all directions due to lack of interference between wavelets scattered by different
volume elements dr. However, the real dimensions of the electron cloud are com-
parable to the wavelength of the X-rays used, resulting in interference which causes
scattering to fall off with increasing scattering angle O. It can be shown that thermal
motion, influencing the apparent size of the atom, causes the scattering to fall off
more rapidly with O. Atoms can be assumed to have spherical symmetry, so the
scattering from an individual atom is a function which depends merely on O. This
function is known as the 'atomic form factor' or 'atomic scattering factor' and has
been tabulated for all chemical elements (Wilson, 1992).
The diffraction pattern resulting from the scattering of X-rays by a distribu-
tion of electrons characterised by an electron density function p( rj is the Fourier
transform F(Llk)
(2.2)
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where Ie is the electronic scattering factor and tlk is the scattering vector, which
can be expressed as tlk = k: - k~. Here ~ is the wave vector of the incident beam
and k: the wave vector of the diffracted beam.
If the electron density p(i) is expressed as a function of fractional coordinates
x,y,z and only a unit cell is considered, for which [; can be seen as a constant that
can be taken up in F, one gets
F(tlk) = V lx==11Y==1 r: p(x, y, z)eib.k.(xc/+yb+zC}dxdydz (2.3)
x==o y=o Jz==o
In order to obtain a complete crystal, the unit cell is convoluted with the
crystal lattice. The amplitude of the unit cell diffraction pattern, as described by
equation 2.3, envelops the diffraction pattern of the crystal lattice, which is a series
of sharp peaks forming the reciprocal lattice. The effect of this envelopment is the
sampling of the unit cell diffraction function at points where the crystal lattice gives
rise to a diffraction maximum. The diffraction pattern intensities, representing the
reciprocal lattice weighted by the unit cell contents, can thus be described by means
of delta functions (Sherwood, 1976):
oo oo oo
IF(tlk)12 = [ L 8(tlk.5-2h7r)]2[ L 8(tlk.b-2k7rW[ L 8(tlk.c-217rW (2.4)
h==-= k==-= 1=-=
where 5, band c are unit cell edge vectors, and h, k and I are integers. This function
can only be non-zero at points where tlk . 5 = 2h7r, tlk . b = 2k7r and tlk . c= 217r,
known as the Laue equations. In other words, tlk is restricted to those values which
correspond to the crystal lattice diffraction maxima, so tlk is proportional to the
reciprocal lattice vector c.: as follows:
(2.5)
tlk forms an equilateral triangle with the abovementioned vectors ~ and k:
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(see equation 2.2), where the angle between the incident and diffracted beam vectors
is called the 'scattering angle' 2().
I~kl= 2ksin() (2.6)
where k is the magnitude of both the incident and the diffracted beam vectors; k
is also equal to 2; because of wave theory. The magnitude of the reciprocal lattice
vector c.: in equation 2.5 is inversely proportional to the spacing dhkl between
reciprocal lattice planes (hkl). Thus, following from equation 2.6, d:
kl
= t,,,in(), so
(2.7)
Equation 2.7 is known as Bragg's Law. The angle e is called the 'Bragg angle', and
is equal to half of the scattering angle. The wave vector triangle described above
can be used in a geometrical interpretation of Bragg's Law: the Ewald sphere (see
figure 2.1). The radius of the sphere is taken as k/27r = 1/A.
From this construction it can be seen that, when the crystal rotates around
C and its reciprocal lattice rotates around 0, diffraction maxima only occur when
wave vector flk is an exact chord of the Ewald sphere, i.e. when a reciprocal lattice
point passes through the Ewald sphere. This chord is the reciprocal lattice vector
Ghk1•
For Ghk1 - ha- + kb* + 12*the expression flk . r in equation 2.2 becomes
27r(hx + ky + lz). Equation 2.3 may now be rewritten as
(2.8)
which is known as the 'structure factor' of the diffraction maximum at reciprocal lat-
tice point hkl. Fhkl is a complex quantity and can be expressed as Fhkl=IFhktieiCl'hlcl.
The experimentally observable intensity is hkl=IFhkd2•
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Figure 2.1: The Ewald sphere construction.
I = point where incident beam crosses the Ewald sphere; C = posi-
tion of the crystal; 0 = exit point of direct beam, commonly chosen
as the origin of reciprocal space; P = exit point of diffracted beam;
ki = incident wave vector; kd = diffracted wave vector; fj_k = recipro-
cal lattice vector; ()= Bragg angle; 20 = scattering angle.
One of the more interesting properties of a diffraction experiment is that the
diffraction pattern is the Fourier transform of the electron density function, which
means that the electron density function p( x, y, z) can be expressed as
(2.9)
Because the diffraction pattern is not a continuous function of t6.k but a discrete set
of values represented by Fhkl for each maximum, this expression reduces to
p(x, y, z) = ~ L L L Fhkle-21ri(hx+ky+lz)
h k I
(2.10)
Assuming all Fhkl can be derived from the diffraction pattern, the electron
density can be calculated at every point x,y,z by adding up the contributions from
all the reflections hkl. The total density function p(x,y,z) can be computed from
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the local densities at every point x,y,Z. The computation of the electron density
from structure factors is called 'Fourier synthesis'.
Unfortunately, experimental data does not provide amplitudes F"kl, but inten-
sities hkl' where hkl=IFhkd2• For a Fourier synthesis, the complete information of
Fhkl, i.e. both IFhkll and the phase (}hkl, are needed. Thus part of the information
is lost, giving rise to what is called the Phase Problem.
2.2 Crystallisation
The crystallisation of proteins and protein-like substances has been a science for over
a century. Van Deen (1864) believed that all naturally occurring organic substances
can be crystallised when manipulated effectively. Schimper (1881) reported on the
first active crystallisation attempt by Maschke in 1859, who evaporated the solution
from a preparation of brazil nuts in order to obtain crystals.
Insulin exists in crystalline form in storage granules in the pancreas. Crys-
tallisation of insulin was pioneered by Abel in 1925, after which Scott established
the need for zinc for successful reproducible crystallisation (Scott, 1934). The
first insulin crystals used in X-ray work were grown according to his methods
(Crowfoot, 1935). Over the decades, the protocols for insulin crystallisation were
standardised and extended to produce different crystal forms. Schlichtkrull (1958)
had a major role in the standardisation of the crystallisation with zinc and other met-
als, ultimately leading to the successful crystallisation of suitable heavy atom deriva-
tives for the solution of the structure of native 2Zn insulin in 1969 (Adams et al., 1969).
It became clear that a minimum amount of 2 Zn atoms per rhombohedral cell (trigo-
nal setting) was needed, or 4 Zn atoms per cell in crystallisations with ~ 6% halide.
There is also a maximum amount of 6 Zn atoms per cell, beyond which no crystals
will form or crystallisation is very slow (Schlichtkrull, 1958, Brange, 1987).
Brange (1987) shows a very elegant graph of the crystallisation conditions
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Figure 2.2: The crystallisation behaviour of insulin. Reproduced from
Brange (1987)
for insulin in its various crystal forms (see figure 2.2). In general, crystallisations
of modified insulins are carried out with the purpose of the modification in mind.
Mutants which form supposedly more stable hexamers than native insulin, are crys-
tallised following the 2Zn or 4Zn protocols described in table 3.2 in chapter 3. For
even more stabilisation of the hexamer, phenol is added in some cases, according
to the monoclinic insulin crystallisation protocol. In order to study metal binding,
metal salts are added where appropriate, resulting in either aggregation to hexam-
ers (for which metal ions are necessary in general) or dimers (which can be formed
without metal ions, or may still be formed in their presence when the metal bind-
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ing site is removed). Organic solvents like ethanol and acetone are used in insulin
experiments for various reasons. Insulin is very soluble in acid solutions containing
ethanol, whereas most proteins are not. This property is still utilised in the extrac-
tion of insulin from pancreases. Furthermore, the addition of many organic solvents
miscible with water (such as ethanol and acetic acid) counteracts the association of
insulin molecules due to non-covalent interactions (Brange, 1987). Organic solvents
can also be used as precipitating agents in crystallisations because of their effect in
reducing the dielectric constant of the crystallisation mixture (Xiao, 1990). Some
organic solvents (e.g. 2-methyl-2,4-pentanediol, MPD) and organic polymers (e.g.
lower molecular weight PEG) present in crystallisations as precipitating agents are
directly suitable as cryoprotectants.
2.3 Data collection and processing
Equation 2.8 can be rewritten in a form more suitable for the calculation of structure
factors from the contents of the unit cell, and for the discussion of the symmetry
of a diffraction pattern (Sherwood, 1976). Introducing the atomic electron density
function pj{r-fj) for every atom i. based on a vector triangle r= fj + Rj defining
the position of an electron with respect to its atomic nucleus (Rj) and the position
of the atom in the unit cell (fj), equation 2.8 becomes
(2.11)
assuming the positions of the atomic nuclei are constant so that dRj is equal to
dxdydz. Reversing the integral and the sum, factoring the constant e21fiGhklorJ out of
the integral and changing the limits of the integral from unit cell to atom (re- building
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the integral with the summation over all j atoms), F hkl becomes
(2.12)
The aforementioned atomic scattering factor can now be reintroduced in math-
ematical form:
(2.13)
so that
F -" j. e27ri(hx)+ky) +Iz))hkl - L.J J
J
(2.14)
This expression is central to the determination of the crystal symmetry and
the symmetry of a diffraction pattern. An interesting property of equation 2.14
is that Fhkl and FJiH only differ in phase, in such a way that FliH is the complex
conjugate of Fhkl. Their magnitudes are equal:
(2.15)
which is known as Friedel's Law. Thus the observed intensities of reflections hkl
and hH are equal. This means that a weighted reciprocal lattice will always be
centrosymmetrical in nature. Equation 2.14 can also be used in the determination
of the presence of translational symmetry in the crystal. A simple example is repro-
duced from Sherwood (1976). In the case of a body-centred cubic lattice for metallic
caesium with only two independent sites, (0,0,0) and (1/2,1/2,1/2), the structure
factor only has two terms:
(2.16)
Since the atomic contents of the two sites are equivalent, fj is equal in both cases,
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so
(2.17)
Because h,k and 1 are integral numbers, Fhkl can only be 0, if h + k + I is odd, or
a finite value 2fJ, if h + k + 1 is even. Half of the diffraction maxima arc missing,
the so-called systematic absences. It can be shown that all translational symmetry
gives rise to specific systematic absences. The systematic absences corresponding to
lattice type unambiguously determine, given the crystal system, what is called the
Bravais lattice, of which there are 14.
The reciprocal lattice, and thus a diffraction pattern, does not explicitly have
translational symmetry. Therefore, the symmetry of a diffraction pattern must be
that of one of the 32 point-groups. Only eleven of those have the, by Friedel's Law,
required centrosymmetry, and are referred to as the Laue groups.
Buerger has calculated there are 122 different possible symmetry types for
diffraction experiments, the diffraction symbols, one of which must fully describe
the diffraction pattern. Fifty-eight of these diffraction symbols uniquely define a
space group, the others give rise to ambiguity. Many of the latter 64 contain mirror
planes and inversion centres, which makes them impossible for natural proteins. So
usually in protein crystallography the space group of a crystal is reasonably easily
determined from a diffraction pattern, with the help of data processing computer
programs.
The theory of data processing is mainly concerned with correcting for the as-
sumptions and approximations made above. What is actually measured in a diffrac-
tion experiment, is the total energy scattered by the crystal towards the diffraction
maximum hkl. Sherwood (1976) calls this quantity Ehk/:
(2.18)
The proportionality with the intensity of the incident beam 10 and the volume of the
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crystal V is intuitively obvious. A~kl and ehkl correct for absorption and extinction
effects. w is the angular velocity of the rotation of the crystal, which comes into
play when considering the amount of time needed for a reciprocal lattice point to
pass through the Ewald sphere. f{ represents a number of fundamental constants
involved with the physics of the experiment (e.g. the mass of an electron and the
wavelength of the radiation used). The polarisation factor Phkl is specific for the
type of incident beam used, with different values for e.g. randomly polarised and
monochromated beams. The geometry of the diffraction experiment and the position
of a diffraction maximum relative to 0 (see figure 2.1), have an effect on what is
recorded when the reciprocal lattice point passes through the Ewald sphere, which
is taken into account with the Lorentz factor:
1 W
Lhkl =--
). Vn
(2.19)
where V« is the component of velocity v normal to the Ewald sphere surface in the
direction of C. v is the linear velocity in the direction PI if the crystal is rotating
with angular velocity w around an axis through 0 perpendicular to the plane of the
paper (see figure 2.1). ). is the wavelength of the X-ray experiment.
The effect of thermal motion is taken up in (Fhkl)r, which has (fJ)T =
fJe-BJ(sin20/>.2) as atomic scattering factor rather than just fj, and thus falls off
more rapidly with e, as discussed in section 2.1. B, is the so-called temperature
factor.
In protein crystallography there is another major factor of influence in data col-
lection: protein crystals suffer radiation damage. Performing the diffraction experi-
ment at cryogenic temperatures will reduce this effect dramatically. Any remaining
damage needs to be corrected for during data processing.
Apart from the desired discrete diffraction due to the crystal, there is contin-
uous background scattering of X-rays due to scattering by the air and incoherent
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scattering of the crystal (a quantum mechanical effect). The final number assigned
to a diffraction maximum is obtained by integration, the total area of the spot,
rather than the absolute peak height. It depends on numerous parameters of the
specific diffraction experiment, and thus can not be determined on an absolute scale.
After integration, equivalent reflections are scaled and merged, and standard devia-
tions determined by estimation from the counting statistics, attempting to take into
account systematic errors of the diffraction experiment. Because of counting errors,
some of the resulting measured intensities will have a negative value, although a
true intensity can, of course, not be negative (French and Wilson, 1978). If left
negative, such measurements will pose problems upon taking the square root when
calculating the structure factor modulus. Simply omitting them will bias the re-
sulting structure, as will resetting them to zero without adjusting their standard
deviations. French and Wilson have devised a way of treating negative intensity
measurements more advantageously, based on Bayesian statistics. Their methods
only have an effect on the smallest terms, without the discontinuity observed in
other methods, and without resetting them to a constant value. This should result
in least possible loss of information and least possible bias. Unfortunately, some
data processing programs still insist on the conventional approach of resetting to
zero or omitting.
2.4 Structure Determination
When a new structure can be assumed to be isomorphous with one that is already
known, structure determination is simple: (2Fob• - Fcalc) and (Fob~ - Fca/c) maps can
be calculated with the observed magnitudes of Fhkl from the new structure, and the
calculated magnitudes and phases of Fhkl from the presumed isomorphous known
structure. These maps should show the small differences between the two structures
well. Isomorphism can be assumed on the basis of a strong similarity between the
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cell constants of two structures, and a low value for the isomorphous R-factor:
«: = Lhkl "FpHI- IFp"
LhkllFpl
(2.20)
In all other cases the crystallographer has to deal with the aforementioned
Phase Problem. For small molecules this problem can be solved with several meth-
ods based on the Patterson function, or by so-called Direct Methods. Direct meth-
ods are based on statistical relationships between structure factors, and often involve
probability functions which depend on the reciprocal of the number of atoms. More-
over, they usually require data to extend to atomic resolution. For proteins, with
relatively large numbers of atoms and generally lower than atomic resolution data,
these methods are in general not powerful enough to solve the structure. However,
a lot of effort is applied to determine ever larger structures ab initio, with some
successes for small proteins and peptides (see for example Sheldrick et al. 1993).
The Patterson function is defined as
P( u, v, w,) = ~ L L L IFhkd2e-27ri(hu+kv+lw)
h k I
(2.21)
which is the inverse Fourier transform of the relative intensities IFhkd2 which are the
experimentally measurable quantities. Because of the symmetry of direct and inverse
Fourier transforms, it is valid to say the Patterson function is simply the Fourier
transform of IFhkd2• Invoking some complex number theory, the convolution theorem
and the notion that the electron density is the Fourier transform of the structure
factor, it can be proved that
P(u,v,w) = V[p(x,y,z)®p(-x,-y,-z)] (2.22)
Or, in words, the Patterson function is the convolution of the electron density with
its centrosymmetric image, scaled by the volume of the unit cell. (u, v, w) represents
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a set of vectors between all pairs of atoms in the unit cell. The peaks in the Patter-
son function occurring at (u, v, w) have the strength of the product of the strengths
at either side of the vector, which are directly linked to the number of electrons of
the atoms in the atom pair, apart from scale factors. For a structure with N atoms
there are N(N-1) non-origin peaks. Thus the Patterson map of a protein would con-
tain a large number of peaks, many of which coincide or overlap, since the width of
a Patterson peak is the sum of the widths of the appropriate two peaks in the cor-
responding electron density maps. This generally makes the direct determination of
a protein structure from a Patterson map impossible, although there are exceptions
(see for example Frazao et al., 1995). The protein crystallographer therefore has to
resort to one of two other methods to overcome the Phase Problem: isomorphous
replacement or molecular replacement. Molecular replacement can be used when
the structure of a similar protein is known, e.g. a native protein in the case of a
mutant, the same protein from a different species, a model from NMR studies, or an
otherwise homologous protein which might serve as a model for the protein under
study. In the case of a completely "new" protein for which no related structure is
known, isomorphous replacement is the only available option. It is by this method
that the very first insulin structure was determined (Adams et al., 1969).
2.4.1 Isomorphous replacement
The isomorphous replacement method is based on the heavy atom technique as de-
veloped for small molecules. The idea is that the diffraction pattern and phases are
dominated by the contribution of one or a few heavy atoms if their atomic number
is sufficiently large relative to that of the other atoms present. The position of the
heavy atoms can be determined from a Patterson map, after which an electron den-
sity map can be phased on those atoms only. This map should reveal the positions
of the other atoms. If no heavy atom is present, a suitable atom might be replaced
by a heavy atom. If this heavy atom derivative can be crystallised isomorphously,
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the heavy atom method will facilitate the solution of both the native and modified
structures. In proteins the production of a heavy atom derivative is often reduced
to the soaking in of suitable heavy atoms into the solvent channels. When the pro-
cedure is effective, the structure of the protein is not disturbed and the heavy atoms
bind sufficiently to certain groups. The small changes in the diffraction pattern can
then be directly attributed to the heavy atoms. If Fp is the structure factor for the
native protein and FpH that for the derivative, the contribution of the heavy atoms
IS
(2.23)
Although only the magnitudes IFpl and IFpHI can be measured, the vector FH can
be calculated once the positions of the heavy atoms have been determined. The
interpretation of the Patterson function can be made easier by taking (IFPH I -
IFpl)2 = IFHI2coS2( arn - aH) as coefficients. This is called isomorphous-difference
Patterson Synthesis and in the resulting Patterson map all the available information
which the native protein and the derivative have in common, has cancelled out,
leaving a clearer picture of the heavy atom information, although some noise has
been introduced. This noise stems from the cosine term in the derivation of the
coefficients: tIFHI2 + tlFHl2cos2( o=n - aH). Since «t-n and on are not correlated,
this term only contributes noise.
In centric zones the structure factors are real quantities, so IFHI = IFPHI±IFpl·
Usually, because IFHI is relatively small, the difference is the correct estimate. Only
when IFpHI and IFpl are both also small, the sum can be correct. In acentric cases
the Phase Problem is more complicated. It can be solved with the aid of a phasing
diagram as devised by Harker (1956). Figure 2.3 shows a phasing diagram for one
isomorphous derivative. It can be seen that the phasing circles for the native protein
and that for the derivative intersect at two points, giving rise to two phase triangles
fulfilling equation 2.23. The Phase Problem is not solved unambiguously.
This can be remedied by adding another derivative circle as in figure 2.4.
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Figure 2.3: Phasing diagram for Single Isomorphous Replacement.
Two circles are drawn, one with radius IFpl centred on the origin, and
one with radius IFpHI about the end of the vector -FH. The two
points of intersection A and B of the two circles correspond to two
possible values of the protein phase.
So long as the heavy atoms do not occupy the same sites, i.e. the derivatives are
sufficiently different, and the native protein and the derivatives are sufficiently iso-
morphous, so that the phasing circles are well-defined, the ambiguity is resolved.
The correct solution is the point where the three circles intersect.
Another method of resolving the ambiguity is to take into account that the
electrons in the crystal are not really free; atoms scatter X-rays as if they contain
electronic dipole oscillators. This phenomenon, called anomalous scattering, will
be especially noticeable if the X-ray wavelength is just shorter than that which
corresponds to an absorption edge of the atom in question, so that the electrons in
the atom can change quantum state. The atomic scattering factor depends on the
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Figure 2.4: Phasing diagram for Multiple Isomorphous Replacement.
See also legend to figure 2.3. When two derivatives are available, a
third circle can be drawn, and in favourable circumstances the three
circles intersect in one clearly defined point (point A in the diagram),
thus resolving the phase ambiguity.
frequency of the radiation, and is of the form
fJ = (Ij)C + 6:.1' + i/s]" (2.24)
(fJ)C is the centrosymmetrical approximation. 6:.1' is the dispersion component and
does not involve absorption. It is responsible for the change in refractive index away
from unity. 6:.f" is responsible for the absorption coefficient of the medium. This
additional information causes the breakdown of Friedel's Law (see equation 2.15)
and can be used to resolve the phase ambiguity, as can be seen in figure 2.5.
Without anomalous scattering, I(Fhkl)PHI = I (FiiH)PHI (Friedel's Law) and
I(FiiH)PHI = I(FiiH) PH I (complex conjugates). In the presence of anomalously scat-
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Figure 2.5: Phasing diagram for SIR with Anomalous Dispersion. See
also legend to figure 2.3. The effect of anomalous scattering is to
introduce a phase shift, which is different for reflections forming a
Friedel pair. Thus there are circles with radii I(FhkdpHI and I(FhU)PHI
centred at -(FH + F'k) and -(FH - F'k) (points Band C in the
diagram), intersecting with the circle corresponding to IFpl in only
one point (point A in the diagram).
tering heavy atoms, the contribution of the native protein to (Fhkt}PH and (FhH)PH
is identical both in magnitude and phase. The magnitudes of the complex conju-
gates are still equal. The real component of FH, namely FH (based on (fj)c +AJ' of
the atomic scattering factor) is the same for (FhkI)PH and (FhkT)PH' The difference
is in the imaginary component of FH, being F'k, which has different signs, so that
I(Fhkl)PHI and I(FhH)'PHI sweep different circles. They must, however, intersect the
IFpl circle in one point, which will represent the true value of F».
In the case of insulin, anomalous scattering data was used in the form of what
is called the 'anomalous Patterson', which uses (IFhkd -IFhkT1)2 as coefficients. This
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method was first used for proteins by Rossmann (Rossmann, 19G1) and produced
information of the distances between anomalously scattering atoms.
2.4.2 Molecular replacement
Molecular replacement methods were first developed by Rossmann and Blow (IDG2)
to exploit the presence of non-crystallographic symmetry to obtain phase informa-
tion and reduce phase uncertainties. The ideas were extended by Bricogne (1~J7())
for real-space symmetry averaging to improve the electron density. The methods
are based on a simple idea: finding a molecule in different places in a unit cell.
More recently, the term 'molecular replacement 1 is often used for the process of
finding a similar molecule in a different crystal. If the structure of a molecule related
to that under study is already known, it call be used to arrive at starting phases
through orientation and positioning of the known molecule into the unit cell of the
unknown. The basic principle of molecular replacement is rooted in the Patterson
function. A Patterson map contains information of two types of vectors:
1. intramolecular or self-Patterson vectors of pairs of atoms in the same molecule.
These vectors are relatively short and are thus clustered around the origin;
2. intermolecular or cross-Patterson vectors, which are generally longer than self
vectors.
The self vector cluster would be equal for non-crystallographically related molecules
in the same unit cell but also very similar for similar molecules in different crysta.ls,
apart from a rotation difference. The cross vectors provide information Oil the
required translation of molecules to their positions relative to symmetry clements.
Thus the process of molecular replacement can be divided into two: orientation
and positioning, obliterating the need for a direct six-dimensional search, which is
com pu tationally unfeasible.
47
The rotation function
The construction of a Patterson function can be regarded as COllS('CllliH'lyplacing
each atom in the origin and drawing vectors from such all at.om to i111other atoms
in the unit cell. The value assigned to the vector is proport.ional to the product
of the atomic numbers at either end of the vector. Thus, HI!' height of the origin
peak in a Patterson map is proportional to the slim of the squared atomic numbers,
due to the null-vectors from each atom to itself. As stated lx-fore. th(' cross vectors
in a protein Patterson are generally longer than the self vectors, unless t.hr- protein
molecules are unusually closely packed or non-globular ill shape.
In the self-rotation function, the Patterson of t.h« unknown struct.uro is rotated
with respect to itself. Maximum overlap of these Patterson maps will O(,Cllrat zero
rotation (obviously) and at rotations representing (non-crystallographic) symmetry.
The overlap is calculated by integrating the product over an appropriate spherical
part of Patterson space (Rossmann and Blow, 1962). Similarly, two Pat.t('I'SOIlmaps
of related molecules (one known, one unknown) can be superposed when performing
a cross-rotation function. The origin peak may be excluded by using all inner limit
for the integration. The integration radius used should reflect til(' di mcnsions of
the molecule and packing considerations, in order to exclude cross vectors. III the
cross-rotation function the occurrence of cross vectors of the known molecule call be
prevented altogether by putting the molecule in an artificially large P I cell, so that
cross vectors lie well outside the integration radius.
The general notation for the rotation function, seen as an overlap function of
a Patterson function P( 11)and a rotated Patterson function P; (lfr), dependent on
Eulerian angles a, f3, I, is
(2.2.5 )
where U IS the appropriate volume of integration, and 11 IS a Patterson vector
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(u,u,tu).
If there is any prior knowledge of non-crystallographic symmetry, this call jw
used as a constraint in the calculation of what is named the 'locked' rotation [unc-
tion, a procedure first described by Rossmann et al. (1972). Assumed point-group
symmetry can be imposed on the unknown molecule, improving the rotation Iunc-
tion. The explicit use of non-crystallographic symmetry acts as a way of averaging
the previously separate rotation functions H; (Tong and Rossmann, ] 990):
(.) .)(.)_.- )
11.
where 11. is the number of non-crystallographic symmetry clements.
The rotation functions used in the studies of the structures 111 this thesis.
were performed with the program package AMoRe (Navaza, 1994). The rotation
function in AMoRe (Navaza, 1987) is based on the fast rotation function, using
spherical harmonics and Bessel function expansions (Crowther, 1972), the detailed
mathematics of which are beyond the scope of this thesis. The adaptations made by
Navaza permit more accurate computation of the rotation matrices (Navazu, ] 990),
and enhance the resolution of the rotation function peaks. Removal of the origin
(usually performed by using an inner limit for the integration radius) is achieved by
excluding the lower order spherically symmetrical Bessel functions.
A Mo Re. uses an uncommon philosophy at the stage of the structure factor cal-
culation from the model electron density. The model is rotated so that its principle
axes of inertia are aligned with the cell axes and then placed, with its centre of mass,
at the origin of a PI cell with linear dimensions around four times the size of the
model. Continuous Fourier coefficients are then calculated on a fine grid. Therefore
the problem of the need for sampling at non-integral reciprocal lattice points during
the calculation of the rotated Patterson function, does not occur. The structure
factors can be interpolated from the continuous set, rather than being calculated
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for every rotation. The loss of accuracy is small: only I(;{.1Il t.c-rrns of crystallo-
graphic R-factor for the situation of a quadruple-size box. For Cl double-size box
this discrepancy would be 8% (Castellano et al., 1992).
The program outputs a list of rotation function peaks with Eulerian angles
a, (3, I and a correlation coefficient. Because the model has bC('I1 placed at the
origin and rotated, the output is not in straightforward Euler itngl('s. It needs to be
shifted back, away from the origin, after which it may, in sonu- casC's, ('('v('cd directly
interpretable information about the molecule under study.
The translation function
The first fast translation function expression was devised by Crowther and Blow
(1967):
(2.27)
Pjk( il, v) is the cross-Patterson function of the model structure ill which two molecules
(j and k) are related by crystallographic symmetry. v is the intermolecular vector
between the local origins of these two molecules. Poba( il) is the Patterson function
of the unknown structure. This function effectively searches one pair of asymmetric
units, i.e. one crystallographic symmetry element, at a time. The function has two
limitations:
1. The self vectors confuse the picture. They can easily be removed by subtrac-
tion, resulting in the T1 function:
(2.28)
assuming the intramolecular vector set of the unknown structure is the same
as that of the model;
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2. The solution of the translation function only represents one symmetry op-
erator; all other symmetry information (including non-crystallographic sym-
metry) is lost. An improved translation function has been derived, resulting
in peaks for all possible intermolecular vectors. The model now has as many
molecules in the cell as the unknown structure. It is more convenient to express
this translation function in terms of the translation vector T for the identity
asymmetric unit. The expression contains the calculated Patterson for the
correctly oriented model with unknown translation:
(2.29)
Both improvements can be incorporated together in the most commonly used T2
translation function:
T2(i) = i[PObS(il) - ~ Pii(il)).[Pca/c(il, i) - L Pjj(il))dil
I I
(2.30)
Computation of translation functions is usually performed in reciprocal space,
sometimes using normalised structure factor amplitudes
(2.31)
where U hkl is the unitary structure factor
Fhkl
Uhk1 = Ej Ii (2.32)
and (IUhkI12) is the average value of IUhkt!2. The normalised partial structure factor
for the j'th asymmetric unit is related to the symmetry-equivalent structure factor
for the identity by a simple phase shift, so there is no need to completely recalculate
the structure factors every time.
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Translation function calculations can be improved by
• including existing phase information from isomorphous replacement studies,
calculating the so-called 'phased translation function'
(Read and Schierbeek, 1988);
• including information of a partial model by either adding or subtracting par-
tial Patterson functions appropriately during rotation or translation function
calculations (Zhang and Matthews, 1994);
• improving the search model and its orientation before the translation search.
Brunger (1990) has suggested the procedure of Patterson Correlation refine-
ment, minimising a target function based on the correlation between observed
and calculated Patterson functions and including an empirical energy term to
restrain the geometry of the model. The model can be divided into domains
treated as rigid bodies, while the domains are allowed to move with respect to
each other;
• combining the translation search with a limited systematic variation of the
parameters from the rotation function, assessing improvement by R-factor and
correlation coefficient calculations (Fujinaga and Read, 1987);
• fixing one molecule in the asymmetric unit while searching for non-
crystallographically related molecules (as in AMoRe (Navaza, 1994)).
The translation function may be by-passed altogether by a trial and error
search, moving the correctly oriented model through the asymmetric unit and cal-
culating the conventional R-factor as a function of the molecular position
R = LhklllFobBI- klFcalcll
LhkllFobsl
(2.33)
During these R-factor search calculations, the Fourier transform of the molecule only
needs to be calculated once, for translations correspond to a pure phase shift which
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can be applied directly. A slight improvement would be to calculate standard linear
correlation coefficients, which are insensitive to structure factor scaling, rather than
R-factors:
SLGG = Lhkl(IFobsI2_ < IFobsl2 > )·(IFcalcI2_ < IFcalcl2 »
[Lhkl(!FobsI2_ < IFobsl2 >)2. Lhkl(IFca1cI2_ < IFcalcl2 > )2]1/2
(2.34 )
AMoRe uses straightforward TO translation functions (Navaza and Vernoslova,
1995), with the option to incorporate information concerning already placed models
(Navaza, 1994), enabling the positioning of additional molecules in an asymmetric
unit. The program outputs a, (3, /, a translation vector (x, y, z) and an R-factor and
correlation coefficient, the rotation and translation information again in "internal
AMoRe format" (vide supra), which can be converted back to standard Euler angles.
More about AMoRe
A very powerful component of AMoRe is its fast rigid-body refinement procedure,
which is very efficient in the evaluation of the correctness of the molecular replace-
ment solution. The ideas on which it is based, were first developed by Huber and
Schneider (1985). It is not a least-squares rigid-body refinement of coordinates, but
rather a minimisation of the misfit, where rotations and translations are calculated
by interpolation and phase shifts.
The sub-program (FITING) is described by Castellano et al. (1992). The
minimisation procedure involves derivatives which are calculated from analytical
expressions rather than numerical differentiation as used by Huber and Schneider
(1985). The radius of convergence is around 10° for the angles and half the resolution
of the data for the translations (Castellano et al., 1992).
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2.5 Refinement of protein structures
After determination of an initial model, either through molecular replacement or
isomorphous replacement, the structure needs to be refined in order to obtain a set
of atomic coordinates that corresponds best to the observed data. Various systematic
and random errors have an effect on the accuracy of initial models. These errors
have their origin for example
• during the data collection experiment. With the advances in data collection
technology, these errors will become less significant;
• in the weak data (discussed in section 2.3);
• in the corrections during data processing (see section 2.3);
• while solving the Phase Problem. These errors are most prominent in the iso-
morphous replacement method, where 'lack of closure error', 'best phase' and
'phase probability' are terms frequently encountered (Blow and Crick, 1959,
Terwilliger and Eisenberg, 1987, Read, 1991). The phases are inaccurate, so
the map in which the initial model is built, is often not fully interpretable.
In molecular replacement studies there are limitations to the efficiency of the
functions used (Navaza, 1994). Moreover, in many cases the search model for
the molecular replacement calculations is, at least locally, significantly differ-
ent from the molecule under study, leading to a sub-optimal starting point for
refinement;
• in determining certain absolute lengths (e.g. cell axes, bonds). Engh and
Huber (1991) have determined a set of ideal bond lengths and angles etc. on
the basis of small molecule structure data.
Therefore, the initial model is only an approximation, and the structure factors
calculated from the model are in poor agreement with the observed structure factors.
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This agreement is commonly stated in terms of the reliability index R:
R = Lhkl IIFobsl - klFcalcl1
LhkllFobsl
(2.35)
where k is the scale factor between lFobsl and IFealcl. Wilson (1950) has shown that
for an entirely incorrect non-centrosymmetric structure R=0.586. During the course
of refinement, progress is followed by calculating the reliability index at various
stages. This R-factor may reach artificially low values due to model bias introduced
during the refinement procedure. From the statistical method of cross validation
a new method for avoiding bias in macromolecular structure refinement has been
developed by Brunger (1992). It is based on the idea that a fully refined model should
be equally valid if new data is introduced. In the statistical cross validation method
it is common to omit a single data point from the data, after which refinement takes
place, rather than obtaining new data after refinement. Since the information from
one data point is statistically unreliable, many data points have to be omitted in
turn and the remaining information has to be fully refined. This full protocol would
be impractical in general, because it would involve as many refinements as there are
observations. In protein crystallography, however, the data usually exhibit a certain
degree of redundancy, which means that a statistically relevant number of data may
be omitted from the data prior to refinement. These data can then be used to follow
the progress of refinement by means of the 'free R-factor', as introduced by Brunger
(1992):
R!;ee = LhklET IlFobsl- klFealcl1
LhklET IFobsl
Rt;ee refers to the 'test set T', a set of reflections (commonly 5-10% of the ob-
(2.36)
served data) which are excluded from refinement. Refinement is carried out with
the remaining reflections only, called 'working set W'.
Refinement is usually performed by 'least-squares' minimisation, i. f. the sum
of the squared differences between calculated and observed structure factors is min-
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imised. In traditional least-squares methods in protein crystallography, the function
to be minimised is commonly chosen as
Q =Lw(hkl)(IFobsl - klFcalcl)2
hkl
(2.37)
Q is called the crystallographic residual. The summation is taken over all indepen-
dent reflections hkl, and w( hkl) is the weight applied to each individual observation.
w(hkl) can be any weighting scheme, but is usually, at least initially, chosen to be
1. Some computing packages have the option of use of a, the standard deviation of
the observation hkl, in the form of q2(~kl)" The minimum of Q is reached when the
first derivative with respect to each parameter Pi is zero:
(2.38)
or
I:w(hkl)6" BIFcalcl = 0
hkl Bpi
where 6" = IFobsl-IFcalcl (assuming absolute scale). Starting from a set of parame-
(2.39)
ters p and necessary corrections e, 6" can be expanded as a Taylor series to the first
order:
6,,(p +0 = 6,,(p) - tei BIFcalcl
i=l Bpj
for n parameters. Combining equations 2.39 and 2.40 results in normal equations
(2.40)
of the form:
(2.41)
The n normal equations may be expressed in matrix form:
(2.42)
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where
(2.43)
and
bj =Lw( hkl)~ BIFcalcl
hkl Bpi
These equations are solved by matrix inversion for the set of shifts e which
(2.44 )
are then applied to the estimates p. The process is repeated until convergence is
reached, i.e. when the ei become negligible.
In protein crystallography the sheer size of matrix A prohibits calculation of
all the elements and full inversion. A method must be chosen to approximate these
steps. In the various refinement packages available today, different ways have been
chosen for the minimisation:
• Simulated annealing, used by X-PLOR (Brunger et al., 1987) In the early
stages of refinement, while later On it uses
• Conjugate-gradient, a particular variant of the conjugate-direction method
(Fletcher and Reeves, 1964). This is used by TNT (Tronrud et al., 1987) and
REFMAC (Murshudov et al., 1996a). TNT and REFMAC also have the op-
tion of using the more general conjugate-direction method;
• Diagonal approximation to the normal matrix, used by SFRF (Agarwal, 1978)
and EREF (Jack and Levitt, 1978);
• Sparse-matrix approximation. The sparse matrix may then be inverted, which
in PROLSQ (Hendrickson and Konnert, 1980, Konnert and Hendrickson, 1980,
Hendrickson, 1985), REFMAC and CORELS (Sussman et al., 1977, Sussman,
1985) is done by conjugate-gradient methods.
The success of protein structure refinement depends largely on the degree of
overcletermination of the system, i.e. the number of observed data for every param-
eter to be refined. The ratio of observed data over parameters may be changed
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favourably either by providing additional data (often the incorporation of stereo-
chemical knowledge in the form of restraints) or by reducing the number of param-
eters (often by constraining features of the structure to specific values). In the case
of restrained refinement, in practice the function minimised is then a composite of
diffraction and stereochemical information:
Qcomposite = Q + Qstereo (2.45)
In PROLSQ Qstereo contains terms for bonding distances, planar groups, chiral cen-
tres, nonbonded contacts and torsion angles. The formalism of equation 2.45 can
also be used for the description of the minimisation function in refinement pack-
ages other than PROLSQ. For example, in CORELS Q would be the usual sum of
structure factor differences, while Qstereo would be replaced by three terms, namely
for all interatomic distances, nonbonded close contacts and a term to prevent the
structure from moving away too far from the input coordinates (Sussman, 1985).
In EREF again the Q represents the crystallographic term, and Q stereo takes on the
form of a conformational energy term consisting of contributions for bonds, bond
angles, torsion angles and nonbonded interactions as described by Levitt (1974).
Each term in Q composite requires appropriate weighting and scaling.
In general, least-squares refinement as described above, has a limited radius
of convergence. It generally does not correct errors in atomic coordinates which are
larger than lA and is easily trapped in local minima. To avoid this, a refinement
technique is required which will allow up-hill steps away from the nearest minimum.
Simulated annealing is such a method. Metropolis and co-workers (1953) introduced
an algorithm to simulate a collection of atoms at a given temperature. In each step
of the simulation an atom is moved at random and the effect on the total energy is
computed. If the energy decreases, the move is accepted, if it increases, it is accepted
with a probability which is proportional to exp[ - ~E / kbT] (~E is the energy differ-
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ence between the two states, kb is the Boltzmann constant and T the temperature).
When the energy function is replaced by the cost function of a minimisation prob-
lem, and the atomic parameters by the parameter set ~, the Metropolis procedure
can be used to generate a set of configurations at a given temperature of the min-
imisation problem. The temperature parameter determines the amount of energy
available to the system to overcome energy barriers, i. e. at a higher temperature
more steps are accepted which lead to an increase in the cost function. This allows
the minimisation to escape from local minima. Simulated annealing is a process
in which the temperature is first raised to a relatively high value, after which the
system is slowly cooled until it freezes and no more changes occur. The maximum
temperature, the rate of cooling, and the number of rearrangements of ~ determine
the 'annealing schedule'. A direct application of the Metropolis algorithm to the
refinement of macromolecules is very inefficient: most of the random changes in ~
would lead to violation of covalent bonds. Instead, molecular dynamics is used to
follow the gradients of a target function which includes an empirical energy term
to introduce stereochemical and other restraints. Thus the total energy is the sum
of an empirical energy describing the restraints and an effective potential energy
to include the X-ray information. The empirical energy contains terms for bond
lengths, bond angles, dihedral torsion angles, chiral centres, planarity of aromatic
rings and Van der Waals and electrostatic interactions:
E, = Ebonds + Eangies + Edihedrais + Echirai,pianar + EvdWaais,elec (2.46)
The program package X-PLOR essentially uses the stereochemical and nonbonded
parameters as formulated for the molecular dynamics program CHARMM (Brooks
et al., 1983). Conventional refinement is performed using a conjugate-gradient min-
imisation algorithm. The application of simulated annealing consists of 'heating
and cooling' the structure. An initial temperature, typically 3000K, is applied to
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the system. Two protocols are possible: either the system is extensively equilibrated
at this temperature after which cooling takes place, or the system is allowed to cool
directly, very slowly. In the first protocol the initial velocities are assigned from a
Maxwellian distribution at the appropriate temperature. The temperature is con-
trolled through rescaling of the velocities at set intervals of the simulation. The
scale factor is determined from:
Wa = O::imViOld(t?)
nkbT
(2.47)
where m is the mass and Vio1d the velocity of atom i at time t, kb is the Boltzmann
constant, T the temperature, n the number of degrees of freedom and () the av-
erage over the time interval between rescaling of the velocities. It has been shown
(Weis and Briinger, 1989) that towards the end of refinement a reduction of the
weight by 10-40% is beneficial, in order to prevent deterioration of the model geom-
etry. Cooling of the system is effected through stepwise lowering of the temperature.
At each temperature the system is allowed to equilibrate employing the rescaling as
expressed in equation 2.47.
A large number of applications (for an extensive overview see Goodfellow et
al., 1989) has shown that the shifts observed are very much larger than for conven-
tional refinement methods. This leads to dramatic improvements for initial models
of macromolecular structures. Although the radius of convergence of refinement
with simulated annealing/molecular dynamics techniques is much increased, manual
intervention in the form of map inspection and model rebuilding is still necessary.
Until a few years ago, manual rebuilding was mainly performed with the graph-
ics program FRODO (Jones, 1978). Recently, the molecular modelling package
Quanta (Molecular Simulations, 1996) has been extended with a large crystal-
lographic module, containing the application X-AUTOFIT (Oldfield, 1996). X-
AUTOFIT is designed to enhance the efficiency of de novo map building as well
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as general model building in later stages of macromolecular refinement. The model
building is carried out with the aid of real space refinement, regularisation and rigid
body refinement algorithms, as well as traditional manual editing facilities. Three
refinement techniques are implemented: grid searching about torsions, torsion angle
real space gradient refinement and Monte Carlo fitting. For the automatic build-
ing and refining of ligand and water coordinates Quanta provides the applications
X-LIGAND and X-SOLVATE, respectively. X-LIGAND is designed to search for
unsatisfied electron density, sort these in order of volume and fit a ligand automat-
ically. It can be used to fit small (in)organic molecules (such as sulfate ions and
phenol molecules), polysaccharides and small polypeptides. X-SOLVATE allows the
search of an electron density map for water peaks in a specified space around the
protein.
Building up the water structure is also very conveniently performed with the
program ARP (Lamzin and Wilson, 1992). The program seeks to improve the fit of
atomic coordinates to electron density maps by appropriate removal and addition of
atoms. This procedure is alternated with reciprocal space refinement of the complete
set of coordinates with, for example, PROLSQ or REFMAC.
2.6 Maximum entropy and maximum likelihood
2.6.1 The concept of entropy
From information theory came the realisation that there is a unique, unambiguous
criterion for the amount of uncertainty represented by a probability distribution
q(x) = I:[:l Xi (N is the number of states of Xi, and I:i qi = 1) or Iv xdx for a
continuous distribution in volume V. This quantity
N
S(qd = - LqJnqi
i=l
(2.48)
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is continuous in qi, increases with increasing uncertainty and is additive for indepen-
dent sources of uncertainty (Shannon and Weaver, 1949). In the simple case where
the system consists of two events x and y, it can be shown that
S(x,y) ~ S(x) + S(y) (2.49)
Or, in words, the uncertainty of a joint event is less than or equal to the sum of
the individual uncertainties (equality only occurring if the events are independent).
Also, the probability of event y is influenced by the occurrence of event x, resulting
in a conditional entropy for event y, Sx(y). It then follows that
S(x,y) = S(x) + Sx(y) (2.50)
Thus the uncertainty of the joint event x, y is the uncertainty of x plus the uncer-
tainty of y when x is known. Combining equations 2.49 and 2.50, it can be seen
that S(y) ~ Sx(y), or, the uncertainty of y is never increased by knowledge of x.
It will be decreased unless x and yare independent events, in which case it is not
changed.
The quantity S is equivalent to the expression for entropy as found in statistical
mechanics (Jaynes, 1957). The minimum value of the entropy, S = 0, is reached
when one of the probabilities qi is 1, i.e. when there is no uncertainty. In that case
there is no freedom of choice and no information is gained from the situation. The
unconditional maximum value for S, namely InN, is reached when all parameters Xi
are equally probable, i.e. for a uniform distribution. Thus S increases when the qi
are more 'average'.
62
2.6.2 Maximum entropy
Whenever an experiment is undertaken, there is some form of prior knowledge, even
if it is only intuitive. Jaynes (1979) writes: "merely knowing the physical meaning of
[the] parameters [of our experiment] already constitutes highly relevant prior infor-
mation which our intuition is able to use at once. Can we analyse how our intuition
does this, extract the essence, and express it as a formal mathematical principle
that might apply in cases where our intuition fails us?". In fact, an experiment
in itself constitutes information, which has an effect on the entropy of the system
under study.
In most experiments, the unconditional maximum value for 5, as described in
the previous section, will not be reached, simply because of the requirements the
prior knowledge puts on the experiment. If testable information is available, the
process of finding the maximum value of 5 will be put under constraints. Here
'testable information' is defined as: such that it may be determined unambiguously
whether the information does or does not agree with the proposed tested distribution
Pi, the posterior distribution. An example of testable information is: "It is certain
that coso: < 0.7". Untestable information (e.g. "The mean value of coso: might be
less than 0.7") can at present not be used in mathematical theory. Jaynes, however,
believes that new principles for this must exist (Jaynes, 1979).
In an experiment undertaken to test information, linear constraints may be
given in the following form:
N
LPdk(Xi) = Fk
i=l
[or k = I,m (2.51)
where Li Pi = 1, which is in fact the zero-order constraint. Fi; is the expected
value of Jk in the experiment (see example I). Jk(Xi) is a set of m functions of
the parameters Xi. If m < N, the maximum entropy may be calculated. The
derivation of the formula for the maximum entropy may be done as follows (for the
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mathematical principle of 'Lagrange multipliers' see appendix A):
(2.52)
where
N
Z().l ... ).m) =L eXp[).t!l (Xi) + ...+ ).mfm(xi)]
i=l
(2.53)
is the partition function, which is a normalisation function so that the sum of the Pi
is 1. ).k are the Lagrange multipliers, which are chosen so as to satisfy the constraints
2.51, namely
for k = I,m (2.54)
This is a set of m equations for m unknowns. The resulting maximum entropy is a
function of the prior information:
S(Fk) = InZ - L ).kFk
k
(2.55)
Example I
An example of the use of entropy in sciences other than physics was given by Jaynes
in 1962, and was reproduced in an extensive article called "Where do we stand
on Maximum Entropy?" (Jaynes, 1979). A seemingly ordinary die has been tested
prior to a real experiment, and the information from this test is: the average number
of spots up is not 3.5 as in an 'honest' die, but 4.5. What is the probability assigned
to i spots (1 ::; i ::;6) on the next throw? The data may be interpreted in the form
of a constraint:
6
Eipi = 4.5
i=l
(2.56)
The partition function is Z()') = EieAi = x(l-xt1(1-x6) with X = eA. Equation
2.56 becomes :.xlnZ = (~:~)~t~::)= 4.5 or 3X7 -5x6+9x-7 = O. The desired root is
x=1.44925, giving ).=0.37105 and Z=26.66365. The maximum entropy probabilities
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are Pi = z+», or {Pl ... P6}={0.05435, 0.07877, 0.11416, 0.16545, 0.23977, 0.34749}.
This is the distribution based on the least assumptions, i.e. the distribution which
is nearest to being uniform under the constraints presented in the description of
the problem. The entropy of this distribution is S=1.61358. The unconditional
maximum entropy, i. e. the entropy of an honest die, is ln6= 1.79176, representing a
system with no constraints and a totally uniform distribution.
2.6.3 Relative entropy
The availability of prior knowledge implies the existence of a prior probability dis-
tribution q(x), which can be either discrete or continuous. After performing an
experiment, a posterior probability distribution p(x) may be calculated. The rel-
ative entropy of the posterior distribution (the distribution of the outcome of the
experiment) with respect to the prior distribution (i. e. before the experiment) is
defined as:
N
S(p, q) = - LPi1n(pdqi)
i=l
(2.57)
where N is the number of possible states of the system. This illustrates that the
probability distribution over the system states is modified by the experiment, from
prior distribution q(x) to posterior distribution p(x) (see example II).
Example II
An experimenter is given a set of dice, commonly expected to have qi=1/6. An
experiment of throwing the dice and calculating the entropy of each system is un-
dertaken (see figure 2.6). From this example it can be seen that the more predictable
the outcome is, the lower is the relative entropy of the system under investigation.
Again totally predictable is seen as gaining no information (compare section 2.6.1).
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Figure 2.6: Throwing dice. Different types of dice and their associated
distributions, indicating the correlation between entropy and informa-
tion. OlnOis assumed to be O. Example reproduced from Kinneging
(1986).
The minimum entropy principle
The main goal of a successful experiment, is obtaining as much undoubtable data
(to avoid confusion, the term 'information' has not been used here) as possible,
leaving the least uncertainty. Entropy may therefore be used as a guideline in the
choice of experiment. An experiment which provides maximum data has minimum
entropy relative to any other experiment pertaining to the same question. These
undoubtable minimum-entropy data provide a boundary for the entropy maximisa-
tion to obtain the best possible distribution based solely on trusted facts and no
unprovable assumptions. In cases where the minimum-entropy experiment can not
be chosen, the resulting data will not be optimal.
2.6.4 Bayes' theorem and likelihood
The use of prior knowledge and the inference of information from the observations
of an experiment may also be dealt with entirely through statistics. To this end,
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Bayes proposed the following theorem:
P(BIA) = P(B)P(AIB) (2.58)
P(B) is the prior probability of event B. P(AIB) is the conditional probability of
obtaining experimental information A in an experiment to test B. P(AIB) modifies
prior probability P(B) in such a way that posterior probability P(BIA) is obtained,
the probability of B when A has been seen. This simple description implies that
experimental information A and the connected probabilities constitute a learning
experience about B. The right-hand side of equation 2.58 can be normalised for a
set of events Br, resulting in
(2.59)
In the next step of the learning process, the previous information A is seen as
prior information H, after which new experimental information A will be obtained
through a new experiment. The following form of Bayes' theorem is used at this
stage:
P(Br, AIH)
Lr P(Br' AIH)
(2.60)
The terms of this equation may be explained as follows:
B, is a set of mutually exclusive and exhaustive events (in the statistical sense), i.e.
the knowledge tested through an experiment.
P(BrIH) is a prior probability, which is the probability of obtaining the parameters
B; solely on the basis of prior information H.
P( B; lA, H) is a posterior probability, i. e. the probability of obtaining new parame-
ters B; on the basis of prior information H and experimental information A.
experimental information A is obtained in an experiment to study parameters Br
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when prior information H is available.
P(Br, AIH) is called the joint probability of B; and A conditional on H.
Thus the theorem states that the probability that B; occurs given the occur-
rence of A and currently available information H, is proportional to the probability
of B; on H multiplied by the probability of A on B, and H. Or in other words, it
gives the probabilities of B; when A is known to have occurred.
Example III
The use of Bayes' Theorem may be explained by means of an example taken from
Kendall's Advanced Theory of Statistics (1987). A box contains four dice, which are
known to be either (a) all white, or (b) two white and two black. A die is drawn at
random and found to be white. What is the probability that all the dice are white?
Based on (a) and (b) there are two hypotheses B, and B2• On Bl the probability
P(AIBn H) (see equation 2.60) of getting a white die is 1, on B2 it is t. From
equation 2.60 it can be seen that
P(BlIA, H) = P(B1IH)
(2.61 )
Bayes postulated that it is reasonable to take prior probabilities to be equal when
nothing is known to the contrary, so P(B1IH) = P{B2IH) = !. Thus
2 1
P{BlIA,H) ="3 and P(B2IA,H) ="3 (2.62)
The experiment continues by replacing the die and again drawing one at random.
If it is found to be black, hypothesis (a) is rejected outright. If it is white, new
posterior probabilities can be calculated in which the probabilities from equation
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2.62 become priors: P(B1IH) = ~ and P(B2IH) = ~, where H includes A, the
occurrences from the previous experiment. The new posterior probabilities based
on the new event A' are
(2.63)
On repeating the process and again drawing a white die, the new posterior probabil-
ity of (a) will be still higher, in agreement with common sense: repeated sampling
(with replacement) without producing a black die increases the probability that
there are no black dice present.
2.6.5 Entropy and likelihood in protein crystallography
In 1982 Collins proposed the use of iterative entropy maximisation for macromolecu-
lar crystallography. The ideas involved have their foundations in information theory
and image enhancement, and their application has the potential to produce electron
density maps of higher interpretability (through higher signal to noise ratio) than
expected for Fourier synthesis ofthe available structure factors (Collins, 1982). Ap-
plying the general statements from sections 2.6.1 to 2.6.3 to crystallography it can
be seen that
• in order to be able to obtain most information from a data collection experi-
ment, the least uncertainties should be left (the minimum entropy principle) by
collecting as much data as possible to the highest multiplicity and resolution
that may reasonably be obtained;
• with the data available, the least assumptions should be made, so that the
maximum entropy principle may be applied in the determination of the atomic
structure, thus avoiding overfitting and bias.
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Although the Phase Problem will not be solved experimentally in the foreseeable
future, and is mathematically indeterminate when only amplitudes are known, some
combinations of phases are more acceptable than others when solving a crystal
structure. This is because the phases will have to yield a chemically valid distribution
of atoms.
Bricogne (1984) proposed the use of a phasing method based on entropy max-
imisation and likelihood ranking as a means of applying probabilistic direct meth-
ods to macromolecules. The mere assumption that a crystal structure is made up
of atoms, is enough to provide statistical restraints on the structure factors derived
from the data, even if the atoms are randomly placed and independent of each other.
There are a number of advantages to maximum entropy methods (hereafter
called MEM) over conventional direct methods (CDM). In principle the starting
point of CDM and entropy/likelihood methods is the same, but the latter do not
require a uniform distribution of the probability distribution of the atoms in the
asymmetric unit (Bricogne and Gilmore, 1990). Also, MEM do not require high
overdetermination by the data, unlike CDM (Bricogne, 1991a). Thirdly, CDM are
most accurate for small Fs because of the method of approximation of the probability
distribution P(F) (the joint probability distribution of all Fs), whereas through
MEM it is possible to use the more informative large Fs (see below). Fourthly, in
deriving P(F) from the random atom model, CDM have, until recently, never made
use of the complete P(F) but instead considered individual terms for small groups
of reflections which were combined (joined) later. However, Peschar and Schenk
(1987) have addressed this problem for CDM.
Bricogne's Multisolution Tree
For a uniform prior distribution of atoms (q( f')=1 IV) the joint probability dis-
tribution P(F) may be calculated to various degrees of approximation. Observed
magnitudes IFI may be substituted into P(F) after which only phases remain as free
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variables, which yields a conditional distribution for the phases under the constraints
of the observed IFls. This conditional distribution should imply that certain com-
binations of phases are more probable than others. For small IFls the conditional
distributions of the phases will be least informative because they do not significantly
narrow down the uncertainty in F. With MEM 'recentering' is possible by setting
up local approximations to P(F) away from IFI = 0 by means of 'trial phase' shifts.
This is equivalent to using a non-uniform prior distribution of atoms, the maximum
entropy distribution qME(f'). From this description of recentering to obtain local
approximations of P(F) it may be seen it is not so much the maximum entropy
distribution qME(f') which is the really useful result, but the optimal approxima-
tion to P(F). The maximum entropy distribution is almost just a by-product of
the calculations of P(F). The resulting joint probability distribution for all Fs is
called pS? (F), the saddlepoint approximation to P(F). In practice, the diagonal
approximation to pSP (F) is used.
The first set of phases H chosen on the basis of the first conditional distribu-
tion may be seen as the origin-fixing phases and are assigned to the 'root node' of
a 'solution tree', which will help to keep track of the phase choices made at var-
ious stages. At this node with corresponding basis set H the unique distribution
qME, having maximum entropy compatible with the data attached to the node, is
constructed by maximising the relative entropy
(2.64)
under the constraints
for all hEH (2.65)
m( f') is the normalised prior distribution of q( f') which comes about because of the
use of unitary structure factors Uh. Bricogne has named m(f') the 'prior prejudice'
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(Bricogne, 1984) and the 'probability density' (Bricogne and Gilmore, 1990). ¢(h)
is the phase of reflection h.
Besides reproducing the amplitudes and phases attached to the node for re-
flections in H, qME has Fourier coefficients UrE with non-negligible amplitude for
many non-basis reflections k. This means that the conditional distribution of IUkl
deviates from the normal Gaussian distribution of Wilson statistics, which would
correspond to IUrEI = 0, and that the atoms are distributed according to qME
rather than uniformly. The two distributions just derived (qO and qM E) under two
different hypotheses on U h can not be easily compared because they involve phases
¢(k) of non-basis reflections. However these phases may be integrated out to obtain
the conditional probability distributions not of structure factors Uk for reflections
k in non-basis set K but of their moduli IUkl. Then the conditional probabilities
assigned to the observed values of the moduli under both hypotheses may be com-
pared, the better assumption being that which assigns the highest probability to
them. This quantity acts as a figure of merit and is called the 'likelihood' of the
hypothesis, defined as 'the probability it assigned to the actual result of an obser-
vation before that observation was performed' (Bricogne, 1991a). The comparison
is best carried out using the 'likelihood ratio':
(2.66)
where ut' = lut'l. The likelihood ratio measures the extent to which the observed
values of yet unphased moduli lutslare made more probable by the assumption that
Uh = UrE than by the assumption that Uh = O. The logarithm of the likelihood
ratio is called the 'log-likelihood gain', which is also often used.
Invoking Bayes' theorem the posterior probability distribution of UfE may
be calculated by
ppost(UfE) ex pSP(UrE) x L(UfE)
72
(2.67)
Then the basis-set phases in U ii can be refined by maximising the posterior proba-
bility with respect to the phases.
From the descriptions so far, it can be summarised that the growth of the
'multi solution tree' has entailed:
1. choice of basis set H of origin-fixing (and/or enantiomorph-defining) reflections
and assignment of the root node;
2. update of the prior distribution of atoms q( f') to the maximum entropy dis-
tribution qME(f') compatible with the phase choices, giving rise to structure
factor values U ii for that node;
3. construction of the conditional distribution P£:g of the yet unphased structure
factors in non-basis set J(;
4. construction of the likelihood function L by integrating the conditional distri-
bution over the unknown phases and substituting the observed values of the
moduli in J(;
5. refining the basis set phases in UrE by maximising L with respect to these
basis phases.
The subsequent growth of the tree involves 'branching out' and 'pruning':
6. identification of the local maxima of the conditional distribution with respect
to a subset of unknown phases when the values of the corresponding moduli
are introduced;
7. expansion of the current node by creating a branch leading to a new tip node
for each of these maxima;
8. in order to avoid development of spurious branches while maximising the
chance of finding the correct set of phases, two criteria are used at each node:
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• the loss of entropy in going from a uniform distribution of atoms m( fj =
~ to the current non-uniform qME(fj, which measures the shrinkage of
the population of 'reasonably probable structures' when the constraints
U¥E are enforced (Shannon and Weaver, 1949);
• the likelihood, which measures the chance of survival of the node by
measuring the degree to which the phase choices made anticipate correctly
the information present in the yet inactive constraints.
The validity of the phase choices for H and some for 1< firmly established, the
tree may be further developed from each surviving node by iteration from step 2.
The entropy and the likelihood are complementary measures of the worth of the
trial phase set, in that the entropy 'looks back' at the cost of accommodating the
current phase assumptions, and the likelihood 'looks ahead' at the match between
its predictions and the actual observations for yet unphased data.
Over the years Bricogne's theories have been updated with the incorporation of
'all sources of phase information normally used in macromolecular crystallography'
(Bricogne, 1993) and the possibility to use the system for data other than from single
crystal X-ray crystallography (e.g. powder diffraction data (Gilmore et al., 1991)).
Bricogne envisages the complete implementation of the 'Bayesian programme', i.e.
the use of Bayesian theory in every stage of macromolecular structure determina-
tion, from first phasing (ultimately ab initio) to full refinement (Bricogne, 1993).
Three program packages have been developed as a direct result of these theo-
ries, namely MICE (Bricogne and Gilmore, 1990), BUSTER (Bricogne, 1991b,
Bricogne, 1991c) and SHARP (de la Fortelle and Bricogne, 1996).
REFMAC
More recently, the program REFMAC (Murshudov et al., 1996b) has been devel-
oped, to perform maximum likelihood refinement. The likelihood function (vide
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infra) is constructed from available parameters at any point in a refinement proce-
dure, whether immediately after structure determination or much later on in refine-
ment. Instead of maximisation of the likelihood function, an equivalent calculation
is performed: the logarithm of this function (the likelihood residual) is minimised
to a desired degree of convergence through conventional methods. This procedure
of constructing the likelihood function and then minimisation may be seen as a
macrocycle of likelihood refinement, which may be iterated to convergence itself.
The program uses prior knowledge of the stereochemistry of macromolecules, like in
least-squares methods, but works with conditional probability distributions rather
than the Gaussian distributions employed in least-squares. Partial phase information
may be added and there is an option to use the information provided byexperimen-
tal standard deviations. Different parts of a structure may be treated in different
ways if the errors in the separate domains are known or suspected to be different.
Bulk solvent scaling according to Tronrud (1996) has been incorporated.
When experimental data (e.g. observed magnitudes IFI) are available and pa-
rameters x (e.g. atomic coordinates) are to be estimated, Bayes' theorem may be
written as:
P(IFI; x)
P(x; IFI) = q(x) P(IFI) = q(x)L(x; IFI) (2.68)
where ';' denotes conditionality to avoid confusion with the 'I' in IFI. P(x; IFI) is the
posterior probability of x on the basis of the data IFI; q(x) is the prior distribution
of the atoms. In theory, this could be the maximum entropy distribution qM E as
described in the previous section. However, REFMAC does not deal with maximum
entropy calculations. Therefore, q( x) is typically the distribution of a Molecular or
Isomorphous Replacement model.
P(IFI; x)
L(x; IF!) = P(IF!) (2.69)
is the likelihood function, where P(IFI; x) is the conditional distribution of experi-
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mental data when the parameters are known. For x Fcalc may be used, since Fcalc
can be calculated directly from x. Thus
P(IFI' x) = P(IF l" reflections. Fall reflections), obs , calc (2.70)
This joint conditional probability function may be built up by generating the con-
ditional probability distribution of each reflection and multiplying these together:
P( IF lall reflections. Fall reflections) =
obs , calc II (2.71)
all reflections
The refinement consists of maximising the likelihood function, which is propor-
tional to the product function of the conditional probability distributions for each
reflection (see equation 2.71). Maximising this function is equivalent to the minimi-
sation of its negative logarithm, giving rise to what is called the '-log-likelihood':
= ln P( x; IFobslall reflections) = -In q( x) - In L(Feale; IFobs!) (2.72)
all reflections
Because P(IFI) (see equation 2.69) will not change, effectively the function to be
maximised is P(IFobsl; Fealc),
The principle of maximum likelihood may be formulated as follows: "an or-
ganised search for those combinations of phases associated with a 'basis set' of
reflections which have maximum likelihood, i. e. which lead to the assignment of
the highest conditional probability to the observed moduli belonging to reflections
outside the basis set" (Bricogne and Gilmore, 1990), as described in the previous
section. This is only one of many ways of formulating the use of Bayesian statistics
and the principle of maximum likelihood in the field of protein crystallography.
One of the parameters of the likelihood function used in REFMAC is aA, which
was first described by Srinivasan and Ramachandran (1965). aA is a combined
measure of the completeness and the accuracy of a partial structure (Read, 1986).
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In REFMAC O"A is estimated from the 'free' reflections (Brunger, 1992) rather
than all reflections as by Read, which can be done satisfactorily using only 200
reflections (Murshudov et al., 1996b). From the theories by Luzzati (1952) and
Read(1986,1990) the parameters m and Dj are derived:
Dj = (cos(27rh . Llrj)) (2.73)
where 0 denotes an expected value or probability weighted average. h is the recip-
rocallattice vector, and rj are the atomic coordinates (in A).
(2.74)
m has different values for acentric and centric reflections, and also depends on
whether the partial structure P is known to contain errors or not. N = P + Q
is the total number of atoms when Q is the missing structure. Therefore
(2.75)
O"A is then
(2.76)
where LN = L.%:l If = (IFNI2jt), in which t is a correction factor for the expected
intensity in the appropriate reciprocal-lattice zone, denoting the number of identi-
cal contributions arising from symmetry (LP analogous to LN). Ij is the atomic
scattering factor. O"A has a value between 0 and 1, where 0 indicates that the partial
structure provides no phase information (because it contains no atoms or the par-
tial structure bears no relation to the total structure), and 1 indicates a perfect and
complete partial structure. Dj varies with resolution, so 0"A needs to be estimated
for several resolution ranges.
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The likelihood function in REFMAC has the following form:
LLl< =Lu.«,
h
(2.77)
where
c - In(IF b I)+ In(2u2 + E ) + lFob.I'+lFwcl' -In 1 ( 2lFob.llFwcl )
o , Fob. we 2q~ +Ewc 0 2u~ +E",cFOr,. Fob.
(acentric)
(2.78)
(centric)
F we = Lf,;iTt DjFjalc = IFwelexp(i<pwc) is the weighted sum of partial calculated
structure factors. Lwc = tLf,;tt Lj(l - DJ) where Lj = Lf~iomRj for j-th par-
tial structure. Natom is the number of atoms, and Npart is the number of partial
structures. O'Fob. is the experimental uncertainty in the amplitude IFobsl. 10 is a zero
order modified Bessel function.
Murshudov et al. (1996b) describe a number of special cases, where the like-
lihood function is reduced to simpler functions because of various assumptions and
approximations:
1. if some atomic parameters are approximately known and it is assumed that
the missing atoms are distributed uniformly over the asymmetric unit the total
distribution reduces to a distribution which neglects experimental errors for
the missing structure (i.e. Dj for the missing structure is 0, and only the
partial structure affects Dj) (Srinivasan and Ramachandran, 1965);
2. if the partial structure may be assumed correct and the only error is due to
missing atoms, in which case D, = 1 and Lwe = LQ (Sim, 1959);
3. in the case of a Wilson distribution (vide supra) no atomic parameters are
known and the contents of the unit cell is distributed uniformly;
4. when 2IF~"Fwel is small the -log-likelihood residual is similar to the normalised
we
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intensity based Patterson correlation function (which is related to normalised
intensity based least squares) (Bricogne, 1992);
5. when lFobs I ~ IFwcl so that In II~~:IIis small, the - LLK residual is similar to an
amplitude based least squares residual, the Gaussian based likelihood function.
This assumption is reasonable near the end of refinement;
6. if all reflections are measured with equal (7Fob. (which is very unrealistic) and
all Dj ~ 1, -LLK will become a unit weighted least squares residual.
From parameters m and Dj Fourier coefficients are generated which are used
in map calculations. Because absent reflections cause unpredictable noise (see for
example Cowtan (1996)) REFMAC approximates them by setting them equal to
their expected value (this is done for all reflections, including the 'free' reflections).
Therefore the map coefficients are:
2FWT = { (2mlFobsl- DjIFcalcl)exp(iacalc)
DIFcalclexp( io:ca1c)
for reflections present in refinement
for missing data
(2.79)
for reflections present in refinement
for missing data
The maps produced are more informative and contain less bias than conven-
tional 21Fobsl - IFcalcl and IFobs I - IFcalcl maps. Luzzati (1953) showed that a map
with coefficients IFobslexp( io:ca1c) shows missing atoms at half weight if the structure
is almost complete, and slightly lower when more of the structure is missing. There-
fore the conventional map with coefficients (2IFobsl-lFcalci)exp(io:calc) will bring up
missing atoms with almost full weight. It has been determined (Vijayan, 1980) that
for different amounts of missing structure a specific value of n in map coefficients
[nIFobsl- (n - 1)IFcalcl]exp(iacalc) is most appropriate. Also, Main (1979) showed
that mIFobslexp(iacalc)~~Fobs + ~Fcalc so that coefficients which reduce model bias
are given by (2mIFobsl-IFcalcl)exp(iacalc) in the case of a perfect partial structure.
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Read (1986) extended this to the case of a partial structure with errors, resulting in
the map coefficients (2mIFobsl- DjIFcalcl)exp(iacalc) (see above).
2.7 Protein structure validation
The best statistical validation of a protein structure would be if it were to be de-
termined and refined independently by a statistically significant number of exper-
imenters. Not surprisingly, this never happens in protein crystallography because
of the time needed to obtain a fully refined protein structure. The correctness and
precision of the atomic parameters in the structure will therefore need to be assessed
thoroughly, both during and after refinement. It has to be kept in mind that val-
idation through computer programs is only as good as the parameters prespecified
as ideal values inside these programs.
Protein refinement is inherently difficult because of the data being weak, not
highly overdetermined, not to atomic resolution and prone to data error. Data
quality has already significantly improved during the past five years for various
reasons (Dodson, Kleywegt and Wilson, 1996):
• two-dimensional detectors are now routinely used, reducing the problem of
systematic errors;
• cryocrystallographic techniques have advanced to a point where crystal qual-
ity stays constant during a complete experiment, often even extending the
resolution that may be obtained;
• synchrotron radiation allows the use of smaller crystals, while higher resolution
data may be obtained and absorption effects are reduced because of shorter
wavelengths;
• data processing techniques are advancing, incorporating information on exper-
imental standard deviations.
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A first indication of the reliability of a protein crystal structure is the resolution
to which the data has been collected and the structure refined. This can only be
a rough measure, but it has been shown that at higher resolution the structure
is closer to the correct structure (Hubbard and Blundell, 1987). A measure of the
accuracy and usefulness of intensity data, by measuring the agreements of equivalent
reflections, is:
(2.80)
where hkl(i) is the i-th measurement of the reflection with indices hkl and (hkl) is
the mean value of the N equivalent reflections. In general, Rmerge values less than
5% indicate excellent data quality, values between 5 and 10% indicate average data
quality, values in the 10-15% range are acceptable but may indicate problems with
crystals or experiment, while values greater than 15% indicate poor quality data that
may not be useful for crystal structure analysis (Ealick, 1995). The value of using
as much data as possible has been demonstrated by various people. As mentioned
before, Cowtan (1996) has shown how missing reflections affect the reproduction of
an image from diffraction data. The completeness of low resolution data is important
in the placement of missing parts of the structure, while refinement may benefit
from the inclusion of high resolution data even if the merging R is up to 40%
(Dodson, Kleywegt and Wilson, 1996). Accurate bond and angle parameters for x-
ray protein structure refinement have been extracted from the Cambridge Structural
Database and compiled by Engh and Huber (1991), providing a reliable measure for
ideal values for bond lengths and angles. Ever increasing computing power allows
for more advanced software, both for refinement calculations and graphics facilities.
The development of program packages like REFMAC and Quanta's X-AUTOFIT,
with extensive maximum likelihood calculations and model building applications
respectively, has only been possible because of this.
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2.7.1 R-factors
A few specific validation techniques have already been described. The conven-
tional R-factor is the most widely accepted indicator of the general quality of a
crystal structure. It is not a good independent validator, since it can be manipu-
lated by excluding data or adding parameters inappropriately. A better indication
of the fit between observed and calculated structure factors is the 'free R-factor'
(Brunger, 1992), which aids bias-free refinement by indicating overfitting. If the
free R-factor does not decrease with a decreasing conventional R-factor in a partic-
ular stage of refinement, the new parameters introduced in that stage do not give
a significantly improved model. Commonly between 5 and 10 % of diffraction data
is excluded from refinement, with a set of between 500 and 1000 reflections consid-
ered to produce reliable statistics. Non-crystallographic symmetry will affect the
discrepancy between conventional and free R-factors because of phase relationships
between reflections in the working and free sets. The expected value of the free
R-factor may be estimated as (Cruickshank, 1996):
EFRF= R (2.81)
where Nobs is the number of observations, Npar is the number of parameters and R
is the conventional R-factor.
R-factors as described above are global indicators, which can not point out
local errors. Therefore the real space R-factor has been devised (Jones et al., 1991),
which can be plotted as a function of the residues along the polypeptide chain:
R,. E IPobs - Pealel
eal "pace = '" I I
L...J pobs + Peale
(2.82)
pobs is taken from a real electron density map calculated from the model on a certain
grid G. Peale is taken from an 'artificial' electron density map calculated on the same
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grid G from a set of idealised Gaussian distribution atoms at all atomic sites in the
model, all with average temperature factors. The maps are scaled together with one
overall scale factor. A mask is determined for the desired subset of atoms (i.e. a
residue, or a side chain) on the same grid G, after which the values for pobs and pcale
for this subset may be read from the two map grids, and the R-factor calculated.
2.7.2 Estimates of coordinate precision
Luzzati plot and Cruickshank's ad
Luzzati (1952) developed the idea of plots of R'= (11F1-(II~t~F") (for centrosymmetric
structures) and R"= (11F1-il~t~FII) (for non-centrosymmetric structures) vs. sinO,
where AF is the error in structure factor F due to coordinate errors t1fj. He argued
that the crystallographic R-factor is dependent on resolution (and even on the way
the structure factors are calculated), while curves of R' and R" are independent
of those factors. They do, however, depend on the assumption that coordinate
errors t1fj are the sole cause of the difference between Fobs and Fcalc. R' and R"
are functions of D, = (cos(27rh. t1fj) (see equation 2.73) only. If t1fj = 0 then
Dj = 1 and R'=R"=O, i.e. a completely perfect structure, which would also have
the crystallographic R=O. For a completely wrong structure, where the distribution
of t1fj is constant, Dj tends to ° and R" (for acentric structures like all natural
proteins) approaches 2 -,;2. The theoretical curves for R' and R" may indicate an
upper limit to the value for t1fj.
At the Validation Workshop (Dodson, Kleywegt and Wilson, 1996) Cruick-
shank showed that the Luzzati (1952) plot per se is not an appropriate indication
of coordinate error. It is a means for estimating how far the refinement still has to
go to reach R = 0, assuming that /Fobs I has no errors, Fcalc is perfect apart from
coordinate errors and the Gaussian probability distribution for the coordinate errors
is the same for all atoms. The atoms are not required to be identical, and the errors
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are not required to be small. However, the assumption of perfection apart from
coordinate errors is not applicable. The Luzzati plot may only indicate an upper
limit for the coordinate error at the end of refinement. Cruickshank has therefore
devised a formula for estimating the expected positional error, caused by diffraction
error only, for an atom x with average temperature factor (Cruickshank, 1996):
(2.83)
where R is the conventional R-factor, N is the number of non-hydrogen atoms in
the asymmetric unit, p is the difference between the number of observations and
the number of parameters, C is the fractional completeness of the data, and dmin
is the resolution. The smaller dmin and R, the better the precision of the struc-
ture. There is a definite direct link between coordinate precision and temperature
factor (Dodson, Kleywegt and Wilson, 1996). With ever higher resolution data it
is already becoming possible to use least squares matrix inversion at the end of re-
finement to obtain estimated standard deviations for the parameters describing the
well ordered parts of the cell. This will allow testing of Cruickshank's Ud.
Luzzati, Read and REFMAC: UA
Another estimate of coordinate error is UA, which has been discussed in section 2.6.
Luzzati showed that
D, - (cos(27rh. ~rj)}
exp[ _7r3( (I~rj I))2(sinf} / ,x?l (2.84)
where () denotes average value. Thus, for UA = Dj(Ep / EN )1/2 as discussed be-
fore, InuA = pn(Ep/EN) - 7r3((I~rjl})2('i~6)2. If UA can be estimated, a plot
of InuA vs. (sinO/)..)2 will yield l~rjl2 from the slope and (Ep/EN) from the
intercept. However, like for the Luzzati plot, the UA theory assumes no errors ex-
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cept coordinate errors, so the a A-plot needs to be interpreted with care. Brunger
has shown that the cross-validated, i.e. free R-factor based, Luzzati and aA plots
correlate better with the actual coordinate errors than those based on conventional
methods (Brunger, 1996). The aA indicator is used in the calculation of several
parameters in REFMAC and thus used explicitly in the improvement of refinement.
Maximum likelihood itself is a validation technique in that it uses proper weighting
of prior and experimental information by separating errors due to a poor model from
experimental errors.
2.7.3 Stereochemistry and residue environment checks
Ramachandran plot
After experiment duplication, the best validation is by criteria that can not and/or
have not been used during the course of refinement. One of the validation tools
that is very hard to use during automatic refinement, is the Ramachandran plot
(Ramachandran et al., 1963). It is therefore a good check of the structure, and
residues in odd positions in the plot need further investigation. This does mean
that most experimenters now use the Ramachandran plot in the model building
stages of structure refinement, so that it is not a completely independent check of
the stereochemistry of the final structure. In X-AUTOFIT (Oldfield, 1996) it is now
possible to apply weak restraints so that residues will assume the Ramachandran
conformation of either a helix, a ;'1-strand, or the nearest allowed region. The default,
however, is not to apply any restraints automatically.
SQUID
SQUID displays and analyses molecular coordinates from crystallography, NMR
and molecular dynamics (Oldfield, 1992). The structure analysis consists of various
atomic checks (e.g. distance, chirality, neighbours, non-bond clashes etc.), analysis
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of local structure by packing angles, Ramachandran plot and other properties, an
overall check of weight, volume, secondary structure, hydrogen bonds and temper-
ature factors, and the possibility of comparison of all those properties with those in
other structures. The program outputs detailed warnings about errors and anoma-
lies in the structure under investigation. It provides better independent checks of
the structure through root mean square deviations of X and wangles, which are not
easily tampered with by the experimenter. The mean and spread of the distributions
of these angles have been determined from a set of reliable structures.
PRO CHECK
PROCHECK is a program to check the stereochemical quality of protein structures
(Laskowski et al., 1993). It outputs various plots and a comprehensive residue-by-
residue listing, providing an assessment of the overall quality of the structure as
compared with well refined structures of the same resolution and highlighting re-
gions which may need further investigation. It may therefore be used to follow the
process of refinement and assess the final structure, as well as in the assessment of
existing structures to be used for modeling or molecular replacement study purposes.
Multiple X-ray crystal structures as well as ensembles derived by NMR spectroscopy
can be checked simultaneously.
WHAT-IF and other geometry checking programs
WHAT-IF is a computer program originally written to aid macromolecular model-
ing and drug design (Vriend, 1990). It provides for displaying, manipulating and
analysing small molecules, proteins, nucleic acids, and their interactions, and in-
corporates access to protein structure databases for reference. WHAT-IF's protein
validation portion, called WHAT-CHECK, checks for clashes between symmetry-
related molecules, and includes the determination of a 'quality factor' assessing the
distribution of different atom types in the environment around side chain fragments.
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The expected distributions are compiled from a data set of high resolutions st.rur-
hires (Vriend and Sander, 1993).
Several smaller program packages have been specifically written for protein
structure validation. The program PAP (Callahan et al., 1990) provides several
plots of main chain geometry, and information on temperature factors. GEOl\1
(Cohen, 199:3) provides an analysis of main chain distances, angles and torsion an-
gles, and of side chain torsion angles. ERRAT (Colovos and Yeates, 199:3) analyses
the relative frequencies of non-bonded interactions between any C, Nand 0 atoms.
Because this results in the consideration of only six different pairs, the statistics are
better but the information is less specific than in the case of analysing all different
atoms specifically, as in c.g. WHAT-IF. The program SurVol (Wodak et al., 1995)
calculates for each atom in the structure the atomic volume and compares it with Cl
pre-computed average for each atom type. A scoring method was devised in which
a high score indicates uncertainty in the structure.
Folding profile methods
Determining the potential fold of a protein sequence is most often approached by
searching databases for sequences of known structure that are similar to the se-
quence under study. This only works if the sequence identity is reasonably high.
The advances of the 'tertiary template method' (Ponder and Richards, 1987) were
limited because of the rigidity of the methods employed. Eisenberg and co-workers
have devised a method which allows more flexibility, both of the backbone of tile
protein and of the spacing between particular residues (Bowie et al., 1991). Three
features determine a residue's environment:
1. the total area of the side chain buried by other protein atoms;
2. the fraction of the side chain area covered by polar atoms or water;
3. the local secondary structure. i.e. a-helix, ,B-sheet and 'other'.
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Each residue is then assigned one of 18 environment classes, converting the three-
dimensional structure to a one-dimensional string.
It is well established that each of the 20 natural amino acid types has a clear
preference for a certain environment. On the basis of well-refined three-dimensional
structures a score is assigned to the occurrence of every amino acid in each of the
18 environment classes. These scores can then be used to find the best alignment
of amino acid sequences to the one-dimensional string of the protein under study,
producing a compatibility score of the sequence with its three-dimensional structure.
Local scores may be calculated as an average over 21 residues with the residue-to-
be-scored in the centre of the 21 residue window.
Instead of stereochemical parameters, SippI (1993) uses knowledge of the forces
which stabilise proteins in solution in the analysis of the energy distribution of a
protein profile. These energy forces are obtained from well-refined structures in
the form of potentials as a function of the spatial separation of two atoms. Co-Co
pairs and Cf3-Cf3 pairs seem to work equally well, indicating that the method can be
applied if only a Co-trace is available. The atom pair interaction energy is a function
of the sequence, and the structure with the correct conformation will have a lower
energy than any alternative conformation. Since no stereochemical parameters are
used in the method, the occurrence of high energies in a particular structure is not
a consequence of violations of basic steric requirements.
2.7.4 Brookhaven Protein Data Bank
Over the last twenty years, the Brookhaven Protein Data Bank (Bernstein et al., 1977)
has grown to be a collection of protein and nucleic acid structural data from various
sources. Most scientific journals require deposition of atomic coordinates (and often
also structure factor data) at the Data Bank upon publication of articles about the
structure of proteins, nucleic acids and complexes. Although coordinate checking
software is available at the Data Bank and rigorous checks are performed, it is the
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ultimate responsibility of the experimenters to provide a reliable set of data pertain-
ing to the structure described in an article. This data may be used for molecular
replacement studies, molecular modelling studies etc., and it should be clear from
the combination of the article and the Data Bank information, what the limitations
are of the information provided.
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Chapter 3
Crystallographic studies of seven
modified insulins
3.1 Introduction to modified insulins
As described in chapter 1, several features are found in every insulin structure known
so far: the three disulfide bridges, the three turn a-helix of residues B9 to B19 and
the two small a-helices in the A chain spanning residues Al to AS and A13 to A19,
together with the short ,a-sheet structure formed in the dimer, are basic building
blocks of insulin (see figure 3.1).
The largest structural differences between insulin monomers in various crystal
forms are found in residues Bl to BS. In 2Zn insulin all six monomers in the hexamer
have B1 to B8 extended, thus exhibiting the so-called T6-state (for an explanation
of the nomenclature of insulin, see chapter 4). In the 4Zn insulin hexamer, Bl to
B8 in one of the two molecules becomes helical, giving rise to the T3R3-state. By
analogy, it is thought possible to produce a 6Zn insulin in the R6-state. Phenol
monoclinic insulin crystals can be obtained in this R6-state, but do not have the
expected six off-axial zinc sites, since these are occupied by the phenol molecules.
Crystallographic studies have been carried out on several modified insulins
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molecule I molecule 2
Figure 3.1: The insulin dimer, 4Zn native rhombohedral structure.
a) View along the local twofold axis. Disulfide bridges and dimer interface
residues B23-B28 from both molecules in thick lines;
b) View perpendicular to the local twofold axis. Disulfide bridges and
residues B23-B28 as before. B chain helices also highlighted in thick lines:
D9-D19 (molecule 1) and BI-BI9 (molecule 2).
as part of an on-going research programme into the structure of insulin in all its
aspects, partly in collaboration with Novo Nordisk A/S who supplied the protein
material. Modified insulins are studied structurally to understand for example the
conformation of specific parts of the protein, the aggregation of insulin to dimers
and hexamers, and metal binding. In the tables and text of this and the following
chapters, abbreviated names will be used for the modified insulins, according to
table 3.1.
3.1.1 B13 Glu~Gln human insulin
In 2Zn insulin, six glutamic acid residues are brought into close contact in the cen-
tre of the hexamer. Electrostatic interactions between those negatively charged
residues are unfavourable and are overcome by the zinc binding of the BID histidine
residues, by hydrogen bonds and probably by other cations (Emdin et al., 1980,
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name full description
B13Q
B9D/B27E
A21G/B9E/B10E
Col
B9H
B13 Glu-+Gln HI
B9 Ser-+Asp, B27 Thr-+Glu HI
A21 Asn-+Gly, B9 Ser-+Glu, BIO His-+Glu HI
Zn2+-+Co2+ HI with iodide
B9 Ser-» His HI
B8S/BI3Q/B30amide B8 Gly-+Ser, B13 Glu-+Gln, B30 Thr-NH2 HI
B25Y(B29-A1 )A4Q A4 Glu-+Gln, B25 Phe-+Tyr, dest B30 single chain HI
Table 3.1: Abbreviations for names of the modified insulins.
HI = human insulin; [des = deleted
Hill et al., 1991). The B13Q mutant is expected to associate specifically into hex-
amers, stabilised by hydrogen bonds between the glutamine residues in a twelve-
membered 'ring' structure in the core as proposed by Markussen et al. (1987), shown
in figure 3.2.
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Figure 3.2: The proposed 'ring' structure of B13 glutamine residues
in B13Q insulin.
Because GIn at position B13 favours the formation of helix at B1 to B8
(Bentley et al., 1992), this more stable hexamer is also expected to have under-
gone the T -+ R structural transition, especially upon binding of zinc: the zinc free,
2Zn (both studied by Xiao and co-workers (Bentley et al., 1992)) and 4Zn forms
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of the B13Q mutant should progressively prefer the R-conformation. According to
Markussen et al. (1987) B13Q has a potency relative to insulin of 0.18 in the free
fat cell assay.
3.1.2 B9 Ser~Asp/B27 Thr~Glu human insulin
Introduction of negative charges at B9 in what is the core of the 2Zn native insulin
hexamer will prevent hexamer and dimer formation. The B9 Ser-Asp mutation is
one of the most effective in reducing dimer formation at neutral pH (Brange et al.,
1988). In a dimer, two B9 residues and two B13 residues (all carboxylate groups in
the mutant) would come very close together, causing strong electrostatic repulsion
(Dodson et al., 1993), which can be alleviated by protonation and hydrogen bond-
ing. In that case the B13 Glu has an elevated pK, as determined by Kaarsholm et al.
(1990). At neutral pH the B13 Glu would be deprotonated, in which case hydrogen
bonding can not take place and the monomers can not approach each other close
enough to form dimers. Dimerisation will also be impaired by changing the interac-
tions of B27 and B28 with the termini of the A chain. The mutant is indeed found
to be monomeric at 1O-3M (Brange et al., 1988). The structure of the monoclinic
form of the mutant has been determined by J. Turkenburg (1992). In that case the
mutant forms hexamers with calcium ions bound in the core which neutralise the
B9 mutation.
3.1.3 A21 Asn~Gly IB9 Ser~Glu/B10 His-s Glu human in-
sulin
Addition of a negative charge at B9 introduces electrostatic repulsion and will pre-
vent hexamer and dimer formation as discussed in section 3.1.2. In addition, aboli-
tion of the metal binding potential at BID is expected to obliterate hexamerisation,
promoting rapid absorption after subcutaneous injection. Substitution of A21 Asn
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by Gly is expected to decrease susceptibility to deamidation and covalent dirncr for-
mation, thus stabilising the mutant in the, often acidic, therapeutic solutions. The
rate of absorption of some A21 substituted insulin mutants from the injection sit.e
appears to be virtually independent of zinc concentrations. The A21G/B9E/B10E
mutant is found to be monomeric under physiological conditions (Xiao, 1990). The
relative biological activity (mouse adipocyte assay) is 58% (N. Kaarsholm, pel's.
comm.). This value is composed of a significantly enhanced activity afforded by the
BI0 Glu substitution, a decreased activity provided by the 139 Glu mutation, and
a slightly decreased effect on activity from the A21 Gly substitution. In acid-base
tit.rations to characterise ionisation patterns of mutant insulins, it is found that car-
boxylatc groups residing close to the monomer-monomer interface have their pI\:
values perturbed upwards (Kaarsholm et al., 1990). Unfortunately, no data are
available for an acidic side chain at BlO. However, the situation will be further
complicated in that case, because of the potential for this side chain to interact
with the 139-B19 helix dipole (which would tend to lower pK) adding to t.he close
proximity of the monomer-monomer interface (which would effect an increased pK
as observed with carboxylates at B13 and B9) (N. Kaarsholm, pel's. comm.}.
3.1.4 Co2+ human insulin
Cobalt is very similar to zinc in size (ionic radii 0.72A. and 0.88A. respectively
(Weast, 1983-1984)) and chemical behaviour, and is therefore probably able to
play the same role in insulin hcxamer formation. In native insulin hexamers, zinc
is present either in octahedral conformation, when the insulin molecule is ill the
T-state, or in tetrahedral conformation, when the insulin molecule is in the H-
state. According to ligand field theory, however, tetrahedral coordination is less
favourable than octahedral coordination for d! ions like Co2+. In the presence of
iodide (and other halide ions), tetrahedral coordination is a possibility for Co2+
(Mackay and Mackay, 1981). The addition of phenol 111 the cryst.a.llisation is ex-
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pected to stabilise a-helix at BI-B8, favouring R- over T-conforlT1ation (Dorcwenda
et al., 1989), which probably forces C02+ into a tetrahedral e-nvironment. Whether a
Co2+ structure has T3R3- or R6-conformation depends OIl t Ill' phenol concentration
(Whittingham et al., 1995) and the temperature of the crystallisat.iou (de Graaff et
al., 1981).
3.1.5 B9 Ser~His human insulin
Introduction of another histidine residue into the core of the insuliu hexamcr is
expected to add to the stability by increased zinc binding. [II fact, solution studies
at pH 8 have shown the B9H mutant is capable of binding around (i zinc ions
per insulin hexamer. As it turns out, this additional stability is not sullicient to
provide a clinically relevant protracted profile following subrut.ancous illjectioll (N.
Kaarsholm, pers. comm.). This mutant could, in rhombohedral c.rysl.al form, be
an example of a 6Zn insulin in the R6-state, with six off-axial ziu« billding sites.
In order to promote T ---t R structural transition to Iacilit.at« t.l«- formation of the
R6-state, phenol was added in an attempt to obtain a differont crystal [orrn.
3.1.6 BB Gly~Ser/B13 Glu~Gln/B30 Thr-NH:l human in-
sulin
Introduction of positive charges at B13 and B30, which raises tile iso-electric point,
is expected to create insulins more soluble in acidic therapeutic solutions. At the
higher pH in the body, they would crystallise readily after injection, reslliting in
prolonged action. A charge-indifferent mutation at B8 is introduced to study the
background of the sequence invariance at that point, which might 1)(' related to
the conformation of the BS residue in the native molecule. The hydrophobicity
of the mutant is increased in comparison with native pig insulin a!'>dd('rmillcd by
HPLC chromatography (Markussen et al., 1987). This is unexpected bocause of
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the hydrophilic nature of the mutation at B8 as such. For the T-conformation of
the mutant Markussen proposes a distortion of the a-helix commencing at B7 (to
accommodate an L-Ser residue rather than a Gly with D-amino acid Ramachan-
dran angles as in the native molecule (Baker et al., 1988)), which might expose
hydrophobic side chains. The glycine at B8 in native insulin in the R-conformation,
however, has Ramachandran angles as expected for an a-helix. The introduction of
serine in that position might in this conformation not have such a significant effect
on the helix. Phenol should stabilise a-helix at B1-B8, like in monoclinic native
insulin (Derewenda et al., 1989).
3.1. 7 A4 Glu---+Gln/B25 Phe-s Tyr / des B30 single chain hu-
man insulin
A4 Glu is involved in protamine binding, which retards the uptake of insulin in the
bloodstream and is used in some therapeutic mixtures (J. Brange, pers. comm.).
Changing this residue from a negatively charged polar Glu to a neutral GIn is ex-
pected to reduce repulsion within the hexamer and generate more effective associ-
ation. This mutation has a profound effect on the position of B25 (Holden, 1991)
and its interaction with A19 Tyr (Xiao, 1990), which for the 2Zn native molecule
is shown in figure 3.3. The interaction between B25 and A19 in T-conformation
insulin is one of the few hydrogen bond interactions between the two chains, and
thus naturally was thought to be important for the stability of the molecule.
Des B30 insulins have biological activities very similar to full length insulins
(Baker et al., 1988). However, introduction of a peptide link, causes nearly com-
plete abolition of activity (Derewenda et al., 1991), attributed to the rigidity of
the molecule, and therefore the impossibility to achieve the conformational change
probably required for binding to the receptor. B25Y(B29-Al )A4Q is a single chain
precursor for an insulin analogue designed for the study of the influence of the bio-
logical activity of amino acid substitutions at position B25. The B25Y(B29-A1)A4Q
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Figure 3.3: The interaction of B25 with A19 in 2Zn native insulin.
B25 and A19 residues from both molecules highlighted in thick lines.
Distances in A.
mutant is found to react only very slowly with trypsin at the B29 Lys residue, while
this reaction is a key step in the final preparation of the desired insulin analogue (P.
Balschmidt, pers. comm.).
3.2 Crystallisation of the modified insulins
The routines for insulin crystallisation in various crystal forms had become well
established by 1975 (Cutfield, 1975). These routines were reviewed by Tolley (1987)
and improved and adapted by Xiao (1990). The present standard routines for the
various crystal forms of native insulin can be found in table 3.2.
Most of the insulins described in this thesis have been crystallised by batch
method by various people. The actual conditions employed in the crystallisation of
the insulins by batch method can be found in table 3.3. Two mutants have been
crystallised by vapour diffusion with the following protocols (both by J. Clarkson):
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rhombohedral monoclinic, orthorhombic] cubic]
2Znt 4Zn:):
additive
insulin 6 mg/rnl 4 mg/rnl 10 mg 3-6 mg 5 mg/ml
0.02M HCI 2.5 ml 1.0 ml 2.0 ml
0.05M HCI 0.5 ml
0.005M H2SO4 1.0 ml
ZnAc 10 mg
0.15M ZnAc 0.15 ml
0.12M ZnAc 0.1 ml
0.05M Na2S04 1.0 ml
acetone 1.0 ml 0.3 ml
0.2M Najcitrate 1.25 ml 0.5 ml 0.5 ml
0.82M NaCI in 0.0136M EDTA 0.88 1111
5%aq phenol 0.4 ml
phenol, m-cresol or xylene 0.3%
salt§ 9% :S 120 mg
H2O 0.25 ml
pH 6.5 6.2 6.5 - 7.8 2.4 - 3.7 9.3
Table 3.2: Standard routines for crystallisation of insulin in various crystal
forms. Adapted from Tolley (1987) and Xiao (1990).
[from Xiao (1990); [from Tolley (1987) with adaptations by Xiao (1990);
~from Tolley(1987); §NaCI, NaBr, NaI or NaSCN
B13Q A21G/B9E/BIOE B8S/BI3Q/B30arrllde Col B9H -1 B9H -2
insulin 4 mgj'ml 4mg 3mg 75 mg zinc free 4.8 mg 3.27 mg
HCI 0.52 ml 0.02M 0.4 m! 0.02M 10 m! 0.02M 560 t-tl 0.02M 600 III 0.02M
NaCI 9% 12 mg 61.0 mg 20.9 mg
NaI 450 mg
Na3cit 0.04M 0.25 ml 0.2M 100 III 0.2M 2.5 m! 0.2M 250 III 0.2M 160 III 0.2M
acetone 16% v/v 0.2 ml
ethanol 200 III
ZnAc2 7.5mM 10 t-t1(lOOmg/ml) 20 t-tl 0.2M 1.7 mg 30 t-tl 0.I5M
COAC2 0.5 ml 0.12M
phenol 80 III 5%aq 2.0 ml 5%aq 130 III 5%aq
pH 6.4 6.57 6.60 6.29 7.43 7.27
temp (QC) 65 20 55 55 55 51
result+ rh or mc rh rh mc
Table 3.3: Crystallisation protocols of the batch crystallisation of five modified
insulins, one of which in two different crystal forms.
[resulting crystal form: rh=rhombohedral; or=orthorhombic; me=monoclinic
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1. B9D /B27E:
• Add 10 mg insulin to 200 pI 0.02 M HCl and 8 pI 0.5 M NaOH. The
mixture precipitates. Store in refrigerator for 72 hours;
• Add 100 pI 0.02 M HCl to partly dissolve the protein. Centrifuge and
use supernatant for crystallisation by vapour diffusion in hanging drop.
Store surplus supernatant in refrigerator for 24 hours;
• Supernatant precipitates. Warm up (45°C) to partly dissolve the pro-
tein. Centrifuge and use supernatant for crystallisation by vapour diffu-
sion in hanging drop. The reservoir solution contained 1 ml 0.02 M cit-
rate/phosphate buffer pH6. The drop solution contained 4 pI of
buffer/protein solution in a 40:60 ratio. This protocol resulted in or-
thorhombic crystals suitable for diffraction experiments.
2. B25Y(B29-A1)A4Q: The reservoir solution was made up of 995 pI 0.02 M
citrate/phosphate buffer pH6 and 5 pI saturated ammonium sulphate. The
drops contained 5pl of a solution of 9.9 mg insulin in 200 pI 0.02 M HC!. This
protocol resulted in cubic crystals under a brown skin, due to the impurities
in the insulin preparation. However, crystallisation attempts after purification
failed. Careful analysis of the original insulin preparation by Novo Nordisk
A/S revealed the presence of 0.25 zinc ion per monomer insulin (P. Balschmidt,
pers. comm.), which would have been removed by the purification steps. Zinc
was obviously a necessity in the successful crystallisation of the mutant.
Further crystallisation experiments include:
• The batch crystallisation of B8S/B13Q/B30amide in cubic crystal form in
order to study the conformation of B8 without the constraints of metal binding
and hexamerisation. The crystals obtained were unsuitable for diffraction
experiments;
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• The batch crystallisation of B9H in rhombohedral crystal form in the presence
of glycerol instead of ethanol. This would facilitate cryocrystallographic exper-
iments. Crystals of rhombohedral B9H grown under the standard conditions
(see table 3.3) deteriorated quickly upon addition of the cryoprotectant. Crys-
tallisation experiments under the new conditions were unsuccessful. Brange
and others (see Brange, 1987) have observed that the addition of glycerol to
a neutral solution of insulin impairs the chemical stability of insulin. Glyc-
erol is, however, also used as an isotonic agent in some pharmaceutical insulin
preparations;
• In a separate attempt to obtain B9H crystals suitable for cryocrystallographic
experiments, a cryoprotectant solution was made with all the constituents of
the standard mother liquor apart from insulin, and 1,2-ethanediol instead of
ethanol to function as cryoprotectant. 346 fil aliquots of a standard solution
containing 1250 fil 0.2M Na3Cit, 8.3 mg ZnAc2, 304.5 mg NaCl, 85 fil 1M
NaOH, 35fil 1M HCI and 280 fil 0.2M HCl, mimicking the original crystalli-
sation solution, were subsequently diluted with varying amounts of ethanediol
and water in order to obtain a suitable cryoprotectant solution. Crystals from
the original rhombohedral crystallisation were submerged in a solution with
30% cryoprotectant, to check their viability in solutions with ethanediol. The
crystals did not change noticeably over a period of 24 hours. The 30% cry-
oprotectant solution was tested separately for glassy appearance upon flash-
freezing, and was found to be unsuitable. However, a 40% ethanediol solution
froze satisfactorily. The crystals in the 30% solution were taken to the syn-
chrotron at Daresbury (UK), where the solution was replaced with the 40%
solution, after which the crystals proved suitable for data collection.
J. Clarkson has attempted to obtain fresh crystals of A21G/B9E/B27E and
B25Y(B29-A1 )A4Q for data collection at cryogenic temperatures, without success.
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insulin source] detector! temp' processed with reso (A)
B13Q rot.an. Xen RT Xengen 1.9
B9D/B27E rot.an. Xen RT XDS 2.3
A21G/B9E/BI0E -1 rot.an. Rigaku RT teXsan 2.8
A21G/B9E/BI0E -2 rot.an. Xen cryo XDS 2.3
B25Y(B29-Al)A4Q DL 9.6 (0.89A) Raxis RT MOSFLM/DENZO 2.8
B8S/B 13Q/B30amide rot.an. Raxis RT RDPS§ 2.1
Col rot.an. Xen RT XDS 1.9
B9H rhombohedral-l rot.an. Xen RT XDS 2.0
B9H rhombohedral -2 DL 9.6 (0.89A) Mar cryo DENZO 1.9
B9H monoclinic rot.an. Raxis RT DENZO 2.1
Table 3.4: Data collection information.
[rot.an. = rotating anode; DL = Daresbury Laboratory
tXen = Xentronics Area Detector; Raxis = R-AXIS IIC Imaging
Plate;
Rigaku = Rigaku AFC5 Diffractometer; Mar = MarResearch Imaging
Plate
~RT = room temperature; cryo = cryogenic temperature, 120K
§RDPS = R-AXIS IIC Data Processing Software for VAX worksta-
tions.
3.3 Data collection and processing
Data were collected by various people on various sources and detectors, according to
availability of apparatus and requirements of individual projects. The information
pertaining to data collection protocols is shown in table 3.4. Statistics of the data
used for refinement, are given in table 3.5.
3.4 Structure Determination
The first structure of the insulin molecule has been known since 1969 (Adams et al.,
1969). Isomorphous replacement studies of modified insulin are, therefore, normally
unnecessary. For modified insulins which seem isomorphous with 2Zn insulin or one
of the other forms of insulin determined so far, structure determination and refine-
ment starts with the calculation of Fourier maps with the phases of the isomorph.
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l/sigl Rmerge
813Q ~3 at 2.2A 15.77% at 2.4A. 31.92% at 2.18A
Col 88% >3 at 1.9A 21.4% at 1.88A
89H-rht 3.67 in highest bin (1.92A) 22.6% in highest bin
89H-m4 72.0% >3 in highest bin (2.1A) 21.1 % in highest bin
88S/813Q/830anlide 2.93 between 2.25 and 2.06A 5.59% at 2.oA
89D/827E - -
825Y(829-Al )A4Q 70.1% >3 at 2.8A 7.2% overall
A21G/89E/81OE - -
completeness comments
813Q 84% at 2.284A
Col 91.9% at 1.996A. 65.2% at 1.88A
89H-rh 94.7% in highest bin
89H-mc 99.7% in highest bin
88S/813Q/830arrlide 92.8% between 2.25 and 2.06A
89D/827E - not retrievable
B25Y(B29-Al)A4Q 81.9% at 2.8A
A21G/B9E/BI0E - complete to 3.6A. strong terms to 2.8A
Table 3.5: Data statistics for the data sets used in the refinements.
Regarding structures described in this thesis, this was possible in most cases, namely
BI3Q, B9D/B27E, B8S/BI3Q/B30amide, Col, and both crystal forms of B9H. Cell
constants, space group and isomorphous R are given in table 3.6 for the modified
insulins studied, with the appropriate information for native structures for compar-
ison.
The remaining structures, namely A21G/B9E/BI0E and B25Y(B29-Al)A4Q,
required complete molecular replacement studies to produce a starting model for
refinement. In order to study the symmetry of the aggregation of all eight different
structures, self-rotation functions were calculated.
3.4.1 Molecular replacement
B9 Ser-tAsp/B27 Thr-o Glu human insulin
The molecular replacement studies of B9D /B27E only served to establish the iso-
morphism of the mutant with orthorhombic native pig insulin. At first, the data
were indexed in a cell with a=37.99A, b=51.54A, c=57.90A. A rotational search in
AMoRe with an orthorhombic native dimer (,Bmax=900) resulted in a set of 15 peaks
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structure" space group cell conetants]' Z't R.. o isomorph
2Zn native R3 a-b-82.500,c-34.000 2 - -
(pig) a=,6=90,"'1=120
4Zn native R3 a=b=80. 700,c=37 .600 2 - -
(pig) a=,6=90,"'1=120
monoclinic native P21 a=61.230,b=61.650,c=48.050 6 - -
(human) a="'I=90,.6=110.50
orthorhombic native P212121 a=57 .979,b=51.534 ,c=38.003 2 - -
(pig) a=,6="'1=90
cubic native 1213 a=b=c=78.900 1 - -
(pig) 0<=.6="'1=90
B13Q R3 a-b-80.815,c_37.591 2 0.166 4Zn native
a=.6=90,"'1=120
B9D/B27E P212121 a=57.90,b=51.54,c=37.99 2 0.452 orthorhombic native
0<={3="'I=90
A2IG/B9E/BIOE P212121 a=46.29,b=51.69,c=44.38 2 0.581§ not isomorphous
a={3="'1=90
B25Y(B29-Al )A4Q P4232 a=b=c=66.78 1 N/AlI not isomorphous'
0<=.6="'1=90
B8S/BI3Q/B30amide P21 a=60.91,b=62.04,c=47.88 6 0.192 monoclinic native
0<="'1=90,.6=110.48
Col R3 a=b=80.48,c=37.92 2 0.208 4Zn native
a=.6=90,"'1=120
B9H rhRT R3 a=b=80.79,c=37.47 2 0.261 4Zn native
a=.6=90,"'1=120
89H rhF R3 a=b=79.878,c=37.427 2 0.289 4Zn native
a=,8=90,"'1=120
B9Hmc P21 a=61.14,b=62.09,c=48.08 6 0.160 monoclinic native
0<="Y-9O,{3=110.43
Table 3.6: Crystallographic information of native and modified in-
sulins.
* rhRT = rhombohedral form, room temperature data collection; rhF
= rhombohedral form, data collection at 120K; me = monoclinic form;
t a, band c in A; Q, f3 and, in 0;
t Z' is the number of molecules in the asymmetric unit;
§ isomorphous R-factor based on orthorhombic native pig insulin
structure;
, B25Y(B29-A1)A4Q is presumably isomorphous with rat insulin II
and insulin from the snake Zaocys dhumnades dhumnades Cantor
which have been reported to crystallise in P4232 with similar cell con-
stants (Wood et al., 1978, and Liang et al., 1984, respectively), but
no coordinates are available for insulin in this space group.
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with a correlation coefficient larger than half of that of the first peale The first four
peaks are given in table 3.7.
solution a {3 , cc
1 55.81 84.94 295.26 35.5
2 72.58 59.53 242.83 34.1
:3 124.35 90.00 115.29 32.0
4 158.16 38.73 285.12 28.3
Table 3.7: Rotation function solutions for B9D /B27E. cc = correlation
coefficient; a,{3" are Eulerian angles within the ..U1oRf' conventions.
solution a {3 'Y ix iy iz cc R
1-1 55.81 84.94 295.26 0.0395 0.2180 0.3007 56.2 4l.4
1-2 .55.81 84.94 295.26 0.0387 0.2851 0.2976 36.0 49.0
2-1 72.58 59.53 242.83 0.4607 0.2829 0.2998 59.1 40.5
2-2 72.58 59.53 242.83 0.4614 0.2196 0.3010 39.5 48.4
3-1 124.35 90.00 115.29 0.4569 0.2172 0.2016 57.2 11.'1
3-2 124.35 90.00 115.29 0.4562 0.2175 0.2829 36.3 49.0
4-1 158.16 38.73 285.12 0.1567 0.3133 0.3423 18.4 55.2
4-2 158.16 38.73 285.12 0.0927 0.2279 0.3673 16.2 56.2
Table 3.8: Translation function solutions for B9D/B27E. ix,ty,iz are frac-
tional translations; R = R-factor. Note that the translations for peak 1-J
and 3-1 are the same, apart from whole and half unit cell translations.
The translation search revealed the true nature of these four peaks, shown in
table 3.8, each along with their second best translations. The rigid-body refinement
clarified them even further, after which the three best solutions, transformed so as
to act on the input coordinates, are as follows:
solution a {3 , ix ty i:; cc R
1 359.25 91.92 359.26 -9.77 -12.07 15.13 n.6 35.2
2 180.76 88.07 179.26 28.77 -12.07 1:3.81 73.6 35.2
3 3S8.43 33.40 0.67 13.S1 -8.78 6.53 69.0 ;3~)']
lOS
The first solution indicates identity with just a rotation of 90° around the y-
axis, which would put the x-axis along -z and the z-axis along +x. This effect can
also be achieved by reindexing (h,k,l to f,-k,h), which at the same time transforms
the unit cell constants in such a way that they resemble closely the orthorhombic
native pig insulin cell constants (see table ;3.6). AMoU( confirms the validity of
reindexing, changing solution 1 to
a
337.41
{3 ,
1.98 21.88
tx
83.63
ty
37.68
cc
72.2
When {3=0, only the sum of a + , is relevant, gIvIng til!' total rotational
component of the transformation of the model molecule into the unknown cell (this
is a well-known property of Euler angles). Hence in this case identity is achieved
by rotating 360°(337.41 + 21.88) around the z-axis. Thus after reindexing the
B9D/B27E mutant is isomorphous, judged from the cell constants and the molecular
replacement, although the Riso is 0.452. Upon careful comparison of the mutant data
with the orthorhombic native data, the relatively high value of Riso can be traced
back to a small percentage of the data. According to SCALEIT (CCP4 suite, 1994),
only 17 out of the 4548 reflections from the mutant data set have a large difference
as compared with those in the native data set, which incidentally was collected on
the same instrument.
The direction cosines of the non-crystallographic twofold axis of the refined
dimer as determined by overlapping the two monomers, correspond to angles of
around (30,90,120), i.e. this axis lies in the zz-plane, 30° away from the positive
x-axis and 120° away from the positive z-axis, The self-rotation function for the
B9D/B27E mutant shows peaks at 37.9% of the maximum height with polar angles
(w, <p, 11:)=(119.5,0,180), which correspond to the same direction cosines as mentioned
before: 0.8703, 0.0000, -0.4925.
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A21 Asn-s Gly /B9 Ser----+Glu/BI0 His----+Glu human insulin
For mutant A21G/B9E/B10E, the cell constants do not resemble those of any known
insulin structure, indicating non-isomorphism. In addition, the Rjso is 0.581, against
the data of the first choice of isomorph, namely native orthorhombic insulin. The
cell volume of the mutant is 6.5% smaller than that of orthorhombic native insulin,
indicating the same protein content in slightly closer packing. Molecular replacement
studies were done with molecule 2 (chains A and B) from the orthorhombic native
dimer as a search model. One peak in the rotation function stood out with a
correlation coefficient (cc) of 23.2, where subsequent peaks are 20.9, 19.7, 19.4 etc.
The highest 50 peaks of the rotation function were then used in a translation search.
The highest peak was very clear, with cc=24.4 and R=51.7, with its second best
translation also the second highest peak overall (cc=14.8 and R=54.5). The highest
peak was fixed in a translation search for a second monomer, using the next 17
highest peaks from the first translation function (with their translations reset to
zero). A second peak was found with a high correlation coefficient (47.1, whereas no
other peak was higher than 25.1), with a translation of roughly O'!,!) compared
to the first monomer:
fixed monomer
output highest peak
ll' f3 I tx ty tz cc R
131.03 57.42 21.74 0.07349 0.38596 0.07461 24.4 51.7
131.03 57.42 21.74 0.57351 0.89027 0.57500 47.1 61.9
Rigid body fitting of these two peaks improved the solution considerably:
cc=70A and R=38.1 for the two monomers together, and rotations and translations
were as follows (internal AMoRe format):
et f3 'Y tx ty tz cc R
132.04 56.25 25.43 0.06372 0.38815 0.05983 70.4 38.1
139.49 53.72 16.82 0.58117 0.91045 0.57870 70.4 38.1
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These monomers are clearly related by a translation of (t, t, t) and a small
rotation, and thus can not form a dimer directly. The possibility of a symmetry
equivalent of one of the monomers complementing the other monomer in dimer for-
mation was investigated. This would necessitate the non-crystallographic twofold
axis of the dimer to be parallel to one of the 2} screw axes of the space group
symmetry. In order to double-check this interpretation, the molecular replacement
calculations were repeated with a full orthorhombic dimer as a model. The correla-
tion coefficient of the first peak in the rotation function is distinctly higher than any
of the others: 30.2 with the subsequent peaks at 20.9, 20.8, 20.8, 19.3 etc. After the
translation function the result is unambiguous: cc=46.0, R=52.0 for the first peak,
with cc=14.6, R=54.9 for the second best peak. The highest peak refines to (shifted
solution)
Q
176.47
(3
29.68
I
184.16
tx
85.15
ty
107.73
tz
19.95
cc
67.3
R
41.2
Investigation of the non-crystallographic symmetry of the refined dimer by
overlapping one monomer on the other, produces direction cosines (0.99932, -0.00497,
0.03672), corresponding to angles of almost (0,90,90). This means the non-
crystallographic twofold axis is indeed parallel to the x-axis and thus to a 21 screw
axis. The self-rotation confirms the presence of twofold axes (20.7% of the height of
the origin peak) almost along the cell axes, with direction cosines (0.9890, 0.1478,
0.0000).
A4 Glu-+Gln, B25 Phe-e Tyr, des B30 single chain human insulin
Two insulins have been crystallised in space group P4232, like mutant B25Y(B29-
Al )A4Q, namely rat insulin II and insulin from an Asian snake. Both have cell
constants very similar to those of the mutant. Atomic coordinates, however, are not
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available. The relatively high solvent content of the rat insulin crystals rendered
them unsuitable for data collection (Wood et al., 1978). The study of the snake
insulin in China was stopped because the supply of the protein was insufficient
(Liang D.C., pers. comm.). The sequences of the three insulins are compared in
table 3.9. The snake insulin has two significant changes: B2 is proline instead of
valine, which puts some restrictions on the conformation of the chain N-terminus,
and B5 is arginine instead of histidine, which will prevent alternative zinc binding.
Molecular replacement studies were done with a variety of models: monomers
from various crystal forms (2Zn rhombohedral, 4Zn rhombohedral, cubic), dimers
and hexamers, either complete or trimmed to the most rigid core by removing chain
termini. The most successful model is a 2Zn rhombohedral dimer, with Bl-7 removed
from both B chains. Hexameric models were mainly used to check the solution and
the packing. The rotation function does not show many features. The highest peak
has a correlation coefficient of 34.3, and 20 other peaks have a correlation coefficient
higher than half that. In the translation function the 20th rotation function peak
(which had a cc of 22.1) is clearly the highest with cc=46.2 and R=46.1:
Q f3
47.90 90.00
I
278.79
tx
0.1010
ty
0.5998
t; cc R
0.2476 46.2 46.1
The mutant has one molecule in the asymmetric unit and from packing studies
of the dimer solution it was clear that molecule 1 was nearest to the correct solution
for the mutant structure. Rigid body fitting was performed on both of the monomers
separately. The refined solutions are
Q
47.53
48.04
f3
89.79
91.41
I
278.53
279.46
tx
0.1045
0.1108
ty
0.6010
0.5936
tz
0.2509
0.2529
cc
52.8
52.8
R
44.3
44.3
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position mutant! rat IF snake" occurrence in nature'!
A4 Gin Asp Glu Glu highly conserved,
alternative mainly Asp
A8 Thr Thr Glu mainly Thr (mammals) and His (fish),
Glu in some reptiles and birds
A9 Ser Ser Asn mainly Ser in mammals,
Asn in most reptiles and birds
AlO lie lie Thr mainly lie (mammals) and Phe (fish),
but Thr common in reptiles, amphibians and birds
A15 Gin Gin Glu Gin conserved in mammals,
mainly Asp and Asn elsewhere, Glu uncommon
Bl Phe Phe Ala mainly Phe in mammals,
but Ala very common in reptiles, birds and fish
B2 Val Val Pro mainly Val (mammals) or Ala elsewhere,
but Pro not uncommon in reptiles and fish
B3 Asn Lys Asn mainly Asn in mammals, birds, reptiles and amphibians,
Lys only in mouse and rat
B5 His His Arg His highly conserved with Arg as only alternative,
all over nature
B16 Tyr Tyr Phe Tyr highly conserved;
Phe only seen in snakes
B18 Val Val lie Val highly conserved;
lIe only seen in snakes, Ala in hagfish
B27 Thr Thr Ser mainly Thr (mammals) and Asn (fish),
but Ser common in reptiles and birds
B29 Lys Met Arg Lys highly conserved, Arg only seen in snakes,
Met only in some rodents
B30 - Ser Thr Thr common in mammals, birds and reptiles;
Ser and Ala also common
Table 3.9: Sequence differences between three insulins in space group
P4232.
1 insulin mutant B25Y(B29-A1)A4Qj
2 insulin type II from rat;
3 insulin from the Asian snake Zaocys dhumnades dhumnades Cantor;
4 from Derewenda (1990)
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The second solution was then applied to a complete molecule 1 from the 2Zn
native insulin dimer in the correct cell. The space group symmetry (see figure 3.4)
causes six monomers to come together in a T6 hexamer of 32 symmetry.
-8--G-
-l' ~
cb cb
r I r9 9
~ ?
-8--G-
t
Figure 3.4: Symmetry of space group P4232. Reproduced from the
International Tables Volume C (Wilson, 1992).
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3.4.2 More self-rotations
B13 Glu---+Gln human insulin
The self-rotation function of the B13Q mutant (space group R3) shows 60° repeats
of two sets of non-crystallographic twofold axes (see figure 3.5). The most prominent
set has peaks of 26.4% of the height of the origin peak, at (w,<p)=(90,(12+n.60)) with
n=0,1,,,.,5. The second set has slightly lower height (22.7%) at (w,<p)=(90,(44+n.60)).
These twofold axes confirm the approximate 32 symmetry of th hexamer. The hex-
amer is built up of three exact dimers around the threefold axis of the space group,
which is along the z-axis. The dimers' non-crystallographic twofold axes are per-
pendicular to the crystallographic threefold axis, and thus lie in the xy-plane.
1BO 0
000
Figure 3.5: Self-rotation function of mutant B13Q; section ~=180°.
w runs from 0 to 900 from the centre to the perimeter, <p runs from 0
to 3600 around the perimeter.
Zn2+ ---+Co2+ human insulin
The the self-rotation functions of the isomorphous Col and B13Q insulins, both
rhombohedral structures in T3R3-conformation, are very similar, as expected. The
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only significant differences are the order and peak height of the peaks for the twofold
symmetry. In Col insulin the most prominent set of twofold peaks (see previous
section) has a height of 23.5% and ¢>-anglesof (44+n.60)0 with n=O,1, ... ,5, while the
second set has a height of 22.5% and ¢>-angles of (12+n.60)0.
B9 Ser-e-His human insulin, rhombohedral form
The B9H mutant in the rhombohedral form is isomorphous with both Col and B13Q
insulin, and therefore has similar self-rotation patterns. The set of twofold peaks
with ¢>-angles of (44+n.60)0 has a peak height of 35.5%, the set with ¢>=(12+n.60)0
has a peak height of 33.5%.
B9 Ser-e-His human insulin, monoclinic form
1)0,0
lBO,Q
~
c·~.~0Q<>I>'0
~
~
-90,0a) b)
Figure 3.6: Self-rotation function of mutant B9H in monoclinic form; section
1>:=180°. For wand ¢>see legend of figure 3.5. Arrow indicates the direction of
the threefold axis perpendicular to one set of twofold axes.
a) orthogonalisation such that the monoclinic axis b is along z, perpendicularly
out of the plane of the paper, with a and c* in the plane of the paper, as indicated;
b) orthogonalisation such that c* is perpendicularly out of the plane of the paper,
with a and b along x and y, respectively, as indicated.
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The asymmetric unit of the B9H mutant in the monoclinic form contains a full
R6 hexamer, for which the non-crystallographic twofold and threefold symmetry
is expected to show clearly in a self-rotation. The non-crystallographic twofold
symmetry is quite strong (figure 3.6a and b). The highest non-crystallographic peak
on section ,,;=180° has a height of 49.7% of the origin peak, with (w,¢)=(90,110.4) in
figure a and (90,0) in figure b. This peak indicates a twofold axis along the crystal
a-axis, and shows the monoclinic angle of 110.4°(figure 3.6a). This axis is one of the
non-crystallographic dimer axes, or rather its symmetry-equivalent, which is along
the reciprocal c-axis. The other two dimer axes are in more general positions in the
self-rotation (see figure 3.6b). The heights of the peaks are indicated.
(~
36.4
36.2 35.7
if. 00
OJ
b)a) 900
Figure 3.7: Self-rotation function of mutant B9H in monoclinic form; section
,,;=120°. For wand ¢ see legend of figure 3.5. For further information see
legend of figure 3.6.
The non-crystallographic threefold symmetry of the hexamer is shown in figure
3.7a and b. The full symmetry of the insulin hexamer is 32, as revealed by the
combination of three twofold axes roughly perpendicular to a thr efold axis in the
direction indicated by arrows in figures 3.6b and 3.7b. In the present mutant, like in
native monoclinic insulin, this local threefold axis is perpendicular to the reciprocal
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c-axis, There is a peak for rotation of dimer 1 onto dimer 2, and one for dirncr
onto dimer 3, and two more peaks because of the space group symmetry.
Additional threefold symmetry is featuring on the section K=120°, with addi-
tional roughly appropriately spaced twofold axes on section fi:=1800at roughly 90°1.0
the threefold axes, indicated by dashed lines in figure 3.6b. The thick dashed line
combines with the higher peak (36.2% of the origin peak) on the left 011 LlIC 0-180
meridian in figure 3.7b, revealing additional 32 symmetry; the actual If-angle of this
peak is 121.4°. The thin dashed line combines with the lower peak (35.7%) on the
right; the actual x-angle of this peak is 110.9°. This :32 symmetry is slightly artificial,
since it involves translational symmetry from the space group 21 screw axis, and is
therefore difficult, to confirm with packing diagrams. A dirner from one hcxamer will
be rotated onto another dimer in another hexamer. The angles between the twofold
and threefold axes are shown in tables 3.10 and 3.11.
twofold axis angle with twofold axis peak numher (0)
peak number 1 2 3 4 5 6 7 8 9 10
1 X 82.78 118.34 95.80 60.33 61.41 141.69 38.15 6i.,la G7.'!3
2 82.78 X 58.60 121.14 57.23 58.64 46.22 133.78 60.71 so.n
3 118.34 58.60 X 87.92 58.79 57.39 46.09 133.91 119.30 119.30
" 95.80 121.14 87.92 X 64.12 62.57 133.65 46.35 124.59 124.595 60.:33 ,57.23 58.79 64.12 X 2.35 90.00 90.00 88.78 88.78
6 (11.'11 58.64 57.39 62.57 2.35 X 90.00 90.00 91.22 91.22
7 141.mJ 46.22 46.09 133.65 90.00 90.00 X 180.00 90.00 90.00
8 38.1;' 133.78 133.91 46.35 90.00 90.00 180.00 X 90.00 90.00
9 67.'13 60.71 119.30 124.59 88.78 91.22 90.00 90.00 X 180.00
10 67.4:~ 60.71 119.30 124.,59 88.78 91.22 90.00 90.00 180.00 X
Table 3.10: Angles between twofold axes in B9H monoclinic insulin
B8 Gly~Ser, B13 Glu-s Gln, B30 Thr-Nfl , human insulin
Since the B9H and B8S/B13Q/B30amide mutants in the monoclinic crystal form
are isomorphous, the self-rotation functions are very similar. Section h:=180oshows
the monoclinic angle of 110.5, sufficiently different from the monoclinic angle of
B9H insulin to be distinguishable in the peak list of the self-rotation function. The
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threefold axis peak number _ 1 2 3 4 5 6
twofold axis peak number 1
1 78.08 - - 102.3:3 91.68 -
2 - 90.24 89.66 - - 89.83
3 90.40 - - 89.70 - 90.00
4 - 89.87 90.09 - 90.51 -
5 87.55 - - 92.60 - -
6 - 87.40 92.45 - - -
9 - - - - 90.00 90.00
Table 3.11: Angles between twofold axes and threefold axes in 8gB
monoclinic insulin. Only combinations of :32 symmetry tabulated.
peak height for this non-crystallographic symmetry element is 4:l.5%. The non-
crystallographic threefold axis lies perpendicular to the z-axis and has a peak height
of 32.6%.
3.5 Refinement
3.5.1 B13 Glu---+Gln human insulin
Refinement of B13Q started with the calculation of (2}~b., - ['~alc) and (}~bs - Fcalc)
maps with the magnitudes from the mutant and the phases fro III the 4Zn native
rhombohedral insulin structure. When more highly refined coordinates became
available for the native structure, the refinement of the mutant was re-initiated,
using some of the knowledge acquired in the previous attempt. An overview of the
refinement of B13Q is shown in figure 3.8.
The preliminary refinement attempt indicated that the zinc ion on the axis in
molecule 2 is absent and should be removed at the beginning of refinement. Residue
B13 was changed from Glu to GIn. The first refinement, starting from an R-factor
of 0.264, consisted of an X-PLOR protocol with full heat. stage, and resetting of
temperature factors for the main chain between 10 and 25A2, and for the side chains
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Figure 3.8: Overview of R-factor during refinement of B13Q insulin.
*: manual rebuild, including water; then PROLSQ refinement of coordinates
when the R-factor is >0.25, refinement of coordinates and temperature fac-
tors at lower R-factors;
#: adapting the matrix value for X-ray relative to geometry contribution
between cycles of PROLSQ refinement;
=: resetting temperature factors prior to PROLSQ refinement (see *);
B1: first indication of the need for swapping the positions of B1/B2 main
chain (molecule 2) and B3 side chain;
B2: B1-B3 (molecule 2) satisfactorily refined to new positions;
!: changing the appropriate waters to chloride ligands for the zinc ions;
P: PROCHECK used to aid rebuilding for the first time;
R: changing from using resolution limits 10-1.9A to 10-2.3A in PROLSQ
refinement;
+: ARP refinement of water structure, incorporating PROLSQ;
D: investigating disorder at B13 (molecule 1).
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between 10 and 30;\2• The maps then confirmed the absence of the axial zinc in
molecule 2. Spikes upwards in figure 3.8 are commonly caused by manual rebuilding
of the structure with FROnO, after which least-squares refinement was performed
using PROLSQ. In the initial stages, at R-factors higher than around 0.25, only
atomic coordinates were refined, while at lower R-factors temperature factors were
allowed to refine isotropically. Temperature factors were reset at various stages to
free the refinement from local minima. The restraints on geometry were adjusted
by adapting the relative weight of the contribution of the X-ray data.
At stage Bl (see figure 3.8) it became clear that the N-terminus of the B chain
of molecule 2 was poorly defined, after which many omit maps were calculated (by
setting the occupancy of appropriate atoms to zero and performing a few cycles
of refinement with the reciprocal space refinement program used at the time) and
rebuilding was attempted. The introduction of information from PROCHECK dur-
ing the rebuilding stages made the spikes upwards smaller on the whole, indicating
more geometrically acceptable changes so that less refinement of the geometry was
required by PROLSQ. The highest resolution data were not as good and complete as
originally assumed, leading to the change in resolution limits at point R. Refinement
of the water structure was made easier and more successful when the automatic re-
finement program ARP (Lamzin and Wilson, 1992) became available. Refinement
of the disorder at B13 (molecule 1) was approached in separate concurrent refine-
ment runs: in run A one conformation of the side chain was included with water in
the remaining electron density, in run B vice versa.
The final R-factor for all data between 25.65 and 2.3;\ resolution is 0.182. For
restraint and geometry information, see table 3.13 at the end of this section.
3.5.2 Zn2+ --+Co2+ human insulin
The starting model for refinement of Col insulin was the native rhombohedral zinc
insulin molecule in T3R3-conformation. Preliminary investigations of the modified
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molecule indicated the presence of two metal ions on the threefold rhombohedral
axis, and a phenol molecule in the position resembling that found in monoclinic
structures in the R6-state (Derewenda et al., 1989), which in the native rhombohe-
dral T3R3-structure is roughly where the off-axial zinc is situated. An overview of
the refinement procedure is shown in figure 3.9.
The first step consisted of rigid body refinement of the protein component of
the molecule in X-PLOR, where the dimer model was refined as a whole rigid body
first, after which it was split up into monomers. Figure 3.9 starts with the R-factors
for the first reciprocal space refinement cycle, in which the metal ions (zinc, in the
initial stages) and phenol molecule were included. The R-factor for all data to 1.9A
was 0.2982 at this stage. The C-termini of both B chains and the N-terminus of the
B chain of molecule 2 were excluded from refinement because of the obvious need
for rebuilding.
At point C (see figure 3.9) the metal ions were changed from zinc to cobalt,
and the axial ligand of the metal ion in molecule 2 was changed from water to iodide.
PROLSQ refinement followed, first without keeping a special distance between the
metals and ligands, and then a few cycles with a special distance imposed between
cobalt and iodide. The distances between cobalt and histidine were allowed to refine
freely.
At point S the density for the N-terminus of the B chain of molecule 2 became
interpretable. The side chain of residue B3 was swapped with the main chain of
residues Bl/B2, changing the last turn of the a-helix to an extended conformation.
At point L a second phenol molecule was included, which has hydrogen bonds with
BID His Nbl and B13 Glu Oe.. The total number of phenol molecules in this
T3R3 hexamer is therefore six. From point R the data between 1.9 and 1.95A were
excluded from refinement because of problems caused by the incompleteness of that
resolution shell of data.
At point G all but the three most obvious waters, one of which is liganded to
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Figure 3.9: Overview of R-factor during refinement of Col insulin.
*: manual rebuild, including water; then PROLSQ refinement of coordinates
only in the first stages, refinement of both coordinates and temperature fac-
tors after point B;
B: changing from coordinates-only to coordinates-and-temperature-factor
refinement;
+: ARP refinement, incorporating PROLSQ.
S: swapping the side chain of B3 with the main chain of BljB2;
w: revising the water structure;
L: second phenol molecule included with hydrogen bonds to BlO and B13;
P: PROCHECK information aiding rebuilding for the first time;
D: sorting out disorder of residue D21 (molecule 1);
=: resetting temperature factors prior to PROLSQ refinement;
0: residues BI-B3 omitted;
i: residues BI-B3 included again;
A: probing of the density around position (0,0,15) (orthogonal A) with var-
ious cations and anions present in the crystallisation solution.
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the cobalt ion in molecule 1, were deleted, after which the water structure was rebuilt
in five runs of ARP. R-factor data were only recorded for the last run: down from
0.1920 to 0.1783. Refinement cycle 250 to 350 were taken up with refinement of the
water structure by detailed rebuilding and reciprocal space refinement. From point
A onwards it was tried to model a threefold degenerate acetate ion on the threefold
axis on the surface of the hexamer, in the shallow depression which is lined by the
three B chain helices in the R-conformation half of the hexamer. The density around
(0,0,15) (orthogonal A) was probed with cobalt and sodium cations, and acetate,
citrate, iodide and chloride anions. None of the combinations of cat- and anions
gave a totally satisfactory result judged by the electron density after refinement,
also reflected by very similar R-factors for every conformation investigated. The
density most resembles an acetate ion, probably coordinated to sodium. The final
R-factor for Col insulin is 0.1933 for all data between 33.33 and 1.95A. For restraint
and geometry information, see table 3.13 at the end of this section.
3.5.3 BB Gly-tSer, B13 Glu-s Gln, B30 Thr-NH2 human in-
sulin
With the advent of new techniques and ideas in protein crystallography, and better
model coordinates being made available, it seemed necessary to re-initiate refine-
ment of the B8S/BI3Q/B30amide a few times. Some of the experience gained in
preliminary stages, was used explicitly at the beginning of the final refinement pro-
cedure.
The hexameric starting model for the refinement was built up from three native
monoclinic dimers from a molecular replacement search with AMoRe. The packing
within the hexamer should resemble the mutant hexamer more closely than the
original hexameric native monoclinic model. The R-factor for this model was 0.4014,
while the free R-factor for the 10% of data to be excluded from the refinement, was
0.3953. An overview of the full refinement procedure is shown in figure 3.10.
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Figure 3.10: Overview
B8S/BI3Q/B30amide insulin,
R-factor in thin line.
*: manual rebuild, including water; then, unless otherwise indicated,
PROLSQ refinement of coordinates only in the first stages, refinement of
both coordinates and temperature factors after point B;
=: resetting temperature factors prior to PROLSQ refinement (see *);
B: changing from coordinates-only refinement to coordinates-and-
temperature factor refinement;
X: X-PLOR refinement followed by PROLSQ coordinate refinement;
+: ARP refinement, incorporating PROLSQ. Water molecules suggested
by ARP were rejected;
w: developing the water structure with X-SOLVATE, followed by reciprocal
space refinement with PROLSQ;
0: rebuilding on the basis of overlaps of all the A and B chains on each
other to keep check of the pseudo-symmetry;
Dl: deleting all waters with temperature factor higher than 7oA2;
D2: deleting all waters with temperature factor higher than gOA2;
R: reciprocal space refinement of coordinates and temperature factors
performed with REFMAC for the first time. Four cycles of refinement in
every stage, only first and last R-factors indicated.
of R-factors during refinement of
conventional R-factor in thick line, free
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The first step in the refinement consisted of real space refinement of all the
main chain peptide bonds and all the side chains with X-AUTOFIT (Oldfield, 1996).
Previously determined coordinates for the zinc ions, chlorides and phenol molecules
were included at this point. The C-terminal residues of all six B chains, the N-
terminal residues of chains Hand L, the atoms of El and 11 and the side chains
of residues A14, D1 and 114 were excluded from the subsequent first round of re-
ciprocal space refinement with PROLSQ. Refinement stage X (see figure 3.10) was
an extensive X-PLOR protocol, with full occupancy for all available atoms. The
protocol consisted of rigid body refinement of the hexamer as a whole, then of the
dimers separately, followed by the monomers. The subsequent simulated annealing
run was of the 'slowcool' type, without full equilibration at high temperatures. This
was immediately followed by PROLSQ coordinate refinement. Stages of manual
rebuilding were aided by information from PROCHECK. The water structure was
built up with X-SOLVATE in QUANTA. After point R (see figure 3.10) reciprocal
space refinement was performed with REFMAC, using the maximum likehood resid-
ual for structure factors. The R-factor for the last point in figure 3.10 is 0.194 (free
R-factor 0.280), calculated for the data between 11.0 and 2.1A. The final R-factor
for all data between 43.44 and 2.1A is 0.215, the free R-factor 0.306. For restraint
and geometry information, see table 3.14 at the end of this section.
3.5.4 B9 Ser-+His human insulin
Monoclinic crystal form
The starting model for refinement of B9H insulin in monoclinic form was con-
structed from three native monoclinic dimers, positioned in the mutant unit cell
with AMoRe. This model should resemble the mutant structure more closely than
the native hexamer model positioned in the mutant unit cell. The R-factor of this
model (which contains no ligands of any kind) is 0.4007, while the R-factor for the
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Figure 3.11: Overview of R-factors during refinement of B9H insulin, monoclinic
form, conventional R-factor in thick lines, free R-factor in thin lines.
*: manual rebuild, including water; then, unless otherwise indicated, PROLSQ
refinement of coordinates only in the first stages, refinement of both coordinates
and temperature factors after point B;
=: resetting temperature factors prior to PROLSQ refinement (see *);
B: changing from coordinates-only refinement to coordinates-and-temperature fac-
tor refinement;
Xl: X-PLOR minimisation (coordinates and temperature factors), no molecular
dynamics involved;
C: changing the fourth ligands for both zinc ions to chloride;
+: ARP refinement, incorporating PROLSQ;
A: ARP refinement, after which the water molecules suggested are removed from
the structure;
w: developing the water structure with X-SOLVATE, followed by reciprocal space
refinement with PROLSQ;
G: reducing the restraints on the geometry slowly over 35 cycles of refinement;
0: rebuilding on the basis of overlaps of all the A and B chains on each other to
keep check of the pseudo-symmetry;
P: using PROCHECK to aid manual rebuilding for the first time;
M: reciprocal space refinement of coordinates and temperature factors performed
with REFMAC for the first time. Four cycles of refinement in every stage, only
first and last R-factors indicated.
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10% of reflections to be excluded from refinement, is 0.4424. An overview of the
refinement procedure is given in figure 3.11.
The first maps gave clear indications for the positions of the B9 mutations, the
presence of two zinc ions and their fourth ligands on the non-crystallographic three-
fold axis, the presence of phenol molecules very similar to the native structure, and
some of the terminal residues that had been omitted from the starting model. This
information was included in the first reciprocal space refinement, the starting point
of figure 3.11. In the first stages, only coordinates were refined. Point Xl represents
two cycles of minimisation in X-PLOR. The water structure was investigated both
with ARP and X-SOLVATE. After point A ARP was only used for refinement, while
any water molecules suggested by ARP were not included in the structure.
From point M reciprocal space refinement was performed with REFMAC, us-
ing the maximum likelihood residual for structure factors. At that stage it became
clear that some of the electron density peaks in the core of the hexamer repre-
sented zinc ions rather than water molecules. The R- factors of the final model are
0.2156 (conventional R-factor) and 0.3167 (free R-factor), for all data between 57.74
and 2.1A. The refinement was performed with all data between 13.0 and 2.1A. For
restraint and geometry information, see table 3.14 at the end of this section.
Rhombohedral crystal form
B9H rhombohedral insulin is isomorphous with native 4Zn insulin. A starting model
for refinement was derived from a molecular replacement search with AMoRe, which
confirmed isomorphism. The advent of new techniques and ideas has had a great
impact on the process of refinement of the B9H mutant. Refinement of the mutant
against data collected at room temperature was not followed through when cryocrys-
tallographic techniques were introduced. However, the success of the first attempt
at collecting data at 120K was limited. The crystal was not very stable in the cry-
oprotectant solution, and upon freezing only diffracted to around 2.5A. These data
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were complete and reliable to 2.6A resolution. A later attempt at data collection
was more successful, when more experience had been gained with chosing a cryopro-
tectant and the techniques of flash freezing. Crystals were submerged in a solution
with 1,2-ethanediol instead of glycerol which had been the earlier choice, and one of
these diffracted well to 1.9A resolution. Data sets could not be merged because of
non-isomorphism due to temperature effects upon freezing (see table 3.12).
Refinement of the mutant with REFMAC was started with a model including
zinc ions on the rhombohedral axis, and indications for chloride ions and other zinc
ions in the form of water molecules. Unfortunately, REFMAC is as yet incapable of
dealing effectively with restraining special distances when atoms in special positions
and atoms from symmetry-related molecules are involved. The refinement of the
rhombohedral B9H mutant has therefore stagnated at R-factors of 0.2338 (for the
working set, data between 17.08 and l.92A) and 0.3097 (for the 10% of reflections
kept 'free'). Refinement with X-PLOR was only effective in the earliest stages of
refinement, not for the detailed refinement of water structure and the intricate zinc
ion structure of the mutant. For restraint and geometry information, see table 3.13
at the end of this section.
data set characteristics unit cell edges
temperature resolution (A) effective resolution (A) a=b= (A) c= (A)
room temp 2.0 2.3 80.79 37.47
120K 2.5 2.6 79.84 36.65
120K 1.9 1.92 79.878 37.427
Table 3.12: Unit cell parameter change upon freezing B9H rhombohedral insulin
3.5.5 B9 Ser--+Asp, B27 Thr-s Glu human insulin
The starting model for B9D/B27E insulin was produced with AMoRe, although
the mutant is isomorphous with native orthorhombic insulin. The refinement is
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described below, with an overview shown in figure 3.12.
i
OAOO .j
R
w- -II! ~X7~ :5, \~I\~6! \ /\
w I' /IX3 X4 ji \ \,/" \XB. b
: 7 xl/\ • / \. V\ ~r v \ w
'~~ j ItV \\*! vv v '. \ \ w
X4
0.300
3
0.350
0.250
·-·-·----r-·-·--------r-·- ..··------
w ~ 00 W
cycle number
Figure 3.12: Overview of R-factors during refinement of B9D/B27E insulin, conven-
tional R-factor in thick lines, free R-factor in thin lines.
*: manual rebuild, including water; then, unless otherwise indicated, REFMAC re-
finement of coordinates and temperature factors;
w: developing the water structure with X-SOLVATE, followed by reciprocal space
refinement with REFMAC;
=: resetting temperature factors prior to REFMAC refinement (see *);
X1,X3,X4,X5,X6,X7: X-PLOR full refinement protocol (slowcool), immediately fol-
lowed by REFMAC;
X2: X-PLOR full refinement protocol (slowcool) with all non-water atoms included
with occupancy 1.0;
X8: X-PLOR full refinement protocol (slowcool), followed by 4 cycles of REFMAC;
no waters included, experimental standard deviations not used;
b: temperature factors of water molecules reset to average temperature factor of
protein.
The conventional crystallographic R-factor for the starting model was 0.5119
for all data to 2.3A. Ten percent of the reflections were excluded from the refinement
procedure, reserved for calculations of the free R-factor. Reciprocal space refinement
was performed with REFMAC and X-PLOR. In the second cycle of X-PLOR re-
finement all atoms present in the coordinate set (apart from water molecules) were
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refined, without omitting uncertain ones. After X-PLOR step 8 it was discovered
that the low resolution reflections produced erratic statistics. Some trials were done
where experimental standard deviations were not used in the scaling of reflections,
different resolution limits were used, and ultimately the idea of using the free R-
factor was given up. The refinement of 829 atoms (at the last point of figure 3.12)
with 3632 reflections, keeping 384 reflections separate for free R-factor calculations,
is not warranted. It seemed justified to use the test reflections for scaling purposes
in REFMAC until the number of parameters became too large.
The unpredictable behaviour of both R-factors is probably due to the fact
that the structure factors calculated from the model are all systematically lower (in
the range used for refinement) than the observed structure factors (see figure 3.13),
which is caused by the significant differences of just a few low resolution reflections.
This must be due to incorrect measurements or a systematic error.
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Figure 3.13: Indication of problems with a small subset of reflections. In the
resolution range used for refinement, all reflections have Fobs higher than
F calc, which can not be corrected with a scale factor because of the low
resolution reflections. Structure factors on arbitrary scale.
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The conventional R-factor at the end of the refinement procedure for B9D /B27E
insulin for all data between 13.0 and 2.3A is 0.2286. The R-factor is 0.3265 for all
data between 29 and 2.3A, further illustrating the problem at low resolution. For
restraint and geometry information, see table 3.14 at the end of this section.
3.5.6 A2I Asn-s Gly, B9 Ser-+Glu, BID His-s Glu human in-
sulin
The molecular replacement study of A21G/B9E/B10E insulin revealed a new pack-
ing of insulin dimers. The data collected at room temperature extended to 2.8A
resolution, which made detailed refinement impossible. The data collected at 120K
were incomplete and of insufficient quality. These data could not be merged with
the data collected at room temperature because of non-isomorphism.
Although the results of refinement of a protein structure at 2.8A resolution
have to be interpreted with extreme care, the process can usually be done very
rapidly. An attempt was made with the A21G/B9E/B10E mutant, when the maps
after molecular replacement, and rigid body refinement and minimisation in X-
PLOR proved easily interpretable. The mutant aggregates in dimer form very
closely resembling that of the native orthorhombic molecule, but in different pack-
ing. This puts the C-termini of the B chains in close contact with symmetry-related
molecules. The maps, however, clearly showed the possibilities for change. Also,
the mutations could be modelled in these maps. The first stage of reciprocal space
refinement brought the R-factors down to 0.286 and 0.370. After rebuilding the
protein molecules and modelling some of the solvent structure, the 10% 'free' reflec-
tions were included in the refinement to increase the number of reflections for every
parameter refined. Within four steps of six minicycles of REFMAC refinement, the
R-factor had dropped to 0.182. An overview of the limited refinement of the mutant
is shown in figure 3.14. For restraint and geometry information, see table 3.14 at
the end of this section.
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Figure 3.14: Overview of R-factors during refinement of A21G/B9E/BI0E
insulin.
Xr: X-PLOR rigid body refinement of dimers, monomers, and B chain C-
termini;
Xm: X-PLOR minimisation (including temperature factors);
RI: REFMAC refinement of coordinates and temperature factors, followed
by manual rebuilding;
R2: REFMAC refinement of coordinates and temperature factors, preceded
by resetting of temperature factors;
R3: REFMAC refinement of coordinates and temperature factors, preceded
by manual rebuilding of protein and developing water structure with X-
SOLVATE;
R4: REFMAC refinement of coordinates and temperature factors using all
observed reflections, preceded by manual rebuilding of protein and develop-
ing water structure with X-SOLVATE;
R5: REFMAC refinement of coordinates and temperature factors.
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3.5.7 A4 Glu---+Gln, B25 P'he-s Tyr , des B30 single chain
human insulin
The B25Y(B29-Al)A4Q mutant crystallised in a space group for which no detailed
structure has been published. Unfortunately the mutant did not diffract well enough
to warrant detailed refinement. The R-factor of the molecular replacement model
was 0.5767 for all data to 2.sA. Since there were only I3S6 reflections, no free R-
factor was used in the refinement.
The mutations from Phe to Tyr and from Glu to GIn could not be interpreted
unambiguously at this resolution. However, the modifications at the C-terminus of
the B chain were clearly defined in maps. Residue B30 was deleted, after which a
peptide bond was created between residues B29 and AI, the density for which was
clear and continuous. Also, some strong (Fobs - Fca1c) density was interpretable as
a zinc ion close to BID histidine, with the space group symmetry such that three
histidines coordinate to this zinc ion. The coordinates were refined with X-PLOR
and PROLSQ, but refinement was unstable and unreliable at 2.sA resolution. The
refinement was stopped at an R-factor of 0.372S for all observed data, which lie
between 11.6 and 2.sA.
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rms deviations B13Q B9H rhombohedral Col
DISTANCE RESTRAINTS
bond length 0.014 ~0.020) 0.024 \0.020) 0.025 \0.02~~
angle distance 0.045 (0.040) 0.041 (0.040) 0.050 (0.020)
planar distance 0.052 (0.050) 0.043 (0.050) 0.052 (0.050)
PLANAR GROUPS
peptide plane 0.0267 ~0.0300) 0.0253 (0.0300) 0.0290 (0.0300)
aromatic plane 0.0148jO.0200) 0.0154 (0.0200) 0.0162 (0.0200)
CHIRAL VOLUME 0.145 (0.150) 0.171 (0.150) 0.197 (0.150)
NON-BONDED CONTACTS
single torsion 0.200 ~0.300) 0.185 (0.300) 0.187 (0.3001
multiple torsion 0.278 (0.300) 0.254 (0.300) 0.272 (0.300)
Hbond - 0.226 (0.300) 0.316 (0.300)
TORSION ANGLES
planar 6.6 F'O) 4.8 (7.0) 5.2 (7.0)
staggered 18.9 (15.0) 21.0 (15.0) 19.2 (15.0)
transverse 28.7 (20.0) 20.5 (20.0) 16.1 (20.0)
THERMAL FACTORS
main chain bond 2.211 ~2.000) 2.661 (2.000) 2.547 (2.000)
main chain angle 3.452 (2.500) 4.065 (3.000) 3.624 (2.500)
side chain bond 3.715 (3.000) 2.438 (2.000) 4.229 (3.000)
side chain angle 5.520 (4.500) 3.838_(3.000) 5.671 (4.500)
Table 3.13: Geometry restraints of the rhombohedral modified insulin struc-
tures. Root mean square deviations, with target values in brackets.
rms deviations B8S_LBI3Q/B30amide B9H monoclinic B9D/B27E A21G/B9E/B10E
DISTANCE RESTRAINTS
bond length 0.019 \0.0201 0.022 (0.020! 0.019 \0.020) 0.023 \0.02~~
angle distance 0.042 (0.040) 0.045 (0.040) 0.053 (0.040) 0.058 (0.040)
planar distance 0.048 (0.050) 0.050 (0.050) 0.051 (0.050) 0.059 (0.05ql
PLANAR GROUPS
peptide plane 0.0244 0.03~~ 0.0284 (0.0300) 0.0286 (0.0300! 0.0324 ~0.0300J
aromatic plane 0.0140 0.02001 0.0158 (0.0200) 0.0121 (0.0200) 0.014610.0200
CHIRAL VOLUME 0.184 0.150) 0.177 (0.150) 0.167 (0.150) 0.181 (0.150]_
NON-BONDED CONTACTS
single torsion 0.185 ~~.30~! 0.183 (0.3~~ 0.216 (0.300! 0.235 (0.300)
multiple torsion 0.262 (0.300) 0.267 (0.300) 0.282 (0.300) 0.271 (0.300)
Hbond 0.244 (0.30!Jl_ 0.272 (0.300) 0.267 (0.300) 0.213 (0.300)
TORSION ANGLES
planar 4.2 F'O~ 4.8 (7.0) 4.1 (7.0) 5.7 ~7.0~
staggered 21.6 (15.0) 20.0 (15.0) 22.5 (15.0) 28.9 (15.0)
transverse 24.1j20.0) 19.7 (20.0) 34.3 (20.0) 27.2 (20.0)
THERMAL FACTORS
main chain bond 3.142 \2.lXK!! 3.251 (2.000) 3.609 (2.0001 4.970 ~2.~!
main chain angle 5.235 (3.000) 4.688 (3.000) 5.270 (3.000) 7.141 (3.000)
side chain bond 2.891 (2.000) 3.406 (2.000) 5.380 (3.000) 4.550 (2.000)
side chain angle 4.503 (3.00!Jl 5.340 (3.ooo) 7.244 (4.000) 6.793 (3.000)
Table 3.14: Geometry restraints of four non-rhombohedral structures.
Root mean square deviations, with target values in brackets.
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3.6 Description of the structure models
The main features of the three-dimensional structure of insulin are seen in all of the
modified insulins described in this thesis. The insulin monomer is held together by
three disulfide linkages at A6-All, A7-B7 and A20-BI9. The a-helix running from
residues B9 to BIg is largely undisturbed by modifications in its sequence. Where
aggregation takes place, the dimer interface contains the small anti parallel ,B-sheet
structure of residues B23-B28, and the hexameric structures have metal ions in the
cores. N- and C-termini are often disordered, as was already described by Adams et
al. (1969). The main differences of the modified insulin structures will be described
below.
3.6.1 B13 Glu-s Oln human insulin
The mutation of Glu to GIn at position B13 is expected to produce a more sta-
ble hexamer because of the reduction in charge repulsion in the core, possibly with
an elaborate hydrogen bonding 'ring' structure of the six glutamine residues as de-
scribed by Markussen et al. (1987). The mutant readily crystallised in rhombohedral
form (space group R3) in T3R3-conformation. The positions of the mutated residues
were not completely clear immediately at the beginning of refinement (see figure
3.15), so the sites were excluded from initial refinement. An omit map calculated
(as described in section 3.5.1) after completion of refinement confirms the refined
positions (see figure 3.16). Residue B13 (molecule 1) is disordered, and the simple
twelve-membered 'ring' structure of the six glutamines is not observed. Moreover,
the two glutamines in a dimer are within hydrogen bonding distance of each other,
but not of neighbouring symmetry-related B13 glutamines. Contacts in the core of
the hexamer are mediated through water molecules.
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Figure 3.15: Indications for mutated residues in B13Q insulin at the
start of refinement. Stereo view of both B13 residues and Fobs-Fcalc
density at +30".
Figure 3.16: Omit maps for mutated residues in B13Q insulin in fully
refined positions. Stereo view of both B13 residues and Fobs-Fcalc
density at +30", in the same orientation as figure 3.15.
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Figure 3.17: Stereo view of zinc in molecule I of Bl:~Q insulin, oct.a-
hedrally coordinated on the threefold axis.
The zinc binding of the mutant only became clear after repeated trials with all
zinc ions omitted and various combinations of zinc ions included in early refinement
and map calculations. The disorder of the BID histidine (molecule 2) as seen in
native 4Zn insulin, is not present in the B13Q mutant. Instead, the histidine is
solely pointing towards the off-axial zinc site. The BI3Q mutant is therefore Cl true
'four zinc' insulin, in contrast with the native structure which actually contains live
metal binding sites. The binding of zinc in the axial site in molecule 1, ocl.ahedrally
coordinated by three symmetry-related BID histidines and three symmetry-related
water molecules, is shown in figure 3.17. The tetrahedral coordination of zinc hy
BID histidine, a symmetry-related B5 histidine and two chloride ions is shown ill
figure :3.18.
"Cl "Cl
~CI ~CI
)(Zn )(Zn
Jp Jp
Figure 3.18: Stereo view of zinc in molecule 2 of B13Q insulin, tctraheclrally
coordinated.
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The termini of the four chains in the asymmetric dimer may be described as
follows:
• The A chain N-terminus (molecule 2) is clearly in electron density but has
slightly raised temperature factors compared to the average of 33.1A 2 for the
main chain of A. The A chain C-terminus is very clear with temperature factors
lower than the average for the residues up to and including A20;
• The B chain N-terminus (molecule 2) has become helical, thus forming an
R-conformation, but not completely to residue Bl. The side chain of residue
B3 takes up the position of what would be the main chain positions of B2
and B1 were the helix to stretch to Bl. Residues B1 and B2 exhibit an
extended conformation (see figure 4.2). Although the temperat.ur [actors of
these residues are high at >50 whereas the average of the main chain of B is
30.9A 2, the electron density gives an indication for the validi ty of the extended
conformation as compared to the full helical conformation (see figure 3.19).
Figure 3.19: Stereo view of the comparison of electron density for two con-
formations of the N-terminus of molecule 2 in B13Q insulin. 2Fobs-Fcalc
maps and refined coordinates; orange: map at start of refinement, B1-B3
included in map calculations; light blue: map corresponding to coordinates
after rearrangement of the N-terminus to extended conformation, B1-B2
not included in map calculations (coordinates not fully refin cl).
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The Ramachandran plot of the model in the early stages of refinement indi-
cated that residues B2 and B3 were in unacceptable regions (see figure 3.20)
whereas the Ramachandran angles of these residues in the final model are
within the most favoured regions. The B chain C-terminal residues are clear
in the electron density, although they have high temperature factors (53.1-
73.5A 2 for the main chains of the last four residues);
Phi (degrees)
Figure 3.20: Ramachandran plot for the starting model of B13Q insulin.
Darkest grey represents the most favoured regions (A,B,L); medium grey
represents additional allowed regions (a,b,l,p); lightest grey represents gen-
erously allowed regions ("'a,,,,b,,,,l,"'p); white regions are disallowed.
• The C chain termini (molecule 1) have barely elevated temperature factors
(average for the main chain of C is 33.0) and are very clear in the electron
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density;
• The D chain N-terminus (molecule 1) clearly exhibits an extended
T-conformation. The temperature factors of the terminus are elevated gradu-
ally towards the end of the chain to a value of 37.5A2 for the main chain. The
C-terminus has high temperature factors, rapidly increasing to 63.6A 2 for the
main chain of the last residue, but is clear in electron density maps.
Temperature factor plots for main chain and side chain atoms are shown in
figures 3.21 a to d.
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Figure 3.21: Temperature factor plots for the B13Q mutant.
a) Chain A. Average for main chain is 33.1A2, for side chain 34.1A2.
b) Chain B. Average for main chain is 30.9A 2, for side chain 34.9A 2•
c) Chain C. Average for main chain is 33.oA2, for side chain 35.2A2.
d) Chain D. Average for main chain is 26.2A2, for side chain 27.7A2.
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3.6.2 B9 Ser---tHis human insulin
Monoclinic crystal form
The mutation of serine to histidine in position B9 allows for extra zinc binding in
the core of the insulin hexamer, which it was anticipated should result in increased
stability. In order to study zinc binding in the case of all-R-conformation B chains,
the B9H mutant was crystallised in monoclinic form, the most stable hexamer (space
group P21). The hexameric model for the mutant was put together from molecular
replacement studies in AMoRe, with an R2 dimer from native monoclinic insulin
as a search model. A model built up from smaller units could help to avoid model
bias, since the aggregation of the mutant could be slightly different. The molec-
ular replacement solutions were very clear and produced a recognisable hexamer
instantly. Indications of the positions for the new histidine side chains were present
in the first electron density maps (see for example figure 3.22), and became clearer
as refinement progressed.
Figure 3.22: First indication of the mutation sites of B9H insulin, monoclinic
form. Stereo view of one of the B9 residues with F obs- F calc map at +30".
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Omit maps calculated (as described in section 3..5.1) at the end of refinement
confirm the final positions of the mutated residues (see figure 3.23). The six B9
histidines point towards the centre of the hexamer, as shown in figure 3.21.
Figure 3.23: Omit maps for the mutation sites of B9H monoclinic
insulin after refinement. Stereo view of the' same B9 residue with
Fobs-Fca/c map at +30' in the same orientation as figure :J.n.
During the course of refinement it became clear that apart from tlH' two tradi-
tional zinc ions situated on the non-crystallographic threefold axis (ZN 1 and ZN2),
tetrahedrally coordinated by three BID histidines and a chloride ion, 1I10re"inc was
present in the structure. There is potential for zinc in the centre of the hexarner,
coordinated by the N£2 atoms of the B9 hist idines, and by thr- other nitrogen atom
(Nb!) of the B9 histidines, also coordinated by Nbi of a BJO histidinr- of another
monomer within the hexamer. Zinc was included in places where tile ,·l,·droll density
clearly indicated an atomic position, less than -2 ..1A away from a histidine' nitrogen
atom. This resulted in the addition of ten zinc ions, all with half occllpancy. The
zinc ions coordinated by two Nbl atoms from a B9 and a B 10 histidine residue,
were refined with two half occupied chloride ions as third and fourt h li~ands. The
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Figur« :J.2,t: Stereo view of the core of B9H monoclinic insulin
environments of all 12 zinc ions are tabulated in table 3.15. The zinc ions are in-
eluded ill figure :J.21, along with the 1310 histidines and the 813 glutamic acids. The
picture shows t.h« conformation of the B13 residues, all pointing towards the centre
of the hexarner. This would have been highly unlikely without the zinc cations to
countcrbalanrr- the negative charges of the glutamic acids.
There is 110 indication of zinc at B9Nbl or F9Nbl. As may be seen from table
3.15, not aJI zinc positions are equally well-defined. However, the environments are
unsuitable for water molecules. The exact amount of zinc in the crystals can not be
determined unambiguously by crystallographic means at this resolution.
The structural biology of zinc in relation to histidine has been reviewed by
Christianson (1991). Although the zinc ions on the non-crystallographic threefold
axis were refined with occupancy 1.0, full occupancy of any of the zinc ions is not
warranted by the temperature factors, the electron density and the chemistry of zinc
and histidines at the p ll of the crystal (which is 7.27). The temperature factors of
the 'axial' zinc ions is within the same region as those of the nitrogens coordinated
to them (11.G-2G.sA 2), leading to the conclusion that the occupancy of those zinc
ions must be very close to unity. The occupancies of the other ten zinc ions vary,
but judged by their refined temperature factors and those of their ligands, these zinc
ions have occupancies 0 ..5 or less.
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zinc tfl (A") coordination ligands1distance in~
1 20.5 tetrahedral 010Nf2 F10Nf2 L10Nf2 ct.n
2.09 1.96 1.94 2.18
2 19.5 tetrahedral B10Nf2 H10Nf2 J10Nf2 CL21
1.96 2.08 2.05 2.16
3 38.5 tetrahedral B10NSl H9N81 CL31 CL32
2.13 2.12 2.26 2.14
4 35.5 tetrahedral F10NSl 09N81 CL41 CL42
2.12 2.09 2.12 2.63
5 46.5 tetrahedral 010NSl L9N81 CL51 CL52
2.09 2.07 2.65 2.06
6 43.5 tetrahedral H10NSl J9N81 CL61 CL62
2.09 2.09 2.43 1.87
7 45.0 irregular F9Nf2 F130f2 H130f2 HOH443 HOH60S
2.05 2.20 1.67 2.74 2.23
8 55.5 irregular 09Nf2 0130f2 8130<2 ZN22 HOH443 HOH605
2.12 2.68 2.52 2.89 2.73 2.59
9 55.5 irregular H9Nf2 F130fl F130f2 8130d 8130,2 HOH725
2.06 2.55 2.57 3.14 3.27 1.91
10 53.0 irregular J9Nf2 H130f2 J130f2 L130f2 HOH443 HOH712
2.08 3.00 2.80 2.25 2.67 2.43
11 56.0 irregular L9Nf2 J130f2 L130f2 HOH443
2.09 2.70 2.42 2.66
12 48.5 irregular B9Nf2 B130,2 0130,2 ZN8 HOH443 HOH712
2.53 2.63 2.12 2.89 2.70 2.53
Table 3.15: Environments of the zinc ions in monoclinic B9H insulin. Distances
between zinc and histidine nitrogens were restrained to 2.1A. Distances between
zinc and chloride were not restrained. Itf = temperature factor.
In order for histidine to coordinate to two metal ions at the same time, it will
have to lose both its protons. The pKa of the second proton in histidine is 14.0-14.5,
while this pKa may be lowered around two pH units by coordination to a metal
ion. In protein structures, this has been seen in copper-zinc superoxide dismutase
(Tainer et al., 1982). The pH of the present mutant crystallisation is much lower
than the 12.0 seen as viable for binding of two metal ions to one histidine residue, so
the local environment of these histidines has an exceptionally high effective pH. The
locality of the zinc binding potential can also be derived from the geometry around
the metal positions. The geometry of Zn2+ interactions with Sp2 nitrogen-containing
heterocycles (as in histidine) has been examined by Vedani and Huhta (1990). The
metal ion prefers a head-on and in-plane approach to the lone electron pair of the
nitrogen atom. From their study of the small molecule structures containing zinc-
imidazole centres in the Cambridge Structural Database (Allen et al., 1979), Vedani
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Figure 3.25: Preferred binding of zinc to histidine: the clustering of 'head-
on' (left part of the figure) and 'in-plane' (right part of the figure) preference
of zinc in histidine-environment in the Cambridge Structural Database in-
dicates a maximum deviation of 30° in both cases. The figure shows a top
and side view of a histidine ring, and a cone with a 30° opening angle in
dashed lines. The zinc ions in the Cambridge Structural Database are all
found in the area indicated by a black ellipse.
and Huhta have deduced that the zinc ion normally lies well within 30° from the C-N-
C bisector (see figure 3.25). The geometry of some of the zinc ions in the monoclinic
B9H mutant, however, deviates significantly from their findings (see table 3.16).
The four zinc ions tetrahedrally coordinated by two histidines (B9 and BlO, both
by nitrogen Nb1) and two chlorides are significantly out-of-plane. In an ideal zinc-
histidine pair, the plane deviation would be zero and the angles would both be 126°.
In the case of deviations from the histidine plane, 'head-on' only manifests itself in
very similar CC and CN angles (for a definition of these angles, see the legend of
table 3.16), decreasing with increased plane deviation. Therefore, the ZN1-L10Nt2
and ZN9-H9Nb1 pairs are outliers.
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ZInC Ion nitrogen plane deviation angle CC t angle CN t
ZN1 D10Nt2 6.7 120.0 12.5.9
FlONt2 4.7 127.4 123.6
LlONt2 21.0 14S.4 103.2
ZN2 BlONt2 10.0 139.0 11S..5
HlONt2 3.4 120.:J 108.6
JlONt2 13..5 1:J9.2 110.8
ZN3 BIONSI 30.7 112.8 129.8
H9NSl 74.0 10:3.0 97.0
ZN4 FlONSl 26.0 120.2 111.6
D9N81 62.3 123.2 10:3.6
ZN5 DlON81 27.8 118.2 122.9
L9N81 66.7 112.8 93.4
ZN6 HlON81 37.9 118.9 116.7
J9N81 71.8 107.9 9:3.0
ZN7 F9Nf2 18.4 129.1 113.1
ZN8 D9Nt2 16.8 114.8 I:J8.2
ZN9 H9Nt2 22.4 14.5..1 10:3.8
ZNlO J9Nf2 11.4 136.:1 114.8
ZNll L9Nf2 13.6 100J.I 1:38..5
ZN12 B9Nt2 10.8 122.8 126.9
Table 3.16: Geometry of the zinc ions in monoclinic 13911.Plane devi-
ations and angles in ".
tangle CC = angle ZN-Nt2-C82 or angle ZN-Nhl-C/;
tangle CN = angle ZN-Nt2-Cd or angle ZN-Nhl·Ctl.
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Phenol molecules could be identified in positions described by Derewenda et
al. (1989) with hydrogen bonds to main chain oxygen and nitrogen in A6/ All,
C6/Cll, E6/Ell, G6/Gll, 16/111 and K6/Kll all between 2.5 and 3.1A. The refined
positions of the phenol molecules are confirmed by omit maps (as described in section
3.5.1) at the end of refinement (see figure 3.26).
Figure 3.26: Omit maps for the phenol molecules in B9H monoclinic
insulin after refinement. The spatial separation of the molecules in
the figure does not reflect that in the model.
Although the first two residues of chains D, Hand L are not clearly visible in
electron density maps, it can be determined without doubt that the B9H mutant in
monoclinic form is an example of an R6 hexamer. The temperature factors for the
first two residues of chains D and H are relatively high (see figure 3.29), reflecting
their ambiguity in electron density maps. The comparatively low temperature factor
of residue L1 is due to the fact that it was reset but not refined (the residue was
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excluded from further refinement). The N-termini of the B chains are all essentially
helical, as can be seen in figure 3.27, with in some cases a small distortion at the
end resulting in an extended conformation for the first residue.
Figure 3.27: Ribbon diagram of B9H monoclinic insulin. All twelve
chains in the hexamer in different colours.
The C-termini of the B chains are disordered in all six monomers, resulting in
high temperature factors (see figure 3.29). Parts of these C-termini were excluded
from refinement. The electron density for the A chains was easily interpretable and
the temperature factors were fluctuating within the range also seen in other insulin
structures (see figure 3.28).
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Rhombohedral crystal form
The B9H mutant crystallised readily in rhombohedral form (space group R3) in
T3R3-conformation. Cryocrystallographic data collection was successful with a non-
standard cryoprotectant (1 ,2-ethanediol), after which struct 11 re detcrrn ination and
refinement proceeded smoothly until problems were encountered with the restraint
of special distances involving atoms at special positions and atoms from symmetry-
related molecules. The mutant is isomorphous with native 4Zn insulin, and has zinc
ions on the threefold axis, both in the T-conformation and in the It-conformation
trimer (see figure 3.30). Both zinc ions arc tetrahedrally coordinated by three BI0
His N€2 and a chloride anion.
During the course of refinement, the presence of two more zinc ions was firmly
established. A third zinc ion is tetrahedrally coordinated by B!) His N(2 and B9
His Nt:2 (both from molecule 2) and two water molecules (s('(' figuf(' :J.:H). The
temperature factor of this zinc ion is slightly higher than thos« of its ligand atoms:
45A 2 for the zinc ion and 31 to 39A 2 for the ligand atoms. i\ fourth zinc ion
is tetrahedrally coordinated by BI0 His Nb} from molerul« I. B!I His NI>} from
a symmetry-related molecule 1, and two water rnolf'culf's (S('(' figun' :i.:J2). The
geometry of the B9 histidine in relation to the zinc ion, is impr-rfert., but can not be
restrained in this particular refinement program br-caus« it is a sYIIlIIU'try-reiated
residue. This histidine residue may be disordered, which would r-xplam t II(' presence
of B13 Glu from molecule 2 within hydrogen bonding dist.anrr- if t.hr- histidine ring
is in a slightly different orientation. The occupancy of the zinc ion was sd at 2/3,
after which the temperature factor refined to :J4A2. TIH' ligallds for this zinc ion
have temperature factors between 28 and '12A2. If the O(T11l'alH"), of Ihis zin« ion is
assumed to be correctly assigned a value of 2j:J. the stoichiOllwl ry of zinc to BIO
histidine (molecule 1) is 1:1. This means that all hist id iIll'S iII IIII' si rur t 11n- [ose only
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Figure 3.:W: Axial zinc ions in 8gB rhombohedral insulin. Stereo views of both
axial zinc ions; top: situation in molecule 1, T-conformation; bottom: situation in
molecule 2, li-conforrnation. Residues BID from both molecules shown in thick lines,
with symmetry-related BID residues in thinner lines. The spatial separation of the
zinc ions in the figure does not reflect that in the model.
one proton, which is the more appropriate at the pH of the crystallisation (which is
The geometry of the zinc ions in rhombohedral B9H insulin with respect to the
histidine rings is reasonable compared to the averages found by Vedani and Huht a
(1990), for the axial zinc ions and the zinc ion coordinated by histidines B5 and
B9 from molecule 2 (see table :U7). The fourth zinc ion, however, is distinctly
out-of-plane, because the position of the B10 histidine of molecule 1 is fixed by the
axial zinc ion 011 the other nitrogen. The geometry of the tetrahedral coordination
of the fourth zinc ion is, therefore, distorted, while that of the other extra zinc ion
(ZN:3) is regular, as shown in table 3.18.
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Figure 3.31: Extra zinc in molecule 2 in B9H rhombohedral insulin.
Stereo view of the tetrahedral coordination by 85, B9 and two water
molecules, with 2Fob..-Fcalc electron density at +10".
Figure 3.32: Extra zinc in molecule 1 in B9H rhombohedral insulin.
Stereo view of the tetrahedral coordination by BlO, a symmetry-
related B9 and two water molecules, with 2Fob..-Fcalc electron density
at +10".
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ZlllC IOn nitrogen plane deviation angle CC t angle CN t
ZN1 B10Nf2 16.5 110.2 139.1
ZN2 DI0Nf2 11.7 114.5 136.4
ZN3 B9Nf2 16.1 114.3 131.6
B5Nf2 14.1 133.1 118.7
ZN4 DI0N81 27.0 145.0 103.6
#D9N81 34.9 121.8 112.3
Table 3.17: Geometry of the zinc ions in rhombohedral B9H. Plane
deviations and angles in 0.
tangle CC = angle ZN-Nf2-C82 or angle ZN-Nbl-Gy;
tangle CN = angle ZN-Nf2-Cd or angle ZN-Nbl-Cd.
ligand 1 ZlllC IOn ligand 2 tetrahedral angle (0)
WID ZN3 W11 107.8
WI0 ZN3 B9Nf2 103.0
WID ZN3 B5Nf2 113.4
B9Nf2 ZN3 B5Nf2 107.1
B5Nf2 ZN3 W11 114.2
B9Nf2 ZN3 W11 110.8
W3 ZN4 W4 110.8
W3 ZN4 DI0Nb1 113.6
W3 ZN4 #D9N81 97.3
D10N81 ZN4 #D9Nb1 123.2
#D9N81 ZN4 W4 101.1
D10N81 ZN4 W4 109.7
Table 3.18: Tetrahedral environment for the extra zinc in rhombohe-
dral B9H insulin.
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The conformation of the N-terminus of the B chain of molecule 2, although
considered to be in the R-state, is not entirely helical. Like in the B13Q mutant, the
side chain of residue B3 occupies the position of the main chain of residues B1 and
B2 if the helix would have extended to B1, and vice versa. This part of the structure
is shown in figure 4.2. The temperature factors for the B9H rhombohedral insulin
mutant are shown in tables 3.19 and 3.20. The temperature factors for the residues
in the A chains do not deviate much from the average for the whole chain. Both B
chains show similar patterns: low temperature factors for the helical residues and
residues 24-26 of the ,a-sheet, higher temperature factors for the loop at 20-23 and
towards the N-terminus, and high temperature factors for the C-termini indicating
disorder.
chain A chain C
residue main chain(A2) side chain(A2) main chain (A 2) side chain(A 2)
1 56.8 N/A 40.5 N/A
2 52.3 47.1 41.0 37.0
3 56.2 54.9 42.6 43.7
4 58.3 63.3 47.0 55.2
5 55.5 58.8 47.2 52.9
6 50.0 46.1 41.4 45.6
7 54.3 49.3 45.5 44.4
8 63.4 66.4 54.3 57.2
9 61.5 63.9 57.2 58.2
10 53.2 54.0 57.1 58.3
11 45.6 41.7 57.7 56.8
12 37.0 38.7 57.1 57.1
13 33.9 41.4 53.6 53.7
14 35.2 36.7 50.5 50.0
15 35.2 37.3 48.3 58.3
16 35.4 39.1 41.4 43.7
17 35.9 45.9 35.3 47.6
18 39.5 39.6 35.2 36.1
19 34.8 38.5 30.9 33.0
20 35.8 33.6 35.0 33.5
21 48.6 57.1 42.9 40.8
total average 46.592 46.948 45.800 47.422
Table 3.19: Average temperature factor per residue of A chain of B9H
insulin, rhombohedral form
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chain B chain D
residue main chain(iP) side chain] A2) main chain(A2) side chain(i\2)
1 SO.O 50.0 46.5 43.7
2 56.4 50.0 46.1 47.1
3 58.8 63.5 52.2 Stl.2
4 47.3 56.3 48.6 54.2
5 35.7 38.0 44.7 52.5
6 30.4 35.2 40.1 40.9
7 33.4 41.4 33.9 40.3
8 28.6 N/A 31.2 N/A
9 29.6 37.0 25.7 40.8
10 25.7 25.7 25.9 29.0
11 27.4 33.8 27.3 32.S
12 24.9 28.0 26.1 27.4
13 25.1 41.6 21.1l 44.4
14 26.8 21l.7 24.1 20.9
15 26.1 29.4 27.0 2G.0
III 2S.3 27.7 27.8 28.3
17 26.8 30.0 29.5 ;34.'1
18 32.7 34.3 34.7 34.7
19 34.6 26.9 40.7 31.1)
20 39.5 N/A 48.1 N/A
21 43.3 38.0 S6.0 (32.5
22 44.1 52.7 54.6 S8.4
23 38.0 N/A 41.3 N/A
24 32.7 29.1 30.0 29.3
25 35.1 39.4 30.3 33.8
26 39.5 37.0 28.1 34.0
27 55.0 55.7 39.1 36.2
28 66.9 64.3 49.6 44.8
29 77.9 78.0 65.0 61l.6
30 83.8 85.1 72.7 74.8
total average 40.042 42.527 38.947 42.301
Table 3.20: Average temperature factor per residue of B chain of B9II
insulin, rhombohedral form
3.6.3 BB Gly~Ser, B13 Glu~Gll1, B30 Thr-NH2 human in-
sulin
At the neutral pH of the crystallisation, the B8SjB13Q/B30amide mut.ant forms sta-
ble hexamers, in R6-state because of the addition of phenol. Although the preSCller'
of a hydrophilic serine residue in place of glycine at position B8 causes unexpectedly
increased hydrophobicity (characterised by a. high capacity factor rclat.i ve to pig in-
sulin in elution from the IIPLC column (Markussen et al., 1987)), the conformation
of residues B1-B19 is entirely helical without much distortion (see figure 3.:3:{). All
six B8 mutation sites are clear in electron density, and the serines make hydrogen
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Figure 3.33: Stereo view of the overlap of the a-helix at BI-B19 In
B8S/BI3Q/B3Damide and native monoclinic insulin.
Mutant structure in thick lines, native structure in thin lines.
bonds mainly with B26 tyrosine OT} and B1 main chain oxygen of the same chain.
The increased hydrophobicity of the mutant can not be explained from the present
crystal structure. The presence of an intricate hydrogen bonding network of the
B13 glutamine residues in the mutant was investigated. However, five out of six of
the glutamine side chains bend away from the centre of the molecule, and hydrogen
bond to B90 and B90, of the other monomer in the same dimcr. Only F13 points
straight towards a central water molecule, hydrogen bonding to it. 1,13 bends away
from the centre, but not quite towards Jg, hydrogen bonding to two water molecules
instead. There are no hydrogen bonds between the glutamine residues. Thus, the
'ring' structure of six glutamines as proposed by Markussen et al. (1987), is not
observed.
Two ZInC IOns are clearly identifiable on the non-crystallographic threefold
axis of the hexamer. ZNl is tetrahedrally coordinated by N(2 of histidines DID,
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FlO and JIO in the present structure, with chloride as a fourth ligand. ZN2 is
tetrahedrally coordinated by NE2 of histidines BID, HID and LID, and a chloride ion.
Phenol molecules are observed in positions as described by Derewenda et al. (1989),
hydrogen bonded to A60 and AllN of every A chain in the hexamer. The refined
positions of the phenol molecules are confirmed through omit maps (calculated as
described in section 3.5.1) at the end of refinement (see figures 3.34 a to f).
Figure 3.34: Omit maps for the phenol molecules of
B9S/B13Q/B30amide insulin after refinement. The spatial sep-
aration of the molecules in the figure does not reflect that in the
model.
The chain termini of the B8S/B13Q/B30amide mutant are as follows:
• Both A chain termini are clear in electron density maps;
• The B chain N-terminus is helical to B1 and clearly identifiable in electron
density maps. The C-terminus is disordered beyond B28;
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• Both C chain termini are clear;
• The D chain N-terminus is poorly defined but the geometry of the final model
is good. The C-terminus is disordered beyond D28;
• The E chain N-terminus is unclear and its geometry is unfavourable. Repeated
omit maps do not indicate better positions. The C-terminus is very clear.
There is a salt bridge between one of the C-terminal oxygens of E21 and F22
Arg N7]2;
• The F chain N-terminus is helical to Fl and clear in electron density. The C-
terminal residues beyond F28 were not included in the refinement since there
is no indication of their positions;
• The G chain N-terminus is well-defined. The last peptide bond m the C-
terminal region has poor electron density;
• The H chain N-terminus is unclear, resulting in residue HI being excluded
from refinement. The C-terminus is well-defined apart from the side chain of
H29; this residue has therefore been refined with zero occupancy for its side
chain;
• Both I chain termini are clear in electron density;
• The J chain N-terminus is not completely clear in the electron density maps,
but the geometry of the refined positions is good. The C-terminus is inter-
pretable to the end, apart from the lysine side chain of J29, which is excluded
from refinement;
• Both K chain termini are clear in the electron density maps;
• The L chain N-terminus has poor electron density, and seems to come into
contact with the equally poorly defined N-terminus of the H chain. The C-
terminal residues beyond L28 were excluded from refinement.
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Figure 3.35: Average temperature factors per residue for the main
chains of B8SjB13QjB30amide insulin
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Because the C-termini of the B chains are especially flexible, from the crystal
structure of the B8S/BI3Q/B30amide insulin no information is gained about the
amide group of residue B30. More indications of the quality of the chain termini
can be derived from the temperature factor plots, figures 3.35 a to 1.
3.6.4 Zn2+ ~C02+ human insulin
The concentration of Co2+ ions in blood plasma is ten times lower than that of Zn2+
ions (0.002 mM and 0.02 mM, respectively (Glusker,1991)). Although cobalt is
not naturally found in insulin, the ions are similar in size and are expected to be
able to take up the same role in insulin hexamerisation.
The crystallisation solution contained two reagents which have a drastic and
almost antagonistic effect on the process of potential cobalt binding to insulin.
On the one hand phenol promotes R-conformation. This might force Co2+ into
a tetrahedral environment, which is unfavourable for r1' ions like Co2+. On the
other hand halide ions are added, which allows Co2+ in tetrahedral coordination,
as seen in some small molecule structures in the Cambridge Structural Database
(Allen et al., 1979). Co2+ insulin turned out to crystallise in rhombohedral space
group R3, in T3R3-conformation. The disorder of B10 histidine (molecule 2) is
clearly absent in Co2+ insulin, resulting in only two well-defined metal positions on
the rhombohedral threefold axis. In molecule 2, the R-conformation trimer, Co2+
is tetrahedrally coordinated by three symmetry-related BID His Nt:2 and an iodide
anion (see figure 3.36). In molecule 1 Co2+ is octahedrally coordinated by the other
three symmetry-related BID His Nt:2 in the hexamer, and three symmetry-related
water molecules (see figure 3.37).
A phenol molecule is present in the phenol pocket in the R3 trimer of Co2+
insulin, similar to that seen in monoclinic insulin, hydrogen bonded to A60 and
AllN in molecule 2, confirmed by omit maps (as described in section 3.5.1) at the
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Figure 3.36: Cobalt ion in molecule 2 in Col insulin. Stereo view of
the tetrahedral coordination by BID His (thick lines), two symmetry-
related BID His residues (thinner lines) and an iodide ion.
+ + +
Figure 3.37: Cobalt ion in molecule 1 in Col insulin. Stereo view of
the octahedral coordination by B10 His (thick lines), two symmetry-
related BID His residues (thinner lines) and three symmetry-related
water molecules.
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end of refinement. This is the region of the off-axial zinc site in the R3 trimer in
4Zn native rhombohedral insulin, with which Co2+ insulin is isomorphous. A second
phenol molecule is found in the same region of the molecule, with hydrogen bonds to
BID Nb'! and BI3 Oe l. The phenol molecules prevent disorder of BID His, stabilising
it in coordination with cobalt on the threefold axis (sec figure :3.38).
~o
Figure 3.38: Phenol helps stabilise cobalt coordination in molecule 2
of Co2+ insulin. Stereo view of the two phenol molecules, hydrogen
bonding to residues A6, BlO and 81:3; Fob.,- Fcalc electron density at
+30'. The phenol molecules were omitted from these map calculations.
The N-terminus of the B chain in molecule 2, supposedly in R-conformation,
is not entirely helical to residue B 1. As seen with the B 1:3Q and the B9H mutants,
the first two residues of the B chain exhibit an extended conformation, in which not
the main chain of residues B1 and B2 forms the start of the helix, hut the side chain
of residue B3. Although the temperature factors for the first residues of the B chain
are rather high (see figure 3.39), the Ramachandran angles are much better in this
conformation, and the electron density is convincing (see figure 4.2). The C-termini
of both B chains have high temperature factors, reflecting their flexibility.
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3.6.5 B9 Ser-e-Asp, B27 Thr-s Glu human insulin
The B9D/B27E mutant is monomeric in solution (Brange et al., 1988). The mu-
tations in B9D /B27E insulin prevent its aggregation into hexamers because of the
charge repulsion in the region where dimers would pack together into a hexamer.
Without any added ions to balance the charges, the mutant does, however, crys-
tallise as dimers isomorphously with orthorhombic native insulin. Although the pH
of the crystallisation is unclear, it should be close to 6 since that is the pH of the
buffer used. If the carboxylic acids at B9 and B13 have hydrogen bonds with each
other, the pH must have been lower in order to allow partial protonation.
The non-crystallographic axis of the dimer is in the xz-plane, making a 30°
angle with the x-axis. The packing of the mutant is shown in figure 3.40, with the
direction of the dimer axis indicated.
Figure 3.40: Packing of B9D /B27E insulin. Stereo view of the xz-
plane, with the direction of the dimer axis indicated by a thick line.
Cell edges also indicated.
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Because the data for the B9D/B27E mutant were not optimal (see section
3.5.5), the maps were not convincing at every stage of the refinement. In the first
maps, with the side chains at the mutation sites omitted (calculated as described
in section 3.5.1), the electron density for the mutations at positions B9 was reason-
ably clear (see figure 3.41). For residue B27 of molecule 2, however, there was no
indication as to where the side chain might be, while for the same site in molecule 1
there were problems with the positioning of the side chain with respect to residues
B25 from both molecules (see figure 3.42). After a few refinement cycles with REF-
MAC the situation at the B27 site in molecule 1 became much clearer. Omit maps
for the final positions of the mutated residues B27 are shown in figure 3.43. From
figure 3.44 it can be seen that the B25 Phe side chains are aligned, and the B27
side chain of molecule 2 is involved in hydrogen bonding with four water molecules
and a long contact (3.4A) with the N-terminal nitrogen of the A chain of molecule
1 of a symmetry-related dimer. The B27 side chain of molecule 1 is apparently not
solvated, and has one hydrogen bond with the B29 main chain oxygen of the same
chain.
Molecule 1
Molecule 2
Figure 3.41: Omit map of B9 in both molecules of B9D/B27E insulin
before refinement. Fobs-Fca/c electron density at +30'.
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Figure 3.42: Omit map of B27 in both molecules of B9D/B27E insulin
before refinement. Fobs-Fcalc electron density at +30-.
Figure 3.43: Omit map of B27 in both molecules of B9D/B27E insulin
after refinement. Fob,,- Fcalc electron density at +30-.
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Molecule 2
itA I
Molecule 2
Figure 3.44: The situation around B25 and B27 in both molecules of
B9D /B27E insulin. Stereo view including all atoms within 3.5A of
B25 and B27 residues.
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The situation around the four carboxylic acid residues B9 and B13 is unclear.
In an omit map of the final coordinates, the difference density for the aspartate and
glutamate side chains is limited (see figure 3.45). Two conformations were modelled
for the side chain of B13 in molecule 2, both with half occupancy. The five carboxylic
groups as they were modelled all have hydrogen bonds, to each other and to water
molecules. This indicates that the acid groups must have been at least partially
protonated.
Figure 3.45: Omit map for residues B9 and B13 in both molecules of
B9D /B27E insulin after refinement. Stereo view including two nearby
water molecules; F oba - F calc electron density at +30'.
The temperature factors for the main and side chains of B9D /B27E insulin
are shown in figure 3.46. Those of the first three residues of the D chain (molecule
1) have been reset to 20A 2 and then not refined. The C-termini of the B chains
are very flexible and thus have high temperature factors, but could be identified in
electron density maps, apart from the side chains of both B29 lysines. The helical
regions of the B chains have lower values, while the loops at B20 to B23 have slightly
raised temperature factors, as expected.
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3.6.6 A21 Asn~Gly, B9 Ser~Glu, BID His~Glu human in-
sulin
Aggregation of A21G/B9E/BIOE insulin is hampered by charges at the surface
where dimers would make contact to form a hexamer, and by removal of the zinc
binding site. The mutant does, however form dimers in the usual way. The mutant
crystallised in space group P212121, with a packing different from that of native
orthorhombic insulin. The non-crystallographic twofold axis of the mutant dimer
is parallel to the z-axis. The packing of the mutant, indicating the screw axes of
the space group and the direction of the non-crystallographic axis of the dimer, is
shown in figure 3.47.
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Figure 3.47: Packing of A21G/B9E/B10E insulin. Stereo view of
the xz-plane, with the 21 screw axes indicated in thin lines, and the
direction of the dimer axis as a thick line, almost parallel to one set
of screw axes. Cell edges also indicated.
The most significant changes in the mutant with respect to the native dimer
involve the packing of the C-terminus of the B chain of molecule 1 and the B20-B23
loop of molecule 2 with respect to each other, and with respect to the C-terminus of
the B chain of molecule 2 in a symmetry-related dimer. In the starting model, these
regions were in too close contact, but the first maps indicated improved positions,
especially for the main chain of B27-B30 of molecule 1 (see figure 3.48). The refined
positions of B27-B30 of molecule 1, B20-B23 of molecule 2 and B27-B30 of the
appropriate symmetry-related molecule 2 are shown in figure 3.49, together with
the starting positions for comparison.
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Figure 3.48: Indications for improved positions for the C-termini of the B chains of
A21G/B9E/B10E insulin. Stereo view of the 2Fobs-Fca/c map at +10' indicating
a better position for residues B27 and B28 of molecule 1, to avoid clash with B29
from a symmetry-related molecule 2. Symmetry-related atoms in thinner lines.
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Figure 3.49: Final positions for the C-termini of the B chains of A21G jB9EjBlOE
insulin. Stereo view in the same orientation as figure 3.48, with 2Fob ..-Fcalc map
at +111. Starting model (indicated by suffix's' in molecule indicator) in thin
lines, final model (indicated by suffix 'f' in molecule indicator) in thick lines.
Symmetry-related atoms from both starting (dashed lines) and final (thin lines)
models in bottom right-hand corner.
On the dimer surface where hexamerisation usually takes place, the mutant
has six glutamic acid groups. At the pH of the crystallisation, which is 6.57, these
are probably fully ionised and can not hydrogen bond with each other. Since the
resolution of the data is only 2.8A, the final omit maps (calculated as described in
section 3.5.1) are somewhat poor (see figure 3.50). However, the indications for the
positions of the refined side chains are present. Only two of the six glutamates make
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Figure 3.50: Final positions for the six central glutamic acids in
A21G/B9E/BI0E insulin; stereo view with Fobs-Fcalc electron den-
sity at +30-. Symmetry-related atoms in thin lines.
hydrogen bonds with protein: BlO (molecule 2) comes into close contact with A14
Tyr 0"1 of a symmetry-related molecule 1, and B13 (molecule 2) makes a hydrogen
bond with the N-terminal nitrogen of a symmetry-related B chain (molecule 1).
Two glutamates, namely B9 (molecule 2) and B13 (molecule 1), seem to make no
contacts at all, while the other two only make contacts with solvent.
At the resolution of the data (2.sA), refinement is not totally reliable, and the
temperature factors are essentially meaningless.
171
3.6.7 A4 Glu-+Gln, B25 P'he-c-Tyr , des B30 single chain
human insulin
B25Y(B29-A1 )A4Q insulin crystallised in space group P4232 with one insulin molecule
in the asymmetric unit, and six insulin monomers grouped around the special posi-
tions with 32 symmetry to form four hexamers in the unit cell. The packing of the
mutant (see figure 3.51) is equivalent to that seen for rat insulin II and insulin from
the snake Zaocys dhumnades dhumnades Cantor, which has been reported by Wood
et al.(1978) and Liang et al.(1984), respectively.
Figure 3.51: The packing of mutant B25Y(B29-A1 )A4Q in the xz-plane.
Stereo view of the Ca-atoms of 20 hexamers; cell edges also indicated.
Although the structure was not fully refined, some of the modifications were
clearly interpretable from the electron density. The cross-link between residues B29
and AI, and the deletion of residue B30, is shown in figure 3.52. The conformation
of residue B29 is such that after the ,a-sheet of residues B23 to B28 the chain
immediately turns into the a-helix of what was the beginning of the A chain. Thus
this a-helix is slightly longer in the mutant than in native insulin.
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Figure 3.52: The peptide bond between B29 and Al in B25Y(B29-
AI)A4Q insulin. Stereo view with 2Fobs-Fca/c electron density at +10-
showing the elongated stretch of helix.
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The conformation of the side chain of residue B25 from the native model
was inappropriate for the mutant, clashing with the same residue from the twofold
related monomer. A new position for this side chain was obvious from omit maps
(calculated as described in section 3.5.1), even at limited resolution. Although the
mutation from Phe to Tyr could not realistically be modelled, the new positions for
the B25 residues result in convincing stacking of the aromatic rings (see figure 3.53).
The amide group of the A4 GIn is poorly defined in the map. Although the change
in charge must have some effect on the environment around this residue, the low
resolution of the maps (2.8A) prevented interpretation.
Figure 3.53: Aromatic stacking of twofold related B25 residues in
B25Y(B29-A1)A4Q insulin. Stereo view with 2F aba-Feale electron
density at +10-.
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The validity of the molecular replacement result was confirmed by the presence
of convincing electron density for a zinc ion on the threefold axis at the point where
three BID histidine residues come together, as shown in figure 3.54.
Figure 3.54: Electron density for zinc in B25Y(B29-AI)A4Q insulin.
Stereo view of residue BID (thick lines) and two symmetry-related
BID residues (thinner lines) with 2Fobs-Fca/c electron density at -l-Irr.
Position for zinc and a fourth ligand indicated by crosses.
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Chapter 4
Insulin conformation
4.1 Introduction
The first insulin crystal structure described was that of the 2Zn insulin (Adams et
al., 1969). By that time, the ability of insulin to coordinate (for a description of the
distinction between zinc coordination and zinc binding, see chapter 6 and Emdin et
al. (1980)) more than two zinc positions had been recognised (Schlichtkrull, 1958),
and the name 4Zn was devised to describe a second rhombohedral form thought
to contain four zinc ions per hexamer (Bentley et al., 1976). When the structure
of human insulin in this form was solved and refined, it turned out there were five
sites for zinc coordination, with a total stoichiometry of 2.67 zinc ions per insulin
hexamer (Smith et al., 1984).
In 1989, Kaarsholm et al. proposed the use of the terms T (tense) and R
(relaxed), by analogy to the situation in haemoglobin, to describe the conformation
of the structures rather than the zinc content. In what was called 2Zn insulin, the six
N-terminal residues of the B chains are all extended, which was considered to be the
more tense form, and the hexamer was therefore renamed 'T6 insulin'. 4Zn insulin
was renamed 'T3R3 insulin', because in three of the monomers the N-terminus of the
B chain is helical, extending the existing a-helix at residues B9 to B19. The helical
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form is the more relaxed and is therefore named R. The monoclinic crystal form of
insulin with phenol was assigned the name 'R6 insulin' because all six N-termini of
the B chains in the hexamer are helical (Derewenda et al., 1989). Kaarsholm et al.
(1989) also suggest using T3T3' for 2Zn insulin to make clear the deviation from
twofold symmetry in the hexamer.
In the early days of insulin structure determination, the groups from Oxford
and China were using different numberings for the monomers within the asymmetric
dimer of T6 insulin. At some stage it was decided to adhere to the Chinese num-
bering convention, where the monomer that does not change conformation upon
addition of salt, considered to be the more conserved monomer, was designated the
name 'molecule I'.
The differences at the N-terminus of the B chains result in hexamers with quite
different properties. In the T6 hexamer, the zinc ions coordinated by the BID His
residues are almost on the surface of the hexamer, in a shallow depression, from
which they can easily diffuse out of the molecule. In the R6 hexamer, on the other
hand, three a-helices come together in this depression, effectively shielding the zinc
ions from the environment. This property is illustrated in figure 4.1, in which the
T and the R 'faces' of the T3R3 hexamer are shown, representing the T and R
character in one structure.
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Figure 4.1: Stereo views of the T and R faces of the T3R3 hexamer.
Produced with MOLSCRIPT (Kraulis, 1991).
a) T face, showing exposed zinc ion in the center in black;
b) R face, showing zinc ion in black at the end of a narrow channel
formed by three a-helices.
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From the observation that the zinc ions in the R6 hexamer are unable to
diffuse in and out of the molecule, it was concluded that this might be the most
stable hexamer species (Kaarsholm et al., 1989). It has been shown that the R6
hexamer is stable in solution in the presence of phenol (Jacoby et al., 1996). The
most commonly observed monomer species in solution is a T-conformation monomer.
Unfortunately, the molecule is either genetically engineered to stay monomeric in
solution (Ludvigsen et al., 1994) or the solution itself is manipulated in some way
(e.g. very low concentration of insulin), which makes it difficult to determine the
conformation of the native monomer in its active form. Ciszak and Smith (1994)
have postulated that the insulin hexamer probably has to change to T6-conformation
before the zinc ions can be released and the hexamer can dissociate into dimers and
monomers.
The conformations of the N-termini of the B chains have an influence on the
coordination of the zinc ions: in a T3 trimer the zinc coordination is octahedral,
whereas in an R3 trimer it is tetrahedral. This is because in the R-conformation the
B6 Leu side chain comes so close to the BlO His that there is no room for off-axial
water molecules in an octahedral coordination (Smith et al., 1984).
4.2 A different hexamer, T3R3i
In 1995 Smith and coworkers (Ciszak et al., 1995) announced the discovery of a new
type of insulin hexamer, in which the first three residues of the B chain of molecule 2
are in extended conformation in a T3R3-like hexamer. They named it the 'T3R3!'
hexamer, where 'f' stands for 'frayed'. On re-examination it emerged that even
the structure they determined in 1984 (Smith et al., 1984) and the structure first
described as 4Zn insulin (Bentley et al., 1976) had this conformation.
Independently of the structure determinations by Smith and coworkers, the
supposedly T3R3 structures of BI3Q, B9H and Col were all determined to have
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the first three residues of the B chain of molecule 2 extended, resulting in a T3R3!
hexamer rather than a T3R3 hexamer. The presence of surplus electron density
beyond the side chain of residue B3 Asn, the lack of electron density for residue BI
Phe and the observation that the Ramachandran angles for residues B2 Val and B3
Asn were in unfavourable regions of the plot, pointed in the direction of a necessary
change of conformation for those residues. The B3 Asn side chain in the new position
continues the hydrogen bonding pattern of the a-helix, and the Ramachandran
angles of the residues in the new conformation are in the most favourable regions.
The refined conformations of the first three residues of the modified insulins are
shown in figure 4.2, along with the helical conformation of the T3R3 hexamer.
\
\
Figure 4.2: Stereo view of the N-terminus of the B chains of T3R3 insulin
and three modified insulins in T3R3i -conforrnation. Thin lines: Col insulin;
medium thick lines: B9H insulin; thick lines: B13Q insulin. For comparison:
T3R3 insulin in dashed lines.
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Upon careful examination of electron density maps of native T3R3 insulin it
is deemed highly likely that this structure also exhibits the T3R3! -conformation,
This will be investigated by further refinement.
4.3 The T --+ R transition in modified insulin
The structures of more than one crystal form, and more than one hexamer conforma-
tion, have been determined for some of the modified insulins described in this thesis.
B9H insulin forms T3R3! and R6 hexamers in accordance with the crystallisation
protocols (high salt and phenol conditions, respectively). Of the B13Q mutant, three
crystal forms are now known: zinc-free T3R3, 2Zn T6, and 4Zn T3R3!. The first
two are described in Bentley et al. (1992), the latter in this thesis. The conforma-
tion of the zinc-containing T3R3! structures is largely as expected, albeit the zinc
content is different from that of the native isomorph (see chapter 6). No solution
study data are available for this form. The behaviour of the mutant is unexpected,
both in solution and in the crystal. The metal-free form in the crystal has T3R3-
conformation, indicating either that the B13 GIn side chain itself or one of the
additives in the crystallisation solution favour R- over T-conformation. The zinc-
containing form produces T6 crystals, isomorphous to native insulin. In solution,
however, the metal-free and metal-containing forms have the opposite behaviour: T6
for the metal-free and T3R3 for the metal-containing hexamer (Wollmer et al. (1989)
and Bloom et al. (1995), respectively). The metal-containing form is present in the
T3R3-conformation without addition of halides. Halides in the absence of metal do
not affect the conformation, since they normally have their effect through the metal
ion (Bentley et al., 1992). Solution studies on the influence of phenol on the mu-
tant show the presence of the typical R6-conformation (Wollmer et al., 1987). The
most exciting finding from solution studies is that the mutant can form R6 hexamers
without phenol, in the presence of thiocyanate ions (Brzovic et al., 1994), thus by-
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passing all the rules about the Hofmeister series and phenol (de Graaff cl al., 1~)SI).
The B8S/B13Q/B30amide mutant has been described in T3R3 and lW cryst.a]
forms (Dodson et al. (1991) and this thesis, respectively). The R6 crystal was grown
following the monoclinic protocol, and has the expected conformation. The low-salt
zinc protocol resulted in crystals with distorted T3R3 hexamers. The couformatiou
of the N-terminus of the B chain in the T3 trimer is unusual: the residues have Cl
completely different position from that seen in the native T3R3 hcxarncr. This is
due to the B8 SCI' residue having to adopt an allowable chirality in a position take-n
up by a glycine residue in right-handed conformation in the native structure.
Although Col insulin has, as yet, only been described in one crystal form, this
is unusual in itself. The crystallisation conditions would yield R6 hexamer crystals
with zinc ions, but yielded T3R3 hexamer crystals in the case of cobalt ions, The
standard phenol concentration of 0.67% is not high enough to drive Co2+ into Cl
tetrahedral conformation in both trirners, necessary for the total T -4 R structural
transi tion.
4.4 Six glutamines in a single and a triple mutant
Both B13Q and B8S/B13Q/B30amide mutants were designed to have reduced elec-
trostatic repulsion in the core of the hexamer. Markussen et al. (1987) proposed a
model for the six central glutamine residues, regularly arranged in a 'ring'<structurc
with well-defined hydrogen bonding (see figure 3.2). However, in neither of the mu-
tants in any of the forms known, do the glutamines exhibit this regularity (Bentley
et al., 1992, Dodson et al., 1991). Moreover, even in hexamers of the same confor-
mation, namely the T3R3 forms of B13Q with zinc and high salt conccntra.t.ions,
zinc-free Bl:~Q, and low-salt B8S/B13Q/B30amide, the glutamine residues take up
varying positions (see figure 4.3). As can be seen from the figure, the B13 residues in
molecule 2 of the B 1:3Q T3R3i structure (grown in the presence of zinc and high salt
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concentrations) has dual conformation, one of which overlaps reasonably well with
the same residue in the other structures. The B13 residues in the '1':3 trimer) how-
ever, take up different side chain positions in all three structures, getting involved
with different hydrogen bonding.
Figure 4.3: Stereo view of the B13 glutamine residues in three T3R3
structures of modified insulins. Thickest lines: 13l:3Q T:m.:3f structure;
medium thickness lines: zinc-free B13Q structure; thin lines: low-salt zinc
B8S/B13Q/B30amide structure.
4.5 Summary
The conformation of modified insulins has been rationalised in comparisons with pre-
viously known native and mutant insulin in various crystal forms. Seemingly subtle
changes in either the modified insulin itself (e.g.B 1:3Q insulin where one residue is
replaced by one of exactly the same size) or the crystallisation conditions (e.g.Co2+
instead of Zn2+ in Col insulin) have led to unexpected conformations for some of
the modified insulins. Independently of Smith and co-workers (Ciszak et al., 1995)
the T3R3f conformation has been established for all modified insulins isomorphous
with native 4Zn insulin.
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Chapter 5
Aggregation of insulin
5.1 Introduction
The assembly of insulin into hexamers is well understood. In the B-cells of the Islets
of Langerhans single chain preproinsulin is converted to proinsulin, in which the A
and B segments fold spontaneously into the insulin conformation. It then forms
dimers, and with the zinc ions present in the B-cells hexamerisation takes place,
after which conversion to mature insulin hexamers occurs. These hexamers then
precipitate in crystalline form owing to the pH (around 5.5) and the presence of zinc
and calcium ions. Upon extracellular release, the hexamers dissociate into dimers
and eventually into monomers, which are the biologically active species.
The crystallisation of insulin as occurring in nature, can be mimicked in the
laboratory. Several crystallisation protocols have been successful, yielding various
aggregation states and different conformations (see also chapter 4). The assembly
of proteins into polymers is stabilised by salt bridges, hydrogen bonds, dispersion
forces and by the entropic benefit associated with water released by the burial of
non-polar surfaces. An overview of the aggregation of insulin is shown in figure 5.1.
The tendency of insulin to form aggregates causes problems in the diabetic
patient, because of the slow release of insulin from the injection site. Genetically
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Figure 5.1: Aggregation of insulin in various conformations.
A chains in thin lines, B chains in thicker lines, with N-termini in
thickest lines. Monomers and dimer in T-conformation. Upon hex-
amer formation the B chain N-terminus may become helical, resulting
in R-conformation.
engineered insulins are therefore being produced which are not aggregated after
injection and therefore quickly released into the blood stream. On the other hand,
the production of more stable hexamers has led to slower acting insulins which allow
for a more constant basal level of insulin in diabetics. Knowledge about the dimer
and hexamer forming surfaces was used in the design of the mutants.
5.2 Insulin dimerisation
The dimer forming surface of the insulin monomer is almost planar, with mainly
non-polar residues, as shown in figure 5.2. It comprises the B chain C-terminal
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residues B22 to B3D, thereby including residues B24 to B26 which are in ,a-strand
conformation and form an antiparallel ,a-sheet in the dimer. The B chain a-helix
lies against the monomer surface, with residues 9, 12, 13 and 16 pointing outwards.
In the dimer, the two B13 glutamic acid residues are brought together, causing
electrostatic repulsion. In order for dimerisation to take place, this electrostatic
repulsion must be overcome by surplus favourable energies from other interactions.
Residues B2D and B21 of the loop between the B chain a-helix and ,a-strand, also
lie on the dimer forming surface.
Figure 5.2: Stereo view of the dimer forming surface of the in-
sulin monomer, on the right-hand-side in this view. Produced with
MOLSCRIPT (Kraulis, 1991).
The shape of the dimers as seen in various crystal structures is slightly different,
mainly due to the difference in conformation of the N-terminus of the B chains. The
dimers of the four native insulin species relevant to this thesis are shown in figures
5.3, 5.4, 5.5 and 5.6.
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Figure 5.3: The native orthorhombic insulin dimer, T2-state. View of
the smallest dimension on the left; view of the largest dimension on
the right (perpendicular to the first view).
Figure 5.4: The dimer from native insulin in rhombohedral form, T6-
state.
View of the smallest dimension on the left; view of the largest dimen-
sion on the right (perpendicular to the first view).
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Figure 5.5: The dimer from native insulin in rhombohedral form,
T3R3-state.
View of the smallest dimension on the left; view of the largest dimen-
sion on the right (perpendicular to the first view).
Figure 5.6: The dimer from native insulin in monoclinic form, R6-
state.
View of the smallest dimension on the left; view of the largest dimen-
sion on the right (perpendicular to the first view).
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5.2.1 Dimer stability
The insulin dimer is stable in aqueous solution between pH 2 and 8. The packing
interactions that stabilise the insulin dimer are adaptable, even where they involve
close and apparently complementary contacts. Therefore, non-polar mutations of
the monomer, such as B12 Val-e-Leu (Dodson et al., 1993), were ineffective in re-
ducing the association of monomers into dimers. Moreover, the residues in the
,a-strand of the insulin monomer, up to B25, are thought to be important in recep-
tor binding, and mutation of those residues might lower the potency of the mutant
as a therapeutic agent. The more important factor in insulin dimerisation seems to
be the electrostatic interactions. Introduction of more negative charges in the region
of residues B9 to B13 reduces dimerisation in solution. The mutation of B9 to Asp
produces one of the most effective monomers at neutral pH (Brange et al., 1988).
Glutamic acid is more flexible than aspartic acid, and thus more capable of moving
away from the site of repulsion.
The B9D/B27E and A21G/B9E/B10E mutants are indeed found to be mono-
meric under physiological conditions (Brange et al., 1988, Xiao, 1990). The crys-
tallisation environments (in particular the pH), however, can be such that dimerisa-
tion (or even hexamerisation) can still take place. In the case of B9D /B27E insulin,
the carboxylates of B9 and B13 seem partially protonated and can therefore form
hydrogen bonds with each other. There are also hydrogen bonds to water molecules,
for which the water molecules could be the hydrogen donors. The degree of proto-
nation is unclear, because the pH of the crystallisation is unknown. In the case of
A21G/B9E/B10E insulin, for which the crystals were grown at neutral pH, proto-
nation of the glutamates is unlikely. Nevertheless, this mutant forms dimers in the
crystal, by virtue of spatial separation of the six glutamates, and hydrogen bond
formation with other parts of the protein and water molecules.
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The dimer species of insulin is virtually the same, apart from the conformation
of the N-terminus of the B chain, throughout the whole range of aggregates and
crystal forms (see figures 5.3 to 5.6). Although the packing of the A21G/B9E/BIOE
mutant is quite different from that of the native and B9D/B27E insulins, this is
only due to a rearrangement of the flexible C-termini of the B chains. As viewed
along the v-direction, which is along a 21 screw axis, it can be seen from figure 5.7
that the A21G/B9E/BlOE molecule is merely rotated with respect to the native
molecule. This, and the changes at the C-termini of the B chains, allows for the
different packing in a slightly smaller volume.
a)
b)
=====-~=--=~=~-==='
Figure 5.7: Three orthorhombic dimers. Native and B9D/B27E in-
sulin (thin lines) are isomorphs, and A21G/B9E/B10E insulin (thick
lines) has different packing.
a) View of the three dimers along y, showing the cell of native insulin;
b) The same view, showing the cell of A21G/B9E/BlOE insulin.
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5.3 Insulin hexamerisation
The insulin dimer is wedge-shaped (see for example figure 5.3), rounded like an
orange-segment. The hexamer forming surfaces are loosely planar, along the long
dimension of the wedge, almost 70° apart when looking at the triangular side of the
wedge. The differences at the N-termini of the B chains cause the contacts between
dimers to be quite different in the various insulin hexamer types. In the T6 hexamer
of native 2Zn insulin, only around half of the long dimension of the wedge is involved
in dimer-dimer contacts, whereas in the R6 hexamer (the native monoclinic form)
almost all of the residues along the long side of the wedge have contacts with other
dimers. All hexamers have residues B9, BI0 and B13 in the core.
In the T6 hexamer there is strong hydrogen bonding between A14 tyrosine
residues from both molecules, to that of a symmetry relative from the other molecule.
The B13 glutamic acid groups form hydrogen bonded pairs but usually do not come
into close contact in the centre. The extended N-termini of both B chains make
close contacts with the A chains of symmetry-related molecules, with the Bl Phe
side chains in a hydrophobic pocket between the main A chain and A14 Tyr of its
neighbour. There are intricate contacts between residues B9 Ser and BI0 His: from
B9 of molecule 1 to B10 of a symmetry-related molecule 1 and from BI0 of molecule
1 to B9 of the other symmetry-related molecule 1, and vice versa for the B9 and
BI0 of molecule 2. In the R6 hexamer the A14 tyrosine residues do not seem to be
involved in hexamer formation; some can not be seen in electron density maps. Also,
the contacts between residues B9 and BI0 are irregular. Some of the B13 glutamate
groups come into close contact with each other. The N-terminal stretches of the B
chain a-helices come close together to form a channel of approximately 8A diameter,
shielding the zinc sites, with contacts to the A7-A11 loops. In the T3R3 hexamer, the
A chain of molecule 1 is not involved in dimer-dimer contacts at all. The contacts
between B9 and BI0 residues are similar to those in the T6 hexamer, with both
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conformations of residue BlO of molecule 2 making contact with B9 of a symmetry-
related molecule 2. There is no close proximity of the B13 glutamic acid groups.
The N-terminus of the B chain of molecule 1 makes contact with residues B16 Tyr
to B21 Glu of a symmetry-related molecule 2. One of the strongest contacts seems
to be that between B21 from molecule 2 with B3 of a symmetry-related molecule 1,
which limits the flexibility of the B21 Glu side chain.
The insulin hexamer is torus-shaped with dimensions 35A by 50A. It essen-
tially has 32 symmetry. In the T6-state hexamer in the rhombohedral crystal, this
symmetry is nearly exact. The threefold axis lies along the crystallographic c-axis,
and the differences between the two T-state monomers in the asymmetric unit are
only minor. In the T3R3 hexamer in the same crystal form, the 32 symmetry breaks
down. The threefold axis is exact, but the local twofold symmetry is distorted, due
to the changes at the N-terminus of the B chain of molecule 2 (see figure 5.5). In the
R6 monoclinic structure both the threefold and the twofold axes are not exact. The
monomers, however, are similar, and the non-crystallographic symmetry is reason-
ably well preserved (see figures 3.7 and 3.6). In the case of the B25Y(B29-A1)A4Q
mutant, the hexamer is situated on a special position of 32 symmetry in the cubic
unit cell. The monomer is therefore the asymmetric unit.
In a solution free of metal ions, insulin exists as a mixture of monomer, dimer,
tetramer, hexamer and higher aggregates, proportions depending on the concentra-
tion (Blundell et al., 1972). In the presence of zinc ions, as in the B-cells of the
Islets of Langerhans, the hexamer species prevails. It has been found that other
divalent metal ions (e.g. Ni2+, Co2+, Cd2+ and Cu2+) can play the same role in
the hexamerisation of insulin (Schlichtkrull, 1958, Hill et al., 1991). Zinc sites as-
sociated with a T-state molecule are seen to have octahedral coordination, whereas
those associated with insulin in the R-state have tetrahedral coordination.
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5.3.1 Hexamer stability
The insulin hexamer is stable in aqueous solution between pH 5 and 8. Because
both polar and non-polar residues are buried between the dimers, the packing of
dimers into a hexamer is much looser than that of monomers into a dimer. Six
B13 glutamic acid residues come close together in the core of the hexamer, causing
electrostatic repulsion which must be reduced in order for hexamerisation to take
place. The coordination of zinc in the core balances the charges, and is the driving
force in hexamer formation in insulin. The R6 hexamer seems to be the most stable
hexamer species in solution. This is probably because of the favourable contacts of
the N-termini of the B chains. Not only are more residues involved in dimer-dimer
contacts in the R6 hexameric state, but the N-terminal stretch of helix closes off
the solvent channel towards the zinc ions, disabling diffusion of zinc ions into the
solvent. In the T6 hexamer in solution there is a constant exchange of zinc between
protein and solvent (Smith et al., 1984).
The stability of the hexamer may be enhanced through various measures, to
improve prolonged-acting insulin in therapy. In the B13Q mutant the electrostatic
repulsion of the B13 glutamate groups is removed by substitution with the neutral
residue glutamine. The mutant readily forms hexamers under various crystalli-
sation conditions, even without the presence of zinc or other divalent metal ions
(Bentley et al., 1992). Therefore, the absence of repelling negative charges in the
core of the hexamer is enough to nullify the requirement of zinc in the hexamerisa-
tion of insulin. In B8S/B13Q/B30amide insulin the substitution of B13 Glu with
GIn has the same effect as in the single mutant B13Q. The mutant crystallises read-
ily as R6 hexamers in the presence of phenol. It has also been crystallised as T3R3
hexamers under low salt conditions, with the conformation of the T-state quite dif-
ferent from that in native insulin (Dodson et al., 1991), see also chapter 4. In the
B9H mutant, more binding sites for zinc have been introduced. In the rhombohedral
form of this mutant the zinc coordination is well-defined, if geometrically unusual.
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The mutant adapts to different crystallisation conditions by forming monoclinic lUi
hexamers, creating a pool of zinc in the core of the hexamer, with some of the BI:{
glutamic acid residues taking part in zinc coordination. In that structure, all six
glutamic acid residues may be fully ionised without causing repulsion ill t.hc COI'C'
of the hexamer. The Col insulin shows that Co2+ can indeed play the samr: role
in insulin hexamerisation as Zn2+, both in octahedral and tetrahedral coordinaf.iou.
The B25Y(B29-Al )A4Q mutant crystallises as a fully 32 symmetric hexamcr, ill
which the B25 side chains have found a position that allows twofold symmetry of
the dimer axis. For mutant B9D/B27E it is possible to form hexamers when Ca2+
ions are present in the crystallisation solution, balancing the charges of the B9 Asp
residues in the core of the hexamer (Turkenburg, 1992).
5.4 Packing of insulin in crystals
In the T6 conformation, the departure from twofold symmetry in the essentially :32
symmetric hexarner is due to packing contacts. Those for the 2Zn native insulin
in rhombohedral crystal form are described in Baker et al. (1988). The loop A8 to
AI0 protrudes from the hexamer into a gap created by the same stretch of rcsid lies
in a different hexamer along the threefold axis. This would cause B5 histidine' from
molecule 1 in one hexamcr to collide with B5 histidine from molecule 2 in a different
hexamer. To avoid this, one of them is rotated to another, conformationally stable,
position. The packing of three hexamers in the unit cell is shown in figure .5.8 on
the right, viewed along the threefold hexamer axis. The two hexamers in thin lines
are each at different levels of z, along the direction of the threefold axis.
The packing contacts for native monoclinic insulin (the R6 hexamcr ), 4Zn
native insulin in rhombohedral crystal form (the T3R3 hexamer), and native or-
thorhombic insulin (the T2 dimer) have been described by Derewenda (1990). In
the R6 hexamer, the differences in the number of contacts from one chain t.o til('
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Figure 5.8: Packing of two rhombohedral crystal forms of insulin.
T3R3-form ('4Zn') on the left, T6-form ('2Zn') on the right. Hexamers
at three different levels of z around the a1 screw axis, in both cases.
next are marked, ranging from two to as much as ten per chain. Therefore, the sym-
metry within the hexamer is less exact. The packing of the R6 hexarner is indicated
in figure 5.9, viewed along one hexamer's local threefold axis. It can be seen from
this figure that the hexamers do not pack along this threefold axis; the symmetry-
related hexamer in the unit cell is packing behind (in this view) the first hexamer,
with its local threefold axis approximately perpendicular to thc first. The packing
in the plane perpendicular to the first hexamer's non-crystallographic threefold axis
is shown to reveal the crystal contacts in that direction.
In the T3R3 hexamer, the asymmetry of the hexarner and the asymmetry of
the crystal contacts are not attributable to the collision of the B,) histidines, as in
the native T6 hexamer. This is due to a conformational change in the N-terminus
of the B chain of molecule 2, which in itself constitutes a large deviation from exact
symmetry. The crystal contacts of molecule 2 are therefore markedly different from
that of molecule 1. The packing of three hexamers in the unit cell is shown in figure
5.8, alongside that for T6 hexamers in the same view.
In the orthorhombic dimer, B1 Phe of both molecules play an important role
in the crystal contacts between the dimers. As can be seen from figure 5.3, these
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Figure 5.9: Packing of monoclinic insulin, a layer perpendicular to the
local threefold axis of one of the hexamers in the unit cell.
residues protrude far from the bulk of the dimer. Residues A13 and A14, involved in
hexamerisation in rhombohedral crystals, are involved in crystal contacts between
dimers across crystallographic twofold axes in the orthorhombic crystal. The crystal
contacts in orthorhombic insulin are fewer than in hexameric forms, reflecting higher
solvent content. This is shown for one direction in figure 5.10.
I
.'
Figure 5.10: Packing of orthorhombic insulin. Direction compared to figure 5.7:
rotated 90° along an axis perpendicular to the plane of the paper.
The packing of the A21G/B9E/BlOE mutant is different from that of native
orthorhombic insulin, which is shown in figure 5.10. The direction of this figure is
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chosen to match that of figure 5.7, showing the different positioning of the native
and mutant dimers in the cell. The packing of the mutant can be seen in figure 5.11.
b
t...
Figure 5.11: Packing of A21G/B9E/B10E insulin, shown along the
three cell axes.
In comparing the top left part of this figure with figure 5.10, it is quite clear
that the packing of the mutant in this plane is tighter than that of the native
molecule, resulting in a smaller unit cell. The crystal contacts of the mutant are
summarised in table 5.1. As can also be seen in figure 3.50, only one of the mutated
residues is involved in crystal contacts, namely residue BlO. This residue from both
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molecules in the dimer is involved in contacts with an A14 tyrosine residue from the
other molecule of a symmetry-related dimer. The new positions for the C-terminal
residues in both B chains provide new crystal contacts, not observed in the native
structure (Derewenda, 1990).
A chain contacts B chain contacts
chain rest molt chain res mol chain res mol chain res mol
A 5 1 A 18 2 B 1 1 A 14 1
A 12 1 B 4 2 B 1 1 A 17 1
A 14 1 B 1 1 B 1 1 B 22 1
A 14 1 B 3 2 B 1 1 B 13 2
A 14 1 B 6 2 B 2 1 A 17 1
A 14 1 B 10 2 B 3 1 A 14 2
A 15 1 A 18 2 B 4 1 A 18 1
A 15 1 B 4 2 B 4 1 A 12 2
A 17 1 B 1 1 B 6 1 A 14 2
A 17 1 B 2 1 B 10 1 A 14 2
A 18 1 A 5 2 B 14 1 A 13 2
A 18 1 A 18 2 B 17 1 A 17 2
A 18 1 B 4 1 B 17 1 B 17 2
A 19 1 A 5 2 B 18 1 B 17 2
A 19 1 A 18 2 B 22 1 B 1 1
A 19 1 A 19 2 B 25 1 A 4 2
B 27 1 B 30 2
A 4 2 B 25 1 B 1 2 A 14 2
A 4 2 B 25 2 B 1 2 A 17 2
A 5 2 A 18 1 B 3 2 A 14 1
A 5 2 A 19 1 B 4 2 A 12 1
A 12 2 B 4 1 B 4 2 A 15 1
A 13 2 B 14 1 B 6 2 A 14 1
A 14 2 B 3 1 B 10 2 A 14 1
A 14 2 B 6 1 B 13 2 B 1 1
A 14 2 B 10 1 B 17 2 B 17 1
A 14 2 B 1 2 B 17 2 B 18 1
A 17 2 B 17 1 B 25 2 A 4 2
A 17 2 B 1 2 B 30 2 B 27 1
A 18 2 A 5 1
A 18 2 A 15 1
A 18 2 A 18 1
A 18 2 A 19 1
A 19 2 A 19 1
Table 5.1: Crystal contacts <3.6A III A21G/B9E/B10E insulin.
[rese residue; tmol=molecule.
B25Y(B29-A1)A4Q insulin makes few packing contacts, compared to other
hexameric insulins. A detailed picture of the crystal contacts of the mutant is shown
in figure 5.12, and they are summarised in table 5.2. The contact of residue 43 Tyr
(for numbering of this mutant, see the legend to table 5.2) with its symmetry relative
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Figure 5.12: Detailed packing of B2.5Y(B29-A 1 )A1Q insulin. The two
regions of close contact between hexamers ill exploded views.
is included in the table because it constitutes an aromatic stacking interaction,
although the distance is somewhat larger than the other contacts. The enlarged
part on the left of figure 5.12 includes the contacts of 2.'), 2!), 19 and 50, while the
top half of the figure shows the contacts of residues 1, 22, 41, 42 and 43. Residue
5, the histidine residue which causes asymmetry in the native rhombohedral T6
hexamer, is surrounded by solvent in the mutant. Exact :32 symmetry is therefore
possible. The solvent content of the mutant and the lack of precise contacts are
probable causes of the limited diffraction.
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from residue to residue approximate distance (A)
1 22 2.G
1 43 :~.4
25 25 3.4
29 49 2.7
29 50 2.7
41 43 3.3
42 42 3.4
43 43 3.9
.50 50 3.4
Table 5.2: Crystal contacts <3.5A in B25(B29-A1 )A4Q insulin. The
N-terminus of the mutant is equivalent to residue Bl in native insulin,
and the residues arc numbered consecutively, from 1 to .50.
A stereo view of the contents of one unit cell of B2.5Y(B29-Al)/vlQ iusuliu
IS shown in figure 5.13, with the body diagonals of the cube indicated from the
appropriate corner of the cell to the midpoint. The hexamers are located on points
of 32 symmetry, ~ along each body diagonal (from different corners), in a tetrahedral
arrangement with respect to each other.
Figure 5.13: Stereo view of packing of B25Y(B29-A1)A4Q insulin within
one unit cell, showing the tetrahedral arrangement of four hcxamers, with
the appropriate half of each of the body diagonals indicated.
The three-dimensional packing of the mutant is shown in figure 5.14, viewed
along the threefold axis of the central hexamer. The four tetrahedrally arranged
201
hexamers (see figure 5.13 in different view) are shown in thick lines in the main
overlay. The three non-central ones in the tetrahedrally arranged set of four (shown
separately in the circle to the right of the middle overlay) are beh ind the layer of
hexamers shown in the circle to the left of the middle overlay. These tetrahedrally
related hexamers do not make any contacts shorter than 3.5A with the central
hexamer.
Figure 5.14: Extended packing of B25Y(B29-Al)A4Q insulin. Com-
ponents of the middle diagram indicated: contents of one unit cell
(shown on the right) superposed on one full layer of hexamers (shown
on the left).
The crystal contacts of the isomorphous modified insulins B13Q, Col, B9H
and B8SjB13QjB30amide are much the same as those of the native equivalents.
The orthorhombic mutant B9D /B27E is quite different from native orthorhombic
insulin at the N-terminus of the B chain of molecule 1, and therefore has different
crystal contacts at that point. Residue B2 of molecule 1 has an additional contact
with residue A14 of molecule 2 of another dimer, and residue Bl of molecule 1 is in
contact with residue A2 of molecule 2 of yet another dimer.
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5.5 Summary
Aggregation and packing variations have been rationalised using existing structural
knowledge. Mutant studies have drawn attention to the possibility of specific choice
of aggregation state of insulin for therapy (mutations may increase or reduce ag-
gregation specifically). The crystallisation environment does, however, not always
represent a suitable environment for the desired aggregation state, resulting in for
example dimers in the crystal form for mutants which are monomeric under physi-
ological conditions.
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Chapter 6
Metal binding in insulin
6.1 Introduction
Insulin storage vesicles in humans and many other species contain high concentra-
tions of Zn2+ and CaH ions (Howell et al., 1975). Zinc plays an important role in
insulin hexamerisation, which is closely related to some of the processes in insulin
biosynthesis and storage (Emdin et al., 1980). Sudmeier et al. (1981) established
that the 2Zn insulin hexamer is also capable of binding calcium. Detection of cal-
cium in zinc insulin crystals by X-ray diffraction is difficult since calcium and water
only have a slightly different number of electrons (Hill et al., 1991). A zinc-free
insulin hexamer crystal can be artificially produced by soaking out the zinc from
an existing 2Zn crystal with EDTA, after which the B10 histidine residues normally
involved in zinc coordination are in the same conformation, indicating they are held
in place by the hexamer as a whole (Hill et al., 1991).
Insulin has two sites for zinc binding seen in all zinc containing insulin hex-
amers, on the (local) threefold axis, about 15A apart on either side of the centre of
the hexamer. Other divalent metal ions can be substituted easily for ZnH in these
positions, a phenomenon investigated first by Schlichtkrull (1958). In crystals of
native insulin grown with high salt concentrations, three more, off-axial, sites for
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zinc binding occur, with B5 His residues in molecule 2 taking part in the coordina-
tion of the metal. The BID His residues in molecule 2 take up two conformations,
one coordinating to the zinc ion on the threefold axis, the other coordinating to the
off-axial zinc ion. The anion of the salt acts as additional ligand for the metal.
Emdin et al.(198D) make a distinction between zinc coordination and zinc bind-
mg. The first is specific coordination of zinc in the insulin hexamer, holding it to-
gether via the histidine residues. Zinc binding refers to the more aspecific binding
of zinc, mainly to carboxylic acid groups on the surface of the hexamer. The most
convincing site for zinc binding is in the centre of the hexamer between the B13 glu-
tamic acid side chains. Binding of Cd2+, Ca2+ and Pb2+ is tighter in that position
than binding of zinc (Hill et al., 1991). Simply soaking zinc ions into a 2Zn insulin
crystal only increases aspecific zinc binding; the conformational change to the 4Zn
form does not occur (Emdin et al., 1980).
Because Zn2+ is spherical, the crystal field is undistorted and there is no real
preference for either octahedral or tetrahedral coordination. In insulin, the confor-
mation of the molecule (see chapter 4) dictates the coordination of the metal. In the
native T6 hexamer, both zinc ions are octahedrally coordinated by three symmetry-
related BID histidine residues and three symmetry-related water molecules. These
zinc ions are located in a shallow depression of the hexamer, and are easily diffused
in and out of the hexamer. In the native T3R3 hexamer, the zinc coordination in
the T3 trimer is octahedral, equivalent to that in the T6 hexamer. In the R3 trimer,
however, both the axial and the off-axial zinc sites have tetrahedral coordination.
The axial zinc ion is coordinated by the three symmetry-related BlO histidines of
molecule 2, with the salt anion as fourth ligand. The off-axial zinc ion is coordi-
nated by the second conformation of the BID histidines of molecule 2, B5 His from a
symmetry-related molecule 2 and two salt anions. With the different conformation
of the N-termini of the B chains, the axial zinc ion in the R3 trimer is shielded from
the environment by three a-helices, and the rate of diffusion of zinc from the hex-
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amer is decreased, lowering the rate of dissociation of the hexamer itself. The 4Zn
crystal form, when used in pharmaceutical preparations, therefore has slow-acting
properties. In the native R6 hexamer, zinc ions are only found on the local threefold
axis, tetrahedrally coordinated by three BIG histidines and usually a salt anion, if
present in the crystallisation solution, as fourth ligand. Both zinc ions are covered
by a-helices of residues BI to B19 and therefore do not readily diffuse from the
hexamer. As discussed in chapter 4, the R6 hexamer is therefore the most stable
hexamer species in solution (Kaarsholm et al., 1989).
6.2 The role of zinc in insulin biosynthesis
The zinc-free pig proinsulin hexamer has a net charge of -12 at neutral pH and has a
capacity to bind 30 zinc ions (Grant et al., 1972). Proinsulin is therefore positively
charged and thus highly soluble, which is a necessary property as it has to travel
through the endoplasmic reticulum and the Golgi. Most of the zinc binding occurs
on the surface of the hexamer, where pairs of carboxylate groups pair up to bind
zinc. The proinsulin C-peptide provides 24 of the carboxylates involved in this zinc
binding. As the proinsulin is transported through the Golgi, conversion to insulin
starts. In that process, the 24 carboxylate groups on the surface of the hexamer are
lost, drastically reducing the capacity to bind zinc. At the same time, the 24 (6*4)
connecting basic residues are removed. Thus the resulting insulin hexamer also has a
net charge of -12 in the absence of zinc at neutral pH. When an insulin hexamer binds
six zinc ions (the coordinated ions in the centre included), the resulting complex is
neutral and precipitates. The insulin hexamer is very insoluble, and aggregates
in microcrystalline form at pH 5.2-5.6 (Schlichtkrull, 1958). The insulin storage
vesicles are therefore very densely packed with crystalline insulin, which reduces the
susceptibility to enzymes that would break down the protein.
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6.2.1 Charges
The effect of charges and the resulting net charge is obviously very important in the
production of insulin in the body. Modifications of the insulin molecule involving a
change in charges must therefore have some serious implications in insulin therapy.
Most of the modifications introduced in the insulins described in this thesis affect
the charge, as shown in table 6.1.
insulin name modification charge change net charge of
resulting monomer
B13Q GIu-Gln one fewer negative -1
B8S/B 13Q/B30amide Gly-Ser neutral
Glu-Gln one fewer negative
carboxylate-e amide one fewer negative 0
B9D/B27E Ser-e-Asp one extra negative
Thr-Glu one extra negative -4
B25Y(B29-Al)A4Q Phe-vTyr neutral
delete B30 carboxylate one fewer negative
Glu-Gln one fewer negative 0
A21G/B9E/BIOE Asn-Gly neutral
Ser-Glu one extra negative
His-Glu one extra negative -4
B9H Ser-e-His neutral -2
Col Zn~T_Co~T neutral -2
Table 6.1: Calculated net charge of the modified insulin monomers, at
neutral pH
In crystallisations various compounds are added, such as precipitant, buffer,
solvent and cryoprotectant. Anyone of them might have an influence on the net
charge of the polymer species in the crystal. Although it is difficult therefore to
determine the exact charge of the crystal species, and despite the resolution of
crystal structure determination often not being sufficient to determine the occupancy
of ions, it is still possible to discuss the effects of specific mutations (see table 6.2).
The B9D /B27E mutant is given here as if it has the pH of the buffer, namely pH 6.
As the crystallisation was probably at lower pH, there would have been up to four
fewer negative charges in the resulting dimer.
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insulin name crystal species known additives] net charge
zinc-free hexamer - -12
2Zn hexamer 2 Zn2+ -8
4Zn hexarner 2.67 Zn2+, 1 Cl-t -7.67
monoclinic hexamer 2 Zn2+, 2 CI- -10
B13Q hexamer 4 Zn2+, 2 CI- 0
B8S jB 13QjB30amide hexamer 2 Zn2+ 2 CI- +2,
B9DjB27E dimer - -8
B25Y(B29-A1)A4Q hexamer 2 Zn2+ +4
A21GjB9EjB10E dimer - -8
B9H rhombohedral hexamer 7 Zn2+ 2 CI- 0,
B9H monoclinic hexamer 7 Zn2+ 6 CI- -4,
Col hexamer 2 Co2+ 1 l- 1 Na" 1 CI- -9, , ,
Table 6.2: Calculated net charge of the aggregated insulin species, at
neutral pH.
t modelled in electron density and (partly) refined;
t from Smi th et al. (1984)
A net charge of zero for a hexamer with ligands would readily result in precip-
itation or crystallisation. Therefore, the net charges for B13Q insulin and B9H in-
sulin in rhombohedral crystal form indicate a stable species. On the other hand, the
strongly negative charge of the monomers of B9DjB27E and that of A21GjB9EjB10E
combined with the removal of the main potential zinc binding site, leaves the lack of
hexamerisation as no surprise. Both those mutants would bring 24 negative charges
into a hexamer species, which would require binding of 12 metal ions. A hexameric
species of B9DjB27E has been described by J. Turkenburg (1992). It was crystallised
at neutral pH in the presence of 1M calcium and phenol. Upon careful inspection
of electron density maps, six peaks in the core of the hexamer were found to have
higher coordination than possible for water molecules, and were subsequently mod-
elled as Ca2+ ions, reducing the net charge of the hexamer to -12, presumably with
further disordered counterions.
The stability of the hexamer in the crystal obviously does not only depend on
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the charges present. In monoclinic insulin, where the hexamer structure is R6, the
stabilising effect of the zinc coordination itself is enhanced by the inability of the
zinc ions to diffuse out of the hexamer. Zinc-free insulin can be kept in crystal form
as a hexamer, even without the zinc coordination in the core to neutralise (some
of) the charges. The B13Q mutant has also been reported to be stable in crystal
form as zinc-free hexamers (Bentley et al., 1992). Additionally, most crystallisation
solutions contain a certain amount of metal ions other than zinc, such as calcium
or sodium. Detection of these in crystal structures is difficult because they do not
add enough electrons to the electron density maps and may not bind tightly or
specifically enough. Sometimes the number of ligands coordinating to a peak gives
an indication for metal binding. The aspecific binding of metal ions on the surface
of the protein is difficult to detect because the coordination number associated with
a specific electron density peak is often uncertain, as protein residues on the surface
of the molecule are often disordered or so flexible that they can not be modelled.
6.3 The influence of phenol
Phenol was first detected in the monoclinic insulin hexamer (Derewenda et al., 1989)
in a position previously seen occupied by zinc in the 4Zn T3R3 structure (in the
off-axial site), and B6 Leu in the 2Zn T6 structure (see figure 6.1). Phenol and
phenol-like compounds were originally added to insulin preparations as anti-bacterial
agents. As it turns out, phenol has a dramatic effect on the insulin conformation,
driving it to the R-state. Depending on the concentration of phenol present, a hex-
amer may become T3R3 at low concentrations or R6 at high concentrations. Since
phenol has a direct effect on the insulin conformation, it has an indirect effect on
the coordination of the metal ions.
The phenol concentration in the monoclinic crystallisation protocol is 0.67%,
resulting in R6 hexamers at pH 6.5 to 7.8. The B8S/B13Q/B30amide mutant crys-
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Figure 6.1: The phenol pocket region in three native insulin structures.
Overlap of molecules 2 of T3R3 (thin lines) and T6 (medium lines)
rhombohedral insulin onto R6 monoclinic insulin (thick lines) showing
the region occupied by phenol in R6 insulin, zinc in T3R3 insulin and
B6 Leu in T6 insulin.
tals were grown according to this protocol, resulting in monoclinic crystals and R6
hexamers, with two zinc ions on the local threefold axis, tetrahedrally coordinated by
three BlO histidine residues and a chloride anion. B9H insulin was also crystallised
following the monoclinic protocol, with essentially the same results. Because of the
presence of additional histidines, more zinc was found in the core of the hexamer
(see section 6.4).
Upon varying phenol concentration and pH, different crystal forms and differ-
ent hexamers are produced. Whittingham et al. (1995) have reported a rhombohe-
dral crystal form with T3R3i hexamers with a phenol concentration of 0.05% in the
crystallisation solution, at pH 5.2-5.5. Smith and Dodson (1992) have described a
rhombohedral R6 insulin hexamer that binds phenol, crystallised in the presence of
1% phenol at pH 8.49. Col insulin was crystallised with 0.67% phenol, an equivalent
amount to the monoclinic protocol. It did not, however, yield monoclinic crystals.
The rhombohedral crystals produced contain T3R3i hexamers. It appears that the
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preference of Co2+ ions for octahedral coordination has resisted phenol's drive to
the R6 conformation, regardless of the presence of sufficient phenol. In addition
to that, the phenol site contains two phenol molecules instead of one, as shown in
figure 3.38, further stabilising the Co2+ forced in a tetrahedral conformation. Most
complexes with phenol have only one ligand per monomer.
Figure 6.2: Stereo view of the double ligand site in Col insulin and the
insulin/4-hydroxybenzamide complex (Smith et al., 1996), showing
the phenolic derivatives
Smith et al. (1996), however, also describe a complex of insulin with two ligands
per monomer, in which case the ligand is the phenolic derivative 4-hydroxybenzamide.
One ligand is in the usual position, hydrogen bonding to the main chain of A6 and
All of molecule 2. The other ligand is directly hydrogen bonded, through its hy-
droxy group, to N81 of BID His in molecule 2 and the carbonyl group of the first
ligand. There are also indirect hydrogen bonds, through a water molecule, of the
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amide/carbonyl function of the second ligand with the main chain carbonyl and N81
of BIO His in molecule I in a symmetry-related dimer. In Col insulin the hydrogen
bonds of the first ligand are conserved, although that with the main chain nitrogen
of All is slightly long (3.4A). The second phenol molecule has a hydrogen bond to
N8I of BlO His in molecule 2, just like the second 4-hydroxybenzamide. This phenol
molecule also has a short hydrogen bond to the side chain of BI3 Glu in molecule
2. The position of the second ligand is quite different, as can be seen in figure 6.2.
The second phenol molecule takes up a position partly filled by the amide group in
the benzamide ligand, which means that the BI3 Glu residues are able to take up
different positions in the different structures. The bridging to another dimer does
not occur in the double-phenol case, since there is no appropriate functionality on
the para-site of the phenol.
6.4 Coordination of the metal
The T-conformation in the insulin hexamer is linked with a site of octahedral metal
coordination on the (local) threefold axis, whereas the metal coordination in insulin
in the R-conformation is always tetrahedral, whether on or off the axis, because
of steric hindrance. In spectroscopic studies, the substitution of CoH for ZnH
introduces a sensitive chromophoric probe of the structural and chemical events
during the T -+ R transition. Ciszak and Smith (Ciszak and Smith, 1994) argue
that a certain amount of care should be taken over this, since there is evidence
of both octahedral and tetrahedral coordination around the zinc in the T trimer
of the T3R3i structure they describe. This would lead to misinterpretation of the
extent of the T -+ R transition based on spectroscopic evidence alone. Following
the discussion of the preference of CoH for octahedral over tetrahedral coordination,
some consideration needs to be given to the applicability of the ion in the study of
the phenomenon of T -+ R transition in insulin. The conditions under which CoH
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insulin converts from T to R conformation seem to have to be more extreme than
is necessary for Zn2+ insulin.
The Col insulin described in this thesis is in T3R3f conformation and has
the expected octahedral metal site with coordination by three symmetry-related
BID histidines from molecule 1 and three water molecules. The other metal site is
tetrahedral, with the three symmetry-related BID histidines from molecule 2 and an
iodide ion as ligands. The histidines in the R3f trimer are stabilised by an extra
phenol ligand in the phenol pocket. The presence of the iodide further stabilises the
essentially unfavourable coordination of the Co2+ ion.
The B13Q mutant, also in T3R3f conformation, has quite a different distri-
bution of metal in the hexamer. The metal site in the T3 trimer is as expected,
octahedrally coordinated by three symmetry-related BID His residues from molecule
1 and three water molecules. In the R3f trimer, the BID histidines of molecule 2 have
fully changed their side chain conformation to the second alternative seen in native
T3R3f insulin. Hence the mutant has three fully occupied tetrahedrally coordinated
zinc ions in the off-axial sites, as shown in figure 6.3. Bentley et al. (1992) have pos-
tulated that the Glu to GIn mutation in itself favours R-conformation, without the
need for zinc ions or halides. The requirement of the mutant for Zn2+ in the core
of the hexamer to balance the negative charges is absent, which might explain the
total change in conformation of the BID histidine side chain in the R3f trimer away
from the position where it was needed in the native structure to coordinate zinc.
In B8S/BI3Q/B30amide insulin, in R6 conformation, both zinc sites on the
local threefold axis have tetrahedral coordination with three BID histidines, and
probably chloride as a fourth ligand. The T3R3 form of the mutant has been de-
scribed by Dodson et al. (1991). Although it has the same mutation as B13Q insulin,
and thus the same non-requirement for zinc in the core of the hexamer, there is no
indication of off-axial zinc binding in the B8S/BI3Q/B30amide mutant. This might
be related to the different conformations of the side chains of the B13 residues (see
214
"Cl
"Cl
Figure 6.3: Stereo view of off-axial, tetrahedrally coordinated zinc in
BI3Q insulin. BID His in thick lines, symmetry-related B5 His in
thinner lines.
chapter 4).
In the B9H mutant, in both forms, rhombohedral T3R3! and monoclinic R6,
there is additional zinc present in other sites than the axial sites coordinated by BID
histidines. In the mutant T3R3! hexamer, the zinc ions are distinctly organised. In
the T3 trimer the axial zinc ion is unexpectedly tetrahedrally coordinated by three
symmetry-related BlO His residues from molecule 1 and chloride. The electron
density for the fourth ligand is not threefold symmetrical and has therefore been
modelled and refined as a chloride. On the other side of the BID His side chain,
a peak was found in which an additional zinc ion could be modelled, and refined
with an occupancy of 0.67. This zinc ion is tetrahedrally coordinated by the Nol
of the BID His, the NoI of a symmetry-related B9 His, and two water molecules
(see figure 3.32). The geometry of the B9 His residue with respect to the zinc ion is
imperfect, although the coordination of the zinc ion is reasonable at first glance. The
tetrahedral angles around the zinc ion range from 97.3 to 123.2°. In the T3 trimer
of the native T3R3 hexamer, this region is essentially taken up by water structure,
with the side chain of residue B13 from molecule 2 folded slightly more towards
the T3 trimer. In the mutant the carboxylate group of this residue is folded away,
towards its own trimer. In the R3! trimer, the axial zinc ion has regular tetrahedral
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coordination with three symmetry-related B10 histidines from molecule 2 and a
chloride anion, equivalent to the native structure. The other zinc coordination site
is in almost the same position as the off-axial zinc in the native structure (the sites
are less than lA apart). However, instead of the second conformation of the B10 His
of molecule 2 in the native structure, the histidine residue at position B9 is involved
in the tetrahedral coordination of the zinc ion, together with B5 His of the same
monomer. Both histidines have Nf2 directed towards the zinc ion. The other two
ligands are water molecules. The geometry of the histidine side chains with respect
to the zinc ion and the tetrahedral coordination are almost perfect (see tables 3.17
and 3.18), and the main chain conformation is totally conserved as compared to
the native structure. The side chain conformation of B13 Glu in molecule 1 is also
equivalent to that seen in the native T3R3 structure.
In the monoclinic R6 form of the B9H mutant, the zinc sites on the local
threefold axis are as expected: tetrahedral coordination with three BID histidines
and a chloride anion. In an overlap of all six B chain a-helices of the mutant on
the corresponding helices of the native structure, one trimer has significantly better
overlap than the other. The zinc ions connected with the second trimer in the mutant
are almost lA away from the zinc positions in that trimer in the native structure.
This means that building up the mutant hexamer from dimers positioned separately
by molecular replacement was the best approach. There are four zinc coordination
sites involving the N81 atoms of B10 and B9 histidines, all modelled with chloride
anions as third and fourth ligands, and refined with half occupancies for the zinc and
chloride ions. The coordination of these zinc ions is essentially tetrahedral, although
the geometry of the histidines with respect to the zinc ions is very unusual. The
term 'coordination' is perhaps best not used in such cases. In addition to those zinc
sites, there is a pool of density in the centre of the hexamer. With the aid of a peak
searching program (X-SOLVATE (Molecular Simulations, 1996)), six of the peaks
could be modelled as zinc ions, with Nf2 atoms of B9 His and Of atoms of B13 Glu
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residues in the vicinity (less than 2.5A). The coordination of these six zinc ions is
irregular, indicating disorder, and they were refined with half occupancy.
The B25Y(B29-A1)A4Q mutant has not been fully refined, and the resolution
of the data does not allow detailed analysis of the coordination of the (putative)
zinc sites. There is, however, no reason to doubt octahedral coordination in this
particular T6 hexamer.
6.5 Other metals in other places
There is evidence that Ca2+ ions are taken up by rhombohedral insulin crystals in
vivo (Howell et al., 1978). Hill et al. (1991) have described an attempt to detect
Ca2+ ions in a 2Zn insulin crystal, which failed because the calcium ions are not easily
distinguishable from water molecules. In the monoclinic form of the B9D /B27E
mutant, described by J. Turkenburg (1992), calcium ions were found to balance the
charges in the core of the hexamer. In that case the number of ligands involved was
too high for a water molecule.
For the modified insulins described in this thesis, alternative metal binding is
only proposed for the Col insulin. One region of electron density in the R3f trimer on
the threefold axis on the surface of the hexamer, in the channel left by the extended
conformations of the three N-terminal residues of the B chains of molecule 2, could
not be modelled satisfactorily with water molecules. Attempts were made to model
a threefold disordered citrate ion or acetate ion on the threefold axis, bonded to a
sodium ion off the threefold axis. The sodium ion refined reasonably well, and had
a water molecule 2.oA away (see figure 6.4). The modelling of an acetate ion was
promising, although the refinement was unsuccessful, and the ion was not included
in the calculations of the final maps and R-factors.
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Figure 6.4: Sodium acetate in Col insulin. Stereo view down the
threefold axis. 2Fo-Fc electron density at +10- for sodium and water
positions, F0- Fe electron density at +30- for the acetate position.
6.6 Summary
Metal binding and metal coordination in modified insulins have been studied on
the basis of existing knowledge. Binding of zinc is generally accepted to be the
driving force of hexamerisation, although metal-free hexamers can be formed in
certain circumstances. The occurrence of octahedral and tetrahedral coordination
of the metal is linked to the T-state and R-state trimers, respectively, although
one exception to this rule was seen in one of the mutants. The presence of phenol
is also involved in this connection between coordination and conformation. The
detection and refinement of other metal sites in crystal structures is difficult for
various reasons.
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Chapter 7
Conclusions and future work
7.1 Conclusions
The first and foremost conclusion of structural studies of insulin must be that the
protein is extremely flexible and adaptable. Even the native protein can quite easily
be crystallised in numerous crystal forms depending on their specific T and R con-
formations. The flexibility is especially marked in the B chain: the conformation of
the N-terminus gives rise to the T and R naming system, and the flexibility of the
C-terminus is thought to be very important in a conformational change necessary
in receptor binding.
Because the protein is relatively small, even a small change in one of the
chains constitutes a relatively large difference in the structure. For example, one
point mutation represents almost 2% of the protein. This might explain why two iso-
morphous structures of insulin may still have an isomorphous R-factor significantly
higher than 10%. As another example, the flexible termini of the B chain (BI-B3
and B29-B30) represent around 10% of the scattering matter (excluding solvent) in
the X-ray diffraction experiment, and thus their flexibility has a negative effect on
the quality of diffraction.
At the same time, insulin's flexibility provides interesting and unexpected be-
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haviour. Mutants designed to be monomeric in pharmaceutical preparations may
still crystallise as dimers or even higher aggregates. Unexpected metal binding is
seen, both in the position and the coordination of the metal ion. The conformation
of the B chain is not always predictable.
The protein's flexibility and adaptability is and will be used in the formulation
of therapeutic preparations. The adaptability of insulin to its environment can be
used to produce highly stable forms which can be stored for a length of time (e.g.
by incorporating certain additives), after which the protein may change to a form
with a specifically desired activity upon administration to a patient.
A few specific topics have been raised through the studies of the modified
insulins described, namely:
• The T3R3 hexamer, with the B chain N-terminus of one of the molecules in
the asymmetric dimer fully helical, probably does not exist. Even the native
4Zn insulin structure is most likely T3R3f, where residues BI-B3 in molecule 2
of the dimer are extended. This structure will be re-refined in the near future;
• The use of ethanediol in insulin crystallisation instead of the very volatile
solvents ethanol and acetone seems very promising, and should be encouraged
in cases where cryocrystallographic experiments are anticipated;
• The eight structures described in this thesis have all been refined in different
ways. Even in cases where it was tried to use a similar protocol for simi-
lar structures, success was limited. A general protocol for insulin refinement
would have to take into account especially the observation:parameter ratio.
Insulin refinement often involves a limited number of reflections, which causes
problems with the reliability of the statistics, especially those of the free R-
factor.
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7.2 Future work
Following the investigations described in this thesis, a number of projects could be
taken up, involving the modified insulins studied:
• Further refinement of rhombohedral B9H insulin when REFMAC has been
adapted to deal effectively with special positions and special distances involv-
ing symmetry-related atoms;
• Further data collection and refinement of B9D/B27E insulin in orthorhombic
crystal form;
• Renewed attempts to obtain better crystals of B25Y(B29-Al)A4Q and
A21G/B9E/B10E in order to obtain higher resolution data and better struc-
tural information;
• It would be interesting to obtain other crystal forms (to study other confor-
mations) of some of the modified insulins, especially:
1. Col in all-R-conformation (by using more phenol or a more powerful
ligand in the crystallisation), to see if the cobalt ions can both be in
tetrahedral coordination;
2. B8S/B13Q/B30amide in all-T-conformation, to investigate further the
unusual T-conformation seen in the low salt form;
3. B9H in all- T-conformation, to see if the mutant could accommodate 6
zinc ions in that conformation;
• Further study of the conformational preference of the B13Q mutant and its
unusual behaviour in the presence of thiocyanate, a ligand not previously seen
to allow all-R-conformation. An attempt has been made to crystallise B13Q
insulin with thiocyanate, resulting in a rhombohedral T3R3 crystal form (J.
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Whittingham, pers. comm.). A higher concentration of thiocyanate might
produce the desired monoclinic R6 form;
• It would be of interest to attempt to crystallise some of the modified insulins
in the absence of zinc (or closely related ions like cobalt) but in the presence
of calcium. This might be especially revealing for A2IG/B9E/BIOE in which
case calcium could balance the charges at the dimer interface, while the zinc-
binding functionality is removed at BIO;
• The insight into the flexibility obtained from these studies and this flexibility
itself should be used in binding studies of the protein with its receptor, and in
crystallographic studies of the receptor complex.
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Appendix A
Lagrange multipliers
A.1 A general introduction to Lagrange multipli-
ers
The idea for the Lagrange multipliers was first put forward in the ninth of Lagrange's
"Lecons sur le calcul des fonctions" in 1806. A function M = !o(xd for i = 1,2, ...N
is to be maximised, subject to constraints gj for which is known:
for j = 1,]{ (A.l )
This is equivalent to reducing the dimension of the original system.
A new function L is constructed, adding the dimension lost through the con-
straints by incorporating Lagrange multipliers. Therefore, the constrained maximi-
sation of function M is equivalent to the unconstrained maximisation of function L
where
L = !O(Xi) +L ).jgj(Xi) = !O(Xi) + ).191 (X;) + ).2g2(Xi) + ... (A.2)
j
This function has N + K unknowns.
The maximisation is performed by differentiating L with respect to both pa-
rameters. In the maximum the differentials with respect to the appropriate ).k and
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Xk will be 0:
(A.3)
and
oL = ojo + L.Aj ogj = 0
OXk OXk j OXk
We now have N + K equations (equations A.4 and A.3, respectively) to solve the
(A.4)
N + K unknowns of function L.
A.2 Lagrange multipliers in entropy maximisa-
tion
In the general case of maximising entropy, the following entropy formula may be
used (this is equation 2.57):
B
S(p, q) = - LPiln(pdqd
i=l
(A.5)
The constraints may be denoted as follows:
B
LPiCij = Cj
i=l
(A.6)
for B possible system states. j = 1,M where M is the number of constraints. Since
the constraints must always be satisfied, it follows from equation A.6 that
B
L D.piCij = 0
i=l
(A.7)
where D.Pi is a small variation in Pi. In the maximum of S we have:
(A.8)
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Now a multiplier Aj is introduced for each constraint. Multiplying equation A.6 by
Aj for each j and summation of the results leads to
B M
L: L: Aj~PiCij = 0
;=1 j=1
(A.9)
When M ~B, only B - M parameters ~Pi are independent, whereas the parameters
for which i = 1,M are dependent. This means the multipliers Aj may be obtained
from
(A.IO)
A.3 Lagrange multipliers in crystallography
In crystallography the entropy may be maximised in the case of general linear con-
straints of the form
(A.11)
for j = 1,M where M is the number of constraints. C, = e21rihJ.r for every reciprocal
lattice vector hj, and Cj = U( hj) is the unitary structure factor for the reflection
corresponding to hj. p( r) is the unknown optimal distribution of atoms and V the
volume of the unit cell. The normalisation condition, or the origin term with j = 0,
may also be regarded as a constraint:
(A.I2)
The constrained maximisation of the entropy S(p, q) (see equation A.5) is equivalent
to the unconstrained maximisation of
(A.l3)
where Aj are the Lagrange multipliers. q = q( r) is the prior distribution.
Differentiation with respect to Aj returns the constraint equations A.II, while
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differentiation with respect to p( f) yields:
M
-1 - In(pME(f)/q(rj) +L:>'jCj(r) = 0
j=O
(A.14)
or
M
pME(rj = q(rjexp(>.o - l)exp(L: >'jCj(rj)
j=O
(A.15)
where pME is the Maximum Entropy posterior distribution. Solving directly for >'0 by
integrating this equation over rand using the normalisation constraint Iv pM E (rjdr =
1 gives >'0 - 1 = -lnZ where
(A.16)
Z is the partition function which describes the way in which the unit cell has been
divided up in fractions B. Then
(A.17)
and
(A.18)
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Appendix B
Laboratory safety and
reprod uction
B.l Introd uction
Work in a laboratory involved in protein crystallographic research can pose ex-
tra risks for pregnant women compared to the average individual. The risks are
multiple and varied, and some are important even before conception. Moreover,
documentation is available on the risks for foetuses brought on by the male parent,
both before and after conception. For example, it has been reported that expo-
sure of males to anaesthetic gases can lead to adverse pregnancy outcome (mainly
increased incidence of congenital anomalies in the offspring) in their unexposed
wives (Strobino et al., 1978). It has also been suggested that the male can con-
tribute to the incidence of malformations in foetuses if substances absorbed in his
body are secreted into the seminal fluid, subsequently absorbed in the vaginal mu-
cosa during intercourse, after which they can affect a developing embryo or foetus
(Clement Associates, 1981).
In the laboratory in York the research can be divided into three spatially
separated sections according to the type of laboratory involved:
1. Molecular biology/biochemistry
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(a) cloning of genes coding for the desired protein
(b) expression, isolation and purification of the protein
(c) crystallisation
(d) crystallisation and/or soaking of heavy atom derivatives
2. X-ray
data collection
3. Computing
data processing, structure solution and refinement
Each of the above sections and subsections is connected with specific risks
to reproduction, whether the growing foetus or the parents, either before or after
conception.
B.2 Teratogenicity
Teratology is the study of malformations or serious deviations from the normal type
in organisms (Webster's, 1965). A teratogenic agent is defined by its ability to
produce a congenital defect (whether physical or functional) in the conceptus or
offspring (Shepard, 1980).
Some biological and chemical hazards are easily linked with teratogenicity.
The effects of mutagens, carcinogens and radiation (whether X-rays, microwaves or
radioisotopes) on either parent are less obvious candidates.
B.3 Biological hazards
During any period of suppressed immunological response, and thus during preg-
nancy, a person is more susceptible to infections. This is especially true for viral
infections, which have been proved to have disastrous consequences for human foe-
tuses. In an average molecular biological or biochemical laboratory, like in York, no
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pathogenic strains of viruses, bacteria or fungi are used, so primary (direct] or s('c-
ondary (indirect: the male infecting his wife after being infected at work) infect.ions
are unlikely. The risk of contracting viral diseases, like rubella (german measles] or
vari cella (chi cken pox), elsewhere, is far greater.
In addition to being infectious, aetiological agents as described above, may pro-
duce illness after ingestion of certain cell wall components (endotoxins) or exotoxi ns,
or may cause an allergic response after handling them.
A second type of biological hazard involves research with oncogenic VIruses,
which are capable of inducing tumours or cancer after infection. In most of the
literature consulted, it is suggested that pregnant women or women who arc planning
to get pregnant, should not be allowed to work with oncogenic viruses (se(' for
example Rayburn (1990) p.129 and p.298).
More relevant to the situation in York, are the hazards involved in recombi-
nant DNA research. In the early days of the use of the technique a moratorium was
proposed (Berg et al., 1974) as a result of serious concerns that artificial recombi-
nant DNA molecules could, after introduction in as common a bacterium as E. coli,
"become widely disseminated among human, bacterial, plant or animal population
with unpredictable effects". It was suggested that, until hazards were better under-
stood and appropriate precautions could be taken to prevent the spread of .,new"
DNA, no experiments should be undertaken that involved
• introduction of antibiotic resistance or toxin formation in strains that did not
carry such already, or construction of plasmids with combinations of antibiotic
resistance not already existing in nature; or
• introduction of oncogenic viral DNA in autonomously replicating systems that
could spread easily in humans and other species.
The consensus reached at a conference in Asilomar in 1975 formed the basis of
the NIH (National Institutes of Health) guidelines, which are now widely accepted,
though not enforced by any law. In support of recombinant DNA research 011(' could
state that the mechanisms for gene transfer, rearrangement and cloning already exist
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in nature, that hazardous constructs would exist if they were possible, and that the
chances of inadvertently creating a problem are small.
Retrospective studies have shown that the containment techniques proposed
in the guidelines have been effective, with the absence of infections so far. However,
containment may be against the very goal of certain experiments, where competition
of "new" organisms with others in the environment is necessary.
As with the research involving oncogenic viruses, the better-safe-than-sorry
option seems most appropriate for (potentially) pregnant women.
B.4 Chemical hazards
The teratogenicity of certain chemicals is well-documented (Shepard, 1980, Hunt,
1979, Rayburn, 1990). The mode of action of some of them, however, can be sur-
prising, and is often ill-understood.
B.4.1 The male parent
Hunt (1979) devotes a whole chapter to the influence of environmental agents on
male reproductive failure. The effects described include male infertility as well as
adverse pregnancy outcome via mutation of the sperm. Two exposure routes may
account for the effects:
1. exposure of the male results in exposure of the female, and the agent operates
directly through the mother; or
2. exposure damages sperm cells which causes infertility or abnormal develop-
ment of the embryo (the latter usually results in spontaneous abortion).
A number of other agents, like thalidomide, methadone, and certain thera-
peutic agents (epileptic drugs, antibiotics and anti-cancer drugs) are proved to be
excreted into seminal fluid. There they may directly influence the sperm (see table
H.1) or be absorbed in the vaginal mucosa after intercourse.
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AGENT EFFECT
afHatoxin Bl t reduced fertility
alcohol (chronic alcoholism) testicular pathology
anaesthetic gases increased incidence of
congenital anomalies in offspring
anti-cancer drugs reduced fertility
cadmium chloride] reduced fertility
cigarette smoke increase in abnormally-shaped sperm
glutamic acid] reduced fertility
hydrocarbons twofold increased incidence of childhood cancer
iodine( thyroid therapy) atrophy of testes
lead decreased sperm count and motility;
increase in abnormally-shaped sperm
methy lmercurychloride, methy lmercury- reduced fertility
hydroxide, mercury chloride]
nickel sulphate] reduced fertility
nitrous oxide] suppressed spermatogenesis
urologic antibiotics] altered spermatogenesis
Table B.l: Agents affecting sperm (adapted from Hunt (1979)).
[animal study only
B.4.2 The female parent
Similar to the discussion for the male parent, exposure to certain chemicals may
cause infertility or gene mutations in the female. In addition, most teratogenic
chemicals affect the developing foetus in the first trimester of pregnancy, often be-
fore the woman even suspects she has conceived. This leads some organisations to
exclude all fertile women from work with such chemicals (Rayburn, 1990).
A developing embryo or foetus may be affected by chemicals through two
routes:
1. some substances may produce toxic effects to the mother, thus interfering with
placental function; or
2. other substances may cross the placenta, affecting the embryo/ foetus directly.
Adults have a reasonably effective detoxification system for ingested toxins.
The chemical is diluted in the stomach and is often converted to lesser toxic sub-
stances. It is often selectively not absorbed by the intestine but first carried to the
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liver to be detoxified. Unfortunately, the metabolites are sometimes even more toxic
than the original substance. In the foetus and up to shortly after birth, the enzyme
systems for detoxification may not have fully developed. This means that some toxic
material is more dangerous, although the lack of development of the detoxification
system may be an advantage in the case of more toxic metabolites.
Chemicals with a teratogenic effect are very diverse, and the teratogenicity of
a newly synthesised chemical is not easily predictable. Moreover, teratogenic testing
is more difficult than ordinary toxicity testing, and most information documented
stems from accidental human exposure, anecdotal information and extrapolation
from animal data (Safety Handbook, 1992).
For some substances the evidence is inconclusive (e.g. sulfonamides and cad-
mium) or the effects may be brought on or aggravated by other factors (e.g. coffee).
Others seem to have no or only mild effects. Examples are: ammonium chloride,
ascorbic acid, beryllium, chloramphenicol, chromium, cocaine, codeine, copper chlo-
ride, guanine and guanosine, heroin and penicillin. Obviously, the effect depends
largely on the dose and the route of exposure. Many of the hazards mentioned in
table B.2 do not represent an occupational exposure, but rather a problem in acci-
dents. Most teratogens exert their effects in the early stages of pregnancy, during
organogenesis, which starts with budding of the lungs, 28 days after conception.
Formation of the heart membranes is completed after 46-47 days (Shepard, 1980),
by which time the limbs have formed and bone formation has started. This means
that the foetus is almost fully formed before the second missed menstrual period, a
moment when many women would only begin to suspect to be pregnant.
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AGENT EFFECT
anaesthetic gasesf spontaneous abortion, decreased birth weight,
---
stillbirth, increased cardiovascular birth defects
cigarette smokef spontaneous abortion, foetal growth retardation,
placenta problems, increase in neonatal deaths, SIDS,
lag in cognitive development
erhanolf reduced birth weight, increased still birth rates,
increased congenital malformation rates
glycerolj lethal to mother upon injection
iodine/iodide severe thyroid problems
leadt spontaneous abortion, decreased birth weight, prematurity,
stillbirth, mental retardation
lithium chloride cardiovascular malformations
methylmercuryf gross injuries to central nervous system
nickel (salts or air pollution) small defects, microsomia
phenylalanine spontaneous abortion, heart disease
retinoids (vitamin A and similar compoundsj t malformations of ear, palate, cardiac/aortic tissue, brain
salicylates congenital defects, stillbirt.h
certain solvents( e.g. toluene'[ spontaneous abortion, certain rare congenital rnalformat.ions, microsolllia
spray adhesives possibly mild effects upon inhalation
(dihydro )streptomycin deafness
tetracyclin staining of (deciduous) teeth
actinomycinsj various defects
adenine+ cleft palate, digital defects, haematomas
afIlatoxin t liver problems
aminoguanidine] liver problems
monosodium L-aspartatet various defects
sodium azidej all tissues affected above certain concentration
5-bromo deoxyuridine [ polydactylism
cobaltous chloride] anaemia
concanavalin At cranofacial, trunk and limb anomalies
2-deoxy adenosine / guanosine+ skeletal and palate defects
DMSOt bone abnormalities
EDTAt various defects
E.coli endotoxin] hydrocephalus, neuronal necrosis
leucine] various defects
pyridine] muscular hypoplasia, micromelia
selenium+ microsomia, cranofacial defects
spermine] total arrest of development
surfactants( e.g. SDSH effects at maternal toxic dose
rritiumj microsomia, microcephaly, small testes/ovaries
tryptophant various defects
uracil] various defects
zinc chloride'[ bone malformation
Table B.2: Female reproductive toxins. Adapted from Shepard (1980).
[animal study only, typically upon injection.
[confirmed by animal study
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Thalidomide is an example of a chemical that could be harmless and effective
if used correctly. However, it took scientists just too long to discover that it is only
the (+ )-form that is safe, whereas the (-)-form is a potent mutagen. Unfortunately,
the drug contained both forms, resulting in serious birth defects (Roberts, 1989).
In the Netherlands it has been decided (Loodbesluit; Ministerie van Sociale
Zaken(1994)) that a pregnant woman can not be forced to work with lead and lead
derivatives that can be taken up in the human organism, and that employers must
provide alternative work.
B.5 Physical hazards
This section will include various non-biological and non-chemical influences on bi-
ological systems, in this case the human during reproductive years. The effects of
radiation, temperature and work with Visual Display Units (VDUs) will be dis-
cussed.
B.5.! Radiation
Two types of ionising radiation may be encountered in the laboratory in York:
radioisotopes emitting ,a-particles, and X-rays. The radiation hazards of a-particles,
,-rays and neutrons will therefore not be discussed in detail. Figure B.1 shows the
stages of radiation action in time. These times are dependent upon the system
irradiated, and its temperature.
a-particles are helium nuclei produced by large unstable elements. Compared
to other types of radiation, they are high in mass, charge and energy, and have a
high specific ionisation, which means they are relatively efficient in creating new
ion pairs on their way through matter. Although these properties make a-radiation
so destructive when ingested, since all of the energy will be deposited in a small
volume of tissue, on the other hand the particles have a very short range in air and
are easily stopped by a shield or even the skin.
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Figure B.1: Stages of radiation action with time. Reproduced from Rayburn
(1990).
,a-particles are unpaired electrons emitted by naturally occurring eH, 14C,
4°K) or artificially produced e2p, 35S, 45Ca) isotopes. Their range in air and other
matter is directly proportional to their energy and the density of the substance
(Local Rules, 1986). Although they are lower in energy than a-particles, they are
also considerably smaller, which makes them equally hazardous inside the body,
while the external hazard for high-energy ,B-emitters is even somewhat greater tha.n
that for a-particles. High-energy ,B-emitters have the unique characteristic of pro-
ducing X-rays, specifically called 'bremsstrahlung', upon interaction with matter.
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Atoms of higher atomic weight are more efficient bremsstrahlung-producers than
those of lower atomic weight, so that lead, its usefulness as X-ray shielding recognised
as early as 1903 (Fuscaldo et al., 1980), is not the obvious material for ,B-shields,
but plastic. Two other options for radiation hazard control are at the disposal of
people working with ,B-emitters: keeping a distance and reducing exposure time.
The intensity of the radiation drops rapidly, following the inverse square law, as one
moves away from the source. This means that for low-energy ,B-emitters like 14e
and 35S the dose rate is near zero at a separation of as little as IDem. Since the total
dose received is simply (dose rate * time), reducing exposure time is a very effective
measure in decreasing exposure to high-energy ,B-emitters like 32p.
,-radiation and X-rays are types of electromagnetic radiation with identical
physical characteristics but different manner of production. ,-rays arise from the
excited nucleus of certain radioisotopes or reactor-fission-products, as it drops to a
lower energy state, and often accompany the emission of a- or ,B-particles. X-rays
are produced by slowing down of fast electrons in the electron cloud of high atomic-
number atoms, or during the acceleration of charged particles. Because of the lack
of mass and charge, ,- and X-rays have few interactions per unit volume of matter,
which makes them far more capable of penetrating matter than a- or ,B-particles.
They do not undergo electrostatic interactions. Instead, they interact with atoms
to produce electrons which in turn can produce secondary ionisations, which are
extremely penetrating. Therefore, ,- and X-rays pose a significant external as well
as internal hazard. The three factors for limiting external exposure, namely time,
distance and shielding (in this case lead), are all reasonably effective in the case of "t:
and X-rays. The dose intensity decreases with the inverse square of the distance from
the source. In addition, the penetration of ,- and X-radiation declines exponentially
in matter, with the efficiency of attenuation dependent upon density and electron
density of the absorbing material, lead, steel and concrete being used most often.
Neutrons are produced with accelerators, atomic reactors, spontaneously fis-
sioning isotopes and by interaction of a- or ,-radiation on beryllium or certain other
elements. Exposure to neutrons would cause considerable damage to biological sys-
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terns, but fortunately neutrons are very rarely used in biomedical research labora-
tories. Research with neutrons would require specialist training and the availability
of a professional safety expert.
In the descriptions of ionising radiation above, terms like dose rate and dose
intensity have been used. Definitions of these and other radiation-related terms can
be found in the University's Local Rules (1986). The Local Rules also give guidelines
on the amount of radiation acceptable as occupational exposure, see table B.3.
Exposed part of body Dose limit
calendar year calendar quarter
whole body 50 mSv (5 rem)
individual organs (skin, hands, 500 mSv (50 rem)
forearms, feet, ankles)
lens of the eye 150 mSv(15 rem)
abdomen of women of 13 mSv(1.3 rem)
reproductive capacity
abdomen/foetus of 10 mSv (1 rem) between declaration of
pregnant woman pregnancy and delivery
Table B.3: Occupational exposure limits according to University of
York Local Rules (1986)
For members of the general public the limits are 1/10th of the limits in table
B.3. Three other sources, of which only two are more recent, do not agree with
the amounts in table 8.3. Rayburn (1990) treats the skin separate from the other
individual organs, with 30 rem and 75 rem as their maximum annual permitted
doses, respectively. Also, a whole body dose of up to 3 rem per quarter is permitted,
provided the annual dose would not exceed 5 rem. More worryingly, he states a total
of 0.5 rem for the abdomen/foetus of a pregnant woman during the entire gestation
period. Following on from this, fertile women should only be employed in positions
where the annual dose is not likely to exceed 2 to 3 rem to prevent excessive exposure
to the foetus before pregnancy is determined. These are the guidelines adopted by
the US Nuclear Regulatory Commission. Even more recently, the Commission has
added a recommendation that occupational exposure to an embryo/foetus should
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not exceed 50 mrem per month from the time pregnancy is recognised (Paul, 1993).
The older reference containing information about exposure of fertile women and
foetuses, Hunt (1979), mentions exactly the same amounts as Rayburn, based on
the notion that a foetus is to be treated as a member of the public involuntarily
brought into controlled areas.
The biological effect of radiation is dependent on the relative radiosensitivity
of the irradiated organs. For reproductive tissue, classified as moderately highly
radiosensitive by Rayburn (1990), an effect of reduced fertility will be noticeable
at whole-body exposures of 100 rem, and doses between 200 and 300 rem produce
infertility for a period of 12 to 15 months. This irradiation leads to changes in the
germ cells and can cause mutations in future offspring. Germ cell loss in males
results in infertility. In a specific study of normal volunteers who underwent a single
exposure (Rowley et al., 1974) no abnormalities were found with exposures to less
than 10 rad. Doses of 15-50 rad decreased sperm concentration over the course of
three months, with recovery after 9 to 18 months. Doses over 100 rad resulted in
markedly decreased sperm concentrations in 6 weeks, persisting for up to 5 years and
beyond, particularly in men treated with 400 to 600 rad. The same total dose may
produce more injury when delivered in divided increments (Shapiro et al., 1985).
To put this in perspective: some deaths occur at whole body doses of around 300
rem, although the LDso/3o (the dose required to kill 50% of the exposed population
within 30 days of exposure) for man is 450 rem. Tissues with a high turn-over of cells
(e.g. blood-forming organs) are much more radiosensitive than very stable tissues
like muscles and nerves.
For background doses, again Rayburn (1990) does not agree with the Local
Rules (1986), which state an average background dose from naturally occurring
sources of around 0.2 rem per year, and from average medical exposures of 0.025
rem per year. Rayburn shows an extensive table, with a total lower than that in the
Local Rules (see table BA).
Note the entry for 'television sets' in table BA. Comprehensive information
is also available on radiation emissions from Video Display Units (Marriott and
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Source Dose (m rem / y<'ar)
Medical use
Diagnosis 77
Dental 1.4
Radiopharmaceu ticals 13.6
Total 92
Natural background
Cosmic 28
Terrestrial 26
Internal 28
Total s')L_
Technological development
Fallout 5
Power plant and nuclear industry <1
Building materials 5
Television sets 0.5
Aircraft travel 0.5
Total 12
Grand total 186
Table B.4: Total annual radiation dose from nonoccupational. envi-
ronmental sources, compiled for USA population. Reproduced from
Rayburn(1990)
Stuchly, 1986). Data are given about infrared, optical and ult.raviolot radiation.
X-ray emissions, radiofrequencies, extremely low frequencies, electrostatic fields and
acoustic radiation supposedly produced by VOUs. Most of these are emit.t ed in
measurable amounts, but not large enough to produce biological effects. Esp('_
cially X-ray emissions have been subject of research. The main conclusion is that,
due to premarket testing, the emissions are extremely low, even below t.h« nat ural
background, whatever the age of the VDU. Among the nonionising radiation. only
radiofrequencies receive a mention in the recommendations of the art.icle, namely
that it is good practice to avoid unnecessary exposure to radiowaves from the back
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and sides of adjacent VDUs. Within one metre there is a chance of overexposure, if
the VDU has not been tested explicitly and found to have low emission.
With respect to reproduction, Marriott and Stuchly devote one section to
abnormal outcomes of pregnancy. Although there has been ample media coverage,
detailed investigation has been difficult because of the small sample size. However,
even in studies where the statistics are acceptable, the results are negative. There are
no statistically significant differences in pregnancy outcomes between VDU-exposed
and non-exposed women.
Although an accident with ionising radiation in a biomedical laboratory should
be treated as an emergency, having a job with radiation exposure does not reduce
one's average life expectancy any more than the risk of drowning (40 and 41 days,
respectively) (Rayburn, 1990). In contrast, smoking cigarettes takes away 2,250
days for a male and 800 days for a female, and motor vehicle accidents 207 days.
Additionally, all safety improvements made between 1966 and 1976 have increased
life expectancy by 110 days.
In addition to the risks of ionising radiation from various sources and nonion-
ising radiation from VDUs as described above, a biomedical laboratory may contain
other sources of nonionising radiation like microwaves, laser, ultraviolet light and
ultrasound.
Commercially available microwave ovens are tested immediately after produc-
tion, and should not reach the customer if unsafe. So in practice they emit little
or no stray radiation. However, they shoud be surveyed annually to ensure sat-
isfactory performance. Microwave devices built into research apparatus should be
tested during construction, regularly (quarterly) afterwards, and whenever the setup
is changed (Fuscaldo et al., 1980). According to Shepard (1980) microwave energy
is too low for direct effects, regardless of dose; any noticeably effect is due to the
heat generated. Hunt (1979), however, claims that microwaves have an effect on
male fertility. It is not clear whether the reported effect could again be due to
hyperthermia.
For lasers, the eye is the critical organ. Dose limits are based on numerous
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parameters, e.g. whether the laser operates in continuous versus pulsed C'IIIISSI011
mode, and the beam divergence. Protection must be chosen accordi1lgly, awl ap-
pliances should be surveyed upon installation, then on a regular basis [annual Iv),
and whenever changes are made (Fuscaldo et al., 1980). It appears the lise of laser
equipment does not pose particular risks to reproduction. In fact, several types of
laser are actively being used to enhance the chances of pregnancy in lowe-r (nf,ility
women (Spitzer et al., 1995, Fukaya et al., 1995, Kainz et al., 1994) and even dur-
ing gamete intrafallopian transfer to treat endometriosis (Surrey and Hill, 199·1) or
to manipulate the male gamete to enhance fertilisation (Obruca et al., 199·1). This
does not mean that lasers are harmless, for there are reports of the mutagenic risks
of certain UV lasers (Hendrich et al., 1995) and of the, fortunately reversible, dfect
of Argon-lasers on the colour vision of the laser operator (Arden and Hall, 199.1).
Following on from the last points on lasers, it can be seen that ultraviolet light
presents a hazard to the eye and skin. However, it probably has no effect on the
reproductive system (Fuscaldo et al., 1980).
Ultrasound is hazardous only upon direct contact with a portion of the body
(Fuscaldo et al., 1980). Shepard (1980) claims the energy is too low, and any re-
ported effects are due to hyperthermia. However, this most likely relates to inci-
dents without direct contact. Doppler ultrasound is a familiar diagnostic technology
during pregnancy. No associations can be made between the use of Doppler ultra-
sound in pregnancy and childhood maldevelopment, although the incidence of I(·ft.-
handedness and low birth weight after multiple exposures might rise significantly
(Salvesen and Eiknes, 1995).
B.5.2 Temperature and other possible stressors
Under normal circumstances, the core body temperature of healthy humans seldom
fluctuates more than 0.6°C and the foetal core body temperature exceeds maternal
temperature by approximately 0.5°C, creating a favourable gradient for foet.orna-
ternal heat transfer (Paul, 1993). Several studies indicate that. thermorogulat.ion
in pregnant women is equally or even more efficient than in non-pregnant \\'OIlH'1I
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(Jones et al., 1985, Vaha-Eskeli et al., 1991). Hyperthermia has been studied exten-
sively in animals, and has clearly shown teratogenic effects, dependent on the degree,
frequency and duration of the temperature elevation, and the specific gestational pe-
riod during which the temperature elevation takes place. Most of the human data
on the effects of temperature are derived from studies on febrile illness during preg-
nancy. Although the data suggest that sustained fevers of 38.9°C or more in early
pregnancy may have a teratogenic effect on foetal development, none of the studies
can make a clear distinction between effects from the fever, from the illness causing
the fever, or from the treatments of either fever or illness (Paul, 1993). In view of
occupational safety, Paul recommends that a job should be modified if a pregnant
woman complains of discomfort while working in hot environments or when wearing
personal protective equipment that hinders heat transfer. Paul also mentions that
even at only mildly elevated temperatures, pregnant workers whose jobs involve pro-
longed standing or strenuous physical activity may experience problems, especially
in the last trimester of pregnancy. A second physical stressor is involved: exertion.
Prolonged standing will mean reduced cardiac output because of decreased venous
return, while physical activity will cause dilation of blood vessels in the skin to dissi-
pate heat generated by increased metabolic rate. Together, these factors may cause
dizziness or even temporary loss of consciousness because of decreased blood pres-
sure. Because of this, German law states that pregnant women (and breast-feeding
mothers) may not be forced to do heavy physically demanding jobs that lead to an
unbearable physical burden. In particular, their jobs should not involve the regular
lifting or transport of loads of more than 5 kg or the occasional lifting or transport of
loads of more than 10 kg by hand ( i.e. without mechanical aids), the operation of ma-
chinery by foot, repeated stretching or bending, or prolonged stooping or squatting
(Ministerium fiir Arbeit, 1992). In addition to this, Dutch law states that in jobs
where a pregnant woman is exposed to vibrations, her employer must temporarily
provide alternative employment upon request (Ministerie van Sociale Zaken, 1994).
Colie (1993) reviews numerous studies on standing, lifting, strenuous work and con-
stancy and length of work in pregnancy, and their effect on preterm labour. In
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most of the studies the outcome is statistically weak if at all sigllifical1t. illt h01lgh
the avoidance of "occupational fatigue" by taking 01](' rr-st wor-k 1)('1'mont II ill till'
second half of pregnancy seems beneficial.
One other stressor deserves a mention in this section: anxie-ty, depn·ssioll lIlId
other mental stress. Pregnancy in itself is a period full of emot ions illld tt·lIsiolls.
The stress at work which a non-pregnant woman may cope with \\'(·11. could l)('col111'
too much once she is pregnant. This can have a detrimental cff(·et 011 hot.h mot her
and child, and can be prevented by temporarily changing work t imos and work load.
Perkin et al. (1993) have studied the effect of anxiety and depression 011 prcgnanrv
outcome, and come to the conclusion that these circumstances may he undosirnbk-.
but they seem of little importance in pregnancy outcome. They can not. howe-ver.
rule out the existence of negative effects on women who were confident h(·fon· ('011-
ception but become anxious or depressed during or as it result of prcgnancv.
243
244
References
Abel, J.J. (1926) Proc. Natl. Acad. Sci. (Wash) 12. I:l:2-I:Hi
Adams, M.J., Blundell, T.L., Dodson, E.J., Dodson, G.G .. Vijavn n .. \1 .. ltd,f"',
E.N., Harding, M.M., Hodgkin, D.C., Rimmer, B. and Sheaf. S. (I %!)) .Yllllln
224, 491-495
Agarwal, R.C. (1978) Acta Crysl. A34. 791-809
Albisser, A.M., Leibel, B.S., Ewart, T.G., Davidovar , Z .. Botz. ('.1\. a nr] Zillg!.',.
W. (1974) Diabetes 23,389-396
Albrecht, G.A. and Corey, R.B. (1939) J. Am. Chem, Soc. 61. IO~1
Allen, F.H., Bellard, S., Brice, M.D., Cartwright. B.A .. DOllhl('da}·. :\ .. IIiggs.
H., Hummelink, T., Hummelink-Peters, B.G .. Kennard, 0 .. ~lotl)('r\\'('11. \\·.D.S ..
Rodgers, J.R. and Watson, D.G. (1979) Acta Cryst. B35. :!:nl-2:n9
Arden, G.B. and Hall, M.J. (1995) Eye 9, 686-G96
Baker, E.N., Blundell, T.L., Cutfield, .J.F .. Cutfi.-ld. S.i\1.. Dodson, 1-: .. 1.. Dodsull.
G.G., Crowfoot Hodgkin, D.M .. Hubbard. ILE .. Isaacs. i\.W .. H('.\·lIolds. ('.D ..
Sakabe, K .. Sakabe, N. and Vijayan, N.M. (19KK) I>III"/. 1'1'1111 .... HII.II .. "'·Of·. l.o u d,
319, 369-456
Banting, F.G. and Best, C.H. (1922) J. Lab. ('lin .. \/('(/. 7. 2:11<WI;
245
Bell, G.l., Pictet, R.L., Rutter, W.J., Cordell, B., Tischer, E. and Goodman,
H.M. (1980) Nature 284, 26-32
Beks, P.,J., Mackaay, A.,J.C., Neeling, J.N.D. de, Vries, H. de, Router, L.M. and
Heine, R.J. (1995) Diabetologia 38, 86-96
Bentley, G., Dodson, E., Dodson, G., Hodgkin, D. and Mercola, D. (1976) Nature
261, 166-168
Bentley, G.A., Brange, .1., Derewenda, Z., Dodson, E.J., Dodson, G.G.,
Markussen, .1., Wilkinson, A.J., Wollmer, A. and Xiao, B. (1992) J. Mol. Biol.
228, 1163-1176
Berg, P., Baltimore, D., Boyer, H.W., Cohen, S.N., Davis, R.W., Hogness, D.S,
Nathans, D., Roblin, R., Watson, J.D., Weissman, S. and Zinder, N.D. (1974)
Science 185, 303
Bernal, J.D. and Crowfoot, D. (1934) Nature 133, 794
Bernstein, F.C., Koetzle, T.F., Williams, G.,J.B., Meyer, E.F.Jr., Brice, M.D.,
Rodgers, J.R., Kennard, 0., Shimanouchi, T. and Tasumi, M. (1977) J. Mol.
BioI. 112, 535-542
Bliss, M. (1982) The discovery of insulin (McClelland and Stewart, eds). Univer-
sity of Chicago Press, Chicago
Bloom, C.R., Choi, W.E., Brzovic, P.S., Ha, J.J., Huang, S.T., Kaarsholm, N.C.
and Dunn, M.F. (1995) J. Mol. BioI. 245, 324-330
Blow, D.M. and Crick, F.H.C. (1959) Acta Cryst. 12, 794-802
Blundell, T., Dodson, G., Hodgkin, D. and Mercola, D. (1972) Adv. Protein Chern.
26,279-402
Bottazzo, G.F. (1993) Diabetes 42, 778-800
246
Bowie, J.U., Luthy, R. anel Eisenberg. D. (1991) S('i(l/('( 25:~. l(il li()
Brange, J. (1987) Galenics of Insulin - The Physico-chemic»! (llld PIIOIrtll<l('('lIt i(;d
Aspects of Insulin and Insulin Preparations, Sprillger- \'('rlilg B!'I'lill II(·id(·lIwll',.
Germany
Brange, J., Ribel, U., Hansen, J.F., Dodson. G., Hansen. \1.'1' .. l lavclund. S..
Melberg, S.G., Norris, F., Norris, K., Snel, L .. Soronson , A.H. aud '·oi,!!,t. 11.0.
(1988) Nature 333, 679-682
Bricogne, G. (1976) Acta Crys!. A32, 832-8·17
Bricogne, G. (1984) Acta Crust. A40, 410-,11.5
Bricogne, G. (1988) Acta Crust. A44, 517-5·15
Bricogne, G. and Gilmore, C.J. (1990) Acla Cry."l. A46. ~~,1-~97
Bricogne, G. (1991) in: Direct Methods of Solving Crystal St ruct urc-. (Sclwllk.
ed). Plenum Press, New York. 157-175
Bricogne, G. (1991a) in: Mathematics and Molecular Hiology II: )):\:\ S('qlj('II(,('
to Protein Structure. Santa Fe, New Mexico, USA, 2·1-29 March 1~)~)1.:\I,strill't
S2
Bricogne, G. (1991 b) in: Second European Workshop Oil t he (,ryst illIlJl',rdP"~' of
Biological Macromolecules. Como, Italy, 13-Ifi May 1991. Abst.ract ~:)
Bricogne, G. (1992) in: Molecular Replacement. Proc(,cdings of till' ('( 'PI St IId\'
Weekend 1992, 62-75.
Bricogne, G. (1993) Acta Crys!. D49, :37-GO
Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States. ILl .. Sw.uuinnt.han. S. alld
Karplus, M. (1983) J. Comp ui. Clieni. 4,187-:217
247
Brown, L., Munoz, C., Siemer, L., Edelman, E., and Langer, R. (1986) Diabetes
35, 692-697
Briinger, A.T., Kuriyan, K. and Karplus, M. (1987) Science 235,4.58-460
Brunger, A.T. (1990) Acta Cryst. A46, 46-57
Brunger, A.T. (1992) Nature (London) 355, 472-474
Brunger, A.T. (1996) in: Methods in Enzymology. In press
Brzovic, P.S., Choi, W.E., Borchardt, D., Kaarsholm, N.C. and Dunn, M.F.
(1994) Biochemistry 33, 13057-13069
Buchwald, H., Varco, R.L., Rupp, W.M., Goldenberg, F.J., Barbosa, J., Rohde,
T.D., Schwartz, R.A., Rublein, T.G. and Blackshear, P.J. (1981) Lancet 1,1233-
1234
Callahan, T., Gleason, W.B. and Lybrand, T.P. (1990) J. Appl. Cryst. 23, 434-436
Castellano, E.E., Oliva, G. and Navaza, J. (1992) J. Appl. Cryst. 25, 281-284
Collaborative Computational Project, Number 4 (1994) Acta Cryst. D50, 760-763
Chang, W., Stuart, D., Dai, J., Todd, R., Zhang, J., Xie, D., Kuang, B. and
Liang, D. (1986) Scientia Sinica B 29, 1273-1284
Chibnall, A.C. (1942) Proc. Roy. Soc. (London) 131B, 136
Christianson, D.W. (1991) Adv. Prot. Chem. 42, 281-355
Ciszak, E. and Smith, G.D. (1994) Biochemistry 33, 1512-1517
Ciszak, E., Beals, J.M., Frank, B.H., Baker, J.C., Carter, N.D. and Smith, G.D.
(1995) Structure 3, 615-622
248
Clement Associates, Inc., Council on Environ11lC'lIt;t1 Qualitv (I!ISI) ill: ('llI'lllil';d
Hazards to Human Reproduction. {IS (;0\'('1'1111](,111 I'rint ill,!!,Oflicl'. "';I,dliJlL',ltlll
USA. Chapter II. 3
Cohen, G.H. (1993) J. Appl. CrY8/. 26. ·195-,19(j
Colic, C.F. (1993) Scm. in Perino], 17. :H-·',I
Collins, D.M. (1982) Nature 298. 49-51
Colovos, C. and Yeates, 1'.0, (1993) Pro/till Se]. 2. 17'>1I - I ,) I!I
Coustan, D.R. (1993) Diabetes Care 16. 8-15
Cowt.an , K.D. (1996) in: The Refinement of Protein St ruct urcs. Procl'I'diligs uf
the CCP4 Study Weekend 1996, 23-28
Crea, R., Kraszewski, A., Hirose, T. and It.akura. I"':.(19i~) Proc, .\'al/, ..1('(11/, .~'I'I,
USA 75, 5765-5769
Creque, H,M., Langer, R. and Folkman, J. (1980) Diabct c» 29. :li-,IO
Crowfoot, D.M. (1935) Nature 135.591-592
Crowfoot, D. (1938) Proc. Roy. Soc. A164. ,:")SO-G02
Crowfoot, D.M. and Riley, D. (19:39) Nature 144.1011-1012
Crowther, R.A. and Blow, D.l\1. (1967) Aela Cry"'/, 23. :)11-:>18
Crowther, ILA. (1972) in: The Molecular Hcplac(,l1H'llt ~I('{ hod (HO:';SI11ilJlII.I'd),
Gordon and Breach, New York. 173-178
Cruickshank, D.W.J. (1996) in: The Refinement of Protein St rurt.urcs. Procl'!'d
ings of the CCP4 Study Weekend 199G. 11-22
Cutfield, S.M. (1975) D.Phil Thesis, l lniversit.v of Oxford
Cutfield, J.F., Cutfield, S.M., Dodson, E.J., Dodson, G.G., Emdin, S.O. and
Reynolds, C.D. (1979) J. Mol. Bioi. 132, 85-100
Dapergolas, G. and Gregoriadis, G. (1976) Lancet II, 824-827
Deen, J. van (1864) Centralblatt fur die medic. Wissenschaften 2
Derewenda, U., Derewenda, Z., Dodson, E.J., Dodson, G.G., Reynolds, C.D.,
Smith, G.D., Sparks, C. and Swenson, D. (1989) Nature Lond. 338, 594-596
Derewenda, U. (1990) D.Phil Thesis, University of York
Derewenda, U., Derewenda, Z., Dodson, E.J., Dodson, G.G., Xiao, B. and
Markussen, J. (1991) J. Mol. Bioi. 220,425-433
Dodson, E.J., Dodson, G.G., Lewitova, A. and Sabesan, M. (1978) J. Mol. BioI.
125, 387-396
Dodson, G., Glusker, J.P. and Sayre, D. (eds) (1981) Structural Studies on
Molecules of Biological Interest - A volume in honour of Dorothy Hodgkin. Claren-
don Press, Oxford
Dodson, G.G., Hubbard, R.E. and Xiao B. (1991) in: Molecular Conformation
and Biological Interactions (Balaram and Ramaseshan, eds). Indian Academy of
Sciences, Bangalore. 97-113
Dodson, E.J., Dodson, G.G., Hubbard, R.E., Moody, P.C.E., Turkenburg, J.,
Whittingham, J., Xiao B., Brange, J., Kaarsholm, N. and Thogersen, H. (1993)
Phil. Trans. R. Soc. Lond. A 345, 153-164
Dodson, E., Kleywegt, G.J. and Wilson, K. (1996) Acta Cryst. D52, 228-234
Drury, M.l. (1988) in: Clinical Diabetes - An Illustrated Text (Besser, Bodansky
and Cudworth, eds). Gower Medical Publishing, London, England. 20.1
250
Ealick, S.E. (1995) in: Making the Most. of your ],\,10<1,,1.Pr()('('('dill,l',~ (II t lu- (.( '1'1
Study Weekend 1995, 1-9
Emdin, S.O., Dodson, G.G., Cutfield , .J.1\'1. and Cut field. S.M. ( I !J.'-\()) l lial« 10/011111
19, 174-182
Engh, RA. and Huber, R. (1991) Ada Cr.l)81. A47. :192-·lO0
Fletcher, R. and Reeves, C.M. (1964) Comput, J. 7. [·19-1.')·1
Fortclle, E. de la and Bricogne, G. (1996) in: Method ... ill FII::YIIIO/ogy. III I'r{'~~
Frazao, C., Soares, C.M., Carrondo, l\I.A .. Pohl. E .. Dalltel'. Z.. \\·il~oll. I"':.S ..
Hervas, M., Navarro, .J.A., De la Rosa, M.A. and Shcldrick, G.1\1. ( I ~H")) .....'t ru ct 1/1'1
3, 1159-1169
French, S. and Wilson, K. (1978) Acta Cryst. A34 .. 517-')~.')
Fujinaga, M. and Read, R.J. (1987) J. Appl. Crys!. 20. 517-.121
Fukaya, T., Murakami, T., Tamura, M., Wat.a nalie. '1' .. Terada. Y. Cllld Yajim.i.
A. (199,5) Am. J. of Obsiet. and Gynccol. 173. 119-12.5
Fuscaldo, A.A., Erlick, B.J. and Hindman, B. (cds) (19~O) Laborat orv SClI'c! v
Theory and Practice. Academic Press, Inc., New York USA
Gilmore, C ..J., Henderson, K. and Bricogne, C. (1991) ltcla ('1',1/.'01. A47. 1'\:1O-.'-\11
Glusker, .J.P. (1991) Ad'll. Prot. Glum. 42,1-76
Goeddel, D.V., Kleid, D.G., Bolivar. F., Hcynekor. II.L .. Ya nsurn , D.(; .. ('1'(';1.
R., Hirose, T., Kraszewski, A .. If.akura, 1\. and Higgs. A.D. (I !)7!)) 11/'111' .. \'ul/.
Acad. Sci. USA 76, 106-110
251
Goodfellow, J., Henrick, K. and Hubbard, R. (eds) (1989) Molecular Simulation
and Protein Crystallography. Proceedings of the Joint CCP4/CCP.5 Study Week-
end 1989.
Goosen, M.F.A., Leung, Y.F., O'Shea, G.M., Chou, S. and Sun, A.M. (1983)
Diabetes 32, 478-481
Graaff, R.A.G. de, Lewit-Bentley, A. and Tolley, S.P. (1981) in: Structural Studies
on Molecules of Biological Interest - A volume in honour of Dorothy Hodgkin
(Dodson, Glusker and Sayre, eds). Clarendon Press, Oxford. 547-.556
Grant, P.T., Coombs, T.L. and Frank, B.H. (1972) Biochem. J. 126,433-440
Hagedorn, H.C., Jensen, B.N., Krarup, N.B. and Wodstrup, I. (1936) J. Am. Med.
Assoc. 106, 177-180
Hallas-Moller, K. (1956) Diabetes 5, 7-14
Hansen, J.F. and Brange, J. (1987) Prot. Eng. 1, 250
Harfenist, E.J. and Craig, L.C. (1952) J. Am. Chem. Soc. 74, 3087-3089
Harker, D. (1936) J. Chern. Phys. 4, 381-390
Harker, D. (1956) Acta Cryst. 9, 1-9
Hendrich, C., Sudmann, J., Mommsen, J. and Siebert, W.E. (1995) Z. Orthopadie
und ihre Grenzqebiete 133, 520-523
Hendrickson, W.A. and Konnert, J .H. (1980) in: Computing in Crystallography
(Diamond, Ramaseshan and Venkatesan, eds). Bangalore, Indian Academy of
Sciences. 13.01-13.25
Hendrickson, W.A. (1985) Methods in Enzymology 115,252-270
252
Hill, C.P., Dauter, Z., Dodson, E.J., Dodson, C.C. and Dunn, l'vLF. (I ~)!ll) 1/10-
chemistry 30, 917-924
Hirai, S., Yashiki, T. and Mirna, H. (1981) Int. J. Pluirm, 9, 165-172
Hodgkin, D.C. and Riley, D.P. (1968) in: Struct. Chem. ]\/101. BioI. (Hich illid
Davidson, eds). W.H. Freeman Co., San Francisco. 15-28
Holden, P.II. (1991) D.Phil Thesis, University of York
Howell, S.L., Montague, W. and Tyhurst, M. (1975) J. Cell Sri. 19, :l!)!i-·l()!)
Howell, S.L., Tyhurst , M., Duvefelt, H., Andersson, A. and Hellerstrom, C. (1!)7~)
Cell TiSS71( Rcs. 188, 107-118
Hubbard, T ..J.P. and Blundell, T.L. (1987) Prot. Eng. 1,159-171
Huber, R. and Schneider, M. (1985) J. Appl. Crust. 18, 165-169
Hunt, V. It (1~)7~J)Work and the Health of Women, eRe Press, Inc., Boca Hatoll.
Florida {ISA
Jacoby, E., fIua, Q.X., Stern, A.S., Frank, B.H. and Weiss, M.A. (I99G) .1.. \10/.
Bioi. 258, ]:W-].1)7
Jack, A. and Levitt, M. (1978) Acta Cryst. A34, 931-935
Jaynes, E.'1'. (1957) Phys. Rev. 106, 620-630
Jaynes, E.T. (1979) in: The Maximum Entropy Formalism (Levine and Trilms.
eels). Cambridge, MIT Press. 15-118
Jefferson, I.G., Marteau, T.M., Smith, M.A. and Baum , J.D. (19S5) i>ia/nli('
Medicine 2, 49:3-195
Jensen, H. and Evans, E.A. (1935) J. BioI. Chem. 108, 1
253
Johnston, C.F., Shaw, C., O'Hare, M.M.T. and Buchanan, K.D. (1988) in: Clini-
cal Diabetes - An Illustrated Text (Besser, Bodansky and Cudworth, eds). Gower
Medical Publishing, London, England. 1.1
Jones, R.L., Botti, J.J., Anderson, W.M and Bennett, N.L. (1985) Obstei. Gy-
neeol. 65, 340-345
Jones, T.A. (1978) J. Appl. Crust. 11, 268-272
Jones, T.A., Zou, J.-Y., Cowan, S.W. and Kjeldgaard, M. (1991) Acta Cryst.
A47, 110-119
Jorpes, J.E. (1949) Arch. Intern. Med. 83, 363-371
Kaarsholm, N.C., Ko, H.C. and Dunn, M.F. (1989) Biochemistry 28, 4427-4435
Kaarsholm, N.C., Havelund, S. and Hougaard, P. (1990) Arch. Bioehem. Biophys.
283, 496-502
Kainz, C., Sam, C., Sliutz, G., Kolbl, H., Dadak, C. and Reinthaller, A. (1994)
J. Gyn. Surgery 10, 221-227
Kinneging, A.J. (1986) Doctoral thesis, University of Leiden, The Netherlands
Konnert, J.H. and Hendrickson, W.A. (1980) Acta Cryst. A36, 344-350
Kott, A. (1996) Countdown 17, 22-26
Kraulis, P.J. (1991) J. Appl. Cryst. 24, 946-950
Krayenbiihl, C. and Rosenberg, T. (1946) Rep. Stene. Mem. Hosp. 1,60-73
Kung, Y.T., Du,.Y.C., Huang, W.T., Chen, C.C., Ke, L.T., Hu, S.C., Jiang, R.Q.,
Chu, S.Q., Niu, C.l., Hsu, J.Z., Chang, W.C., Cheng, L.L., Li, H.S., Wang, Y.,
Loh, T.P., Chi, A.H., Li, C.H., Shi, P.T., Yieh, Y.H., Tang, K.L. and Hsing, C.Y.
(1965) Scientia sin. 14, 1710
254
Lamzin, V.S. and Wilson, K.S. (1992) in: Molr-cular Heplll(,(·IIWllt. 1)('()('('('dillL',~
of the CCP4 Study Weekend 1992, 76-83
Laskowski, R.A., MacArthur. M. W., Moss. D.S. and Thornt on .. 1.:\1 (Iqq:q ./.
lippl. Crust. 26, 283-291
Lee, J and Pilch, P.F. (1994) Am. J. Physiology 266. CH 9-c:nl
Leslie. A.G.W., Brick, P. and Wonacott., A.J. (I ~)SG) (,(,P{ .Yf II's/r Ilf /' 18. :j:j:j'l
Levitt, M. (1974) J. Mol. BioI. 82, 39:3-420
Liang, D., Zhuli, W., Zhang, Y. and Cao, Q. (1982) Scicli/in Siuirn FJ 27. :!:{:!,
Local Rules for Persons Working with Ionising Iiadia tions (J DS(i) t 'Ili\'('l'~it v or
York
Ludvigsen, S., Roy, M., Thogersen, H. and Kaarsholm, N.C. (I !J!}I) Ii/oc/It nu»! 1'.'1
33, 7998-8006
Luzzati, V. (1952) Acta Crust. 5,802-810
Luzzati, V. (1953) Acta Cryst. 6,142-1.52
Mackay, K.M. and Mackay R.A. (1981) Introduction to Modern Inorgaui« ('IWIIl
istry 3rd ed. International Textbook Company London
Main, P. (1979) Acta Crust. A35, 779-785
Markussen, J. (1982) in: Neue Insuline (Petersen, Schliitcr and Kr-rp, (·ds).
Freiburger Graphische Betriebe, Freiburg, 38-·1·1
Markussen, J., Damgaard, V., Diers, 1., Fiil, N., Hansen, )\1.'1' .• Larse-n. ]l" :\ol'ris.
F., Norris, K., Schou, 0., Snel, L., Thim, L. and Voigt. II .0. (I %(i) nil/h, /0/0.'1111
29, A568-A569
255
Markussen, J., Diers, I., Engesgaard, A., Hansen, M.R., Hougaard, P., Langkjaer,
L., Norris, K., Ribel, D., Serenson, A.R., Serenson, E. and Voigt, H.O. (1987)
Prot. Eng. 1, 215-223
Marriott, I.A. and Stuchly, M.A. (1986) J. Occup. Med. 28, 833-848
Metropolis, N., Rosenbluth, A.W., Rosenbluth, M.N., Teller, A.H. and Teller, E.
(1953) J. Chern. Phys. 21, 1087-1092
Meyer, J. de (1909) Arch. Fisiol. 7,96
Ministerie van Sociale Zaken en Werkgelegenheid (1994) Info. Centrale Directie
Voorlichting, Bibliotheek en Documentatie, Den Haag
Ministerium fur Arbeit und Soziales des Landes Sachsen-Anhalt (1992) Mutter-
schutz. Ziele Druck CmbH, Feldkirchen/Munchen
Mooy, J.M., Grootenhuis, P.A., Vries, H. de, Valkenburg, H.A., Bouter, L.M.,
Kostense, P.J. and Heine, R.J. (1995) Diabetes Care 18, 1270-1273
Murshudov, C.N., Dodson, E.J. and Vagin, A.A. (1996) in: The Refinement of
Protein Structures. Proceedings of the CCP4 Study Weekend 1996, 93-104
Murshudov, C.N., Vagin, A.A. and Dodson, E.J. (1996b) In press
Navaza, J. (1987) Acta Cryst. A43, 645-653
Navaza, J. (1990) Acta Cryst. A46, 619-620
Navaza, J. {1994} Acta Cryst. ASO, 157-163
Navaza, J. and Vernoslova, E. (1995) Acta Cryst. AS1, 445-449
National Diabetes Data Croup (1979) Diabetes 28, 1039-1057
256
Obruca, A., Strohmer, H., Sakkas, D., Menczo, Y.. J\ogoso\\"ski. ,\ .. Ha rnk , Y.
and Feichtinger, W. (1994) Human Reproduction 9. 172:~-172(i
Oldfield, T.J. (1992) J. Mol. Graphics 10. 2tl7-2!"i2
Oldfield, T.J. (1996) In preparation
Otwinowski, Z. (1991) DENZO. A Film Processing Program 1'01" ~liI('rolllOl('("ld;lr
Crystallography. Dallas, Texas, USA
Patterson, A.L. (1935) Z. Krist. 90. 517-5,12
Paul, M.E. (1993) Scm. in Perin.at. 17, 5-16
Peking Insulin Structure Group (1971) Peking Rev. 40. II-](i
Peking Insulin Structure Group (1974) Scieniia Sill. 17, 75'2
Peking Insulin Structure Group (1976) Scieniia Sill. 19. :~j~
Perkin, M.R., Bland, J.M., Peacock. J.L. and Anderson. II.B. (I~l!l:!) Ii,. . .I. of
Obstet. Gynaecol. 100, 629-634
Peschar, R. and Schenk, H. (1987) Ada Cryst. A43. 01:3-022
Pfeiffer, E.F., Thurn, C. and Clemens, A.H. (1974) /101'111. ;\It/ab. u.« 6. :U!)-:~I~
Ponder, J.W. and Richards, F.M. (1987) J. Mol. BioI. 193. 77:")
Quanta96 bet.a release. February 1996, User's Reference. Sill! Di('go: \lol('clIid,
Simulations, 1996
Ramachandran, G.N., Ramakrrshnan , C. and Sasisckhar(lll. \" ..1. (1%:q .I .. \/0/.
Bioi. 7, 95-99
Rayburn, S.R. (1990) The Foundations of Laboratorv Sar('t~· - ;\ (;lIid(' for tilt'
Biomedical Laboratory. Springer-Verlag New 'York Inc .. tiS:\
257
Read, R.J. (1986) Acta Cryst. A42, 140-149
Read, R.J. (1990) Acta Cryst. A46, 900-912
Read, R.J. (1991) in: Crystallographic Computing 5, From Chemistry to Biology
(Moras, Podjarny and Thierry, eds). IUCr Oxford Science Publications. 158-167
Read, R.J. and Schierbeek, A.J. (1988) J. Appl. Cryst. 21, 490-495
Remmers, P. (1994) Libelle 6, 45-47
Roberts, R.M. (1989) Serendipity - Accidental Discoveries in Science. John Wiley
& Sons, Inc. New York
Rossmann, M.G. (1961) Acta Cryst. 14, 383-388
Rossmann, M.G. and Blow, D.M. (1962) Acta Cryst. 15,24-31
Rossmann, M.G., Ford, G.C., Watson, H.C. and Banaszak, L.J. (1972) J. Mol.
BioI. 64, 237-249
Rowley, M.J., Leach, D.R., Warner, G.A. and Heller, C.G. (1974) Radiat. Res.
59, 665-678
Safety Handbook (1992) Department of Chemistry, University of York
Saffran, M., Kumar, G.S., Savariar, C., Burnham, J.C., Williams, F. and Neckers,
D.C. (1986) Science 233, 1081-1084
Salvesen, K.A. and Eiknes, S.H. (1995) Ultrasound in Obstet. Gynecol. 6, 293-298
Sanger, F. (1945) Biochem. J. 39, 507
Sanger, F. (1949) Biochem. J. 44, 126
Sanger, F. (1949) Biochem. J. 45,563
258
Sanger, F. and Tuppy, H. (1951) Biochem. J. 49, 463
Sanger, F. and TliPPY, H. (1951) Biochcm. J. 49, 481
Sanger, F. and Thompson, E.O.P. (1953) Biochem. J. 53, 35:3, :3GG
Sanger, F., Thompson, E.O.P. and Kitai, R. (1955) Biochcm. J. 59, !)O!)
Sanger, F. (1~)!)9) Science 129,1340-1344
Schaffer, L. (1994) Em'. J. Biochem. 221, 1127-1132
Schimper, A.F.W. (1881) Z. Krist. 5, 131-168
Schlichtkrull,.1. (1958) Insulin crystals. Munksgaard, Copenhagen
Schlichtkrull, .1. (1959) in: Diabetes Mellitus III. Kongress del' l nt.erna t ional
Diabetes Federation Diisseldorf (Oberdisse and Jahnke, eds). Georg Thicmo.
Stuttgart. 77:3-777
Schlichtkrull, .1., Funder, J. and Munck, O. (1961) in: 4e Congres de la F{>deratiull
intern ationa.le <ill Diabete, Geneve (Demole, ed). Editions Medecinc et lIygii'Ilt'.
Gcneve. :W:I-:W.1
Schliebtkrull, .1., Brang«, .1., Ege, H., Hallund, 0., Heding, L.G., Jorgensen, 1\.11..
Markusscn, .1., Stahnke, P., Sundby, F. and Velund, Aa, (1970) Diabrt oloqia 6.
80-81
Scott, D.A. (19:l4) Biochem. J. 28, 1592-1602
Shannon, C.E. and Weaver, W. (1949) The mathematical theory of communica-
tion. Urbana, Univ. of Illinois Press
Shapiro, E., Kinsella, T.J., Mahuch, R.W., Fraass, B.A., Glatstein, E., Host'lIilCrg.
S.A. and Sherins, R ..1. (1985) J. C/in. Oncol. 3, 1232-1239
259
Sharpey-Schafer, E. (1916) The Endocrine Organs. 2nd ed., Part 2, Ch. 49, Long-
mans, Green, New York 1926
Sheldrick, G.M., Dauter, Z., Wilson, K.S., Hope, H. and Sieker, L.C. (1993) Acta
Cryst. D49, 18-23
Shepard, T.H. (1980) Catalog of teratogenic agents, revised edition. The Johns
Hopkins University Press, Baltimore, Maryland USA
Sherwood, D. (1976) Crystals, X-rays and Proteins. Longman Group Limited,
London
Shiino, D., Murata, Y., Kubo, A., Kim, Y.J., Kataoka, K., Koyama, Y., Kikuchi,
A., Yokoyama, M., Sakurai, Y. and Okano, T. (1995) Journal of Controlled Re-
lease 37, 269-276
Sim, G.A. (1959) Acta Cryst. 12, 813-815
Sippi, M. (1993) Proteins 17, 355-362
Slama, G., Hautecouverture, M., Assan, R. and Tchobroutsky, G. (1974) Diabetes
23, 732-738
Smith, G.D., Swenson, D.C., Dodson, E.J., Dodson, G.G. and Reynolds, C.D.
(1984) Proc. Natl. Acad. Sci. USA 81, 7093-7097
Smith, G.D. and Dodson, G.G. (1992) Biopolymers 32,441-445
Smith, G.D., Ciszak, E. and Pangborn, W. (1996) Protein Sci. 5. In press
Spitzer, M., Herman, J., Krumholz, B.A. and Lesser, M. (1995) Obsiet. Gynecol.
86, 504-508
Srinivasan, R. and Ramachandran, G.N. (1965) Acta Cryst. 19, 1008-1014
Steiner, D.F. (1977) Diabetes 26, 322-340
260
Steiner, D.F. (1981) ill: Structural Studies 011 l\loll'cllil's of Hiologi";d 1,11('1'1'.,,1
- A volume in honour of Dorothy Hodgkin (Dodson. (;11I:->kl'l' <III" :-1"\11'. I.d~).
Clarendon Press, Oxford. 407-419
Steiner, D.F. (1983) Haroeu Lectures 78. 191-~2~
Strobino, n.n., Kline, J. and Stein, Z. (1978) Early IIl1l11a/l n.« 1. Til
Stuart, A. and Ord, J.K. (1987) Kendall's Advanced 'I'llI'llr.\' or Slali:-.lic:-.. \'(11. I.
Distribution Theory. Charles Griffin & Company Ltd. London
Sudmeier, J.L., Bell, S.J., Storm, M.C. and Dunn. ~I.F. (lq~l) ,1,,('/( /1('( 212 .
.560-.562
Surrey, M.W. and Hill, D.L. (1994) .f. Am. Coli. S'/Il:IJ(OI/S 179. ·1111-·1I:!
Sussman, J.L., Holbrook, S.R., Church, G.M. and Kim. S.-II. (Iq,,) :tda (·ry ...;I.
A33, 800-804
Sussman, J.L. (1985) Methods in Enzymology 115. :2'i I-:W:I
Tainer, J.A., Getzoff, E.D., Beem, lv.M.. Richardson . .J.S. and Hicliardsoll. 1),( '.
(1982) .f. Mol. Bioi. 160, 181-217
Tang, Y.C. (1981) in: Structural Studies 011 Molecules of Biological Iut c-n-st .\
volume in honour of Dorothy Hodgkin (Dodson, GluskeJ' and Savr«. eds). ('lan'll-
don Press, Oxford. 43-44
Terwilliger, T.C. and Eisenberg, D. (1987) Acla CI'Y81. A43. f)-I:!
Tolley, S.P. (1987) D.Phil Thesis, University of York
Tong, L. and Rossmann, M.C. (1990) Acta Crysl. A46. 78:J-7!J:!
Tronrud, D.E., Ten Eyck, L. and Matthews. B. (1987) ..lela ('1'.1181. A4:J. I~~l-:-)()I
261
Tronrud, D.E. (1996) in: Methods in Enzymology. In press
Turkcnburg, J.P. (1992) D.Phil Thesis, University of York
Vaha-Eskeli, K., Erkkola, R. and Seppanen, A., (1991) Eur. J. Obstet. Gynecol.
Reprod. BioI. 39, 169-174
Valuev, L.I. (1995) Vysokomolekulyarnye Soedineniya Seriya A fj Seriya B 37,
1960-1968
Vedani, A. and Huhta, D.W. (1990) J. Am. Chern. Soc. 112,4759-4767
Vigneaud, V. du, Miller, C.L. and Rodden, C.J. (1939) J. Bioi. Chern. 131, 631
Vijayan, M. (1980) Acta Cryst. A36, 295-298
Vriend, G. (1990) J. Mol. Graphics 8, 52-56
Vriend, C. and Sander, C. (1993) J. Appl. Cryst. 26, 47-60
Walters, D.P., Smith, P.A., Marteau, T.M., Brimblet, A. and Borthwick, L.J.
(1985) Diabetic Medicine 2, 496-498
Weast, R.C. (ed.) (1983-1984) CRC Handbook of Chemistry and Physics 64th
ed. CRC Press Inc., Boca Raton, Florida, USA
Webster's Seventh New Collegiate Dictionary (1965) C&C Merriam Co, Spring-
field, Massachusetts USA
Weis, W.!. and Brunger, A.T. (1989) in: Molecular Simulation and Protein Crys-
tallography. Proceedings of the CCP4 Study Weekend 1989, 16-29
Whittingham, J.L., Chaudhuri, S., Dodson, E.J., Moody, P.C.E. and Dodson,
C.G. (1995) Biochemistry 34, 15553-15563
262
Wigley, r.M., Londono, .J.H., Wood, S.II., Shipp, .I.C. and Waldruau. lUI. (1'l,I)
Diabetes 20, 552-556
Wilson, A.J.C. (1950) Acta Cryst. 3 :J9,-:J98
Wilson, A.J.C. (ed] (1992) International Tables for Crystallography \'(11. c. \"If II
ematical , Physical and Chemical Tables. Kluwcr Academic Publishers. I )ordll"cllf .
The Netherlands
Wintersteiner , 0., Vigneaud, V. ell! and .Icnsen , II. (I!J:!~) ./. /J/II/,./I/(/('ol. 1-.'.1)/.
Ther. 32, 397-411
Wintersteiner, O. and Abramson, B.A. (193:3).1. ni.: ('111/11.99.711
Wodak, S.J., Pontius, J., Vaguine , A. and Hichcllc. J. (19!l.1) in: !\Iilki!lg t li.: :\Iost
of your Model. Proceedings of the Cep4 St.udy \V('('kclld 199!),II-r) I
Wollmer, A., Rannefield, B., Johansen, B.B .. llcjnacs, I\.IL Halscluuidr . P. <llId
Hansen, F.B. (1987) Bioi. Chern. Hoppc-Seulcr 368. !H);l-911
Wollmer, A., Rannefield, B., Stahl, J. and Melberg, S.C. (19~9) fliol. a.. 1/,.
Hoppe-Seyler 370, 1045-1053
\,yood, S.P., Tickle, I.J., Blundell, T.L., WolIllJ(,)", :\. and Skill!'r, D.F. (1!)7~)
Arch. Biochem. Biophys. 186, 175-183
Xiao, B. (1990) D.Phil Thesis, University of York
Zhang, X.-J. and Matthews, B.W. (199·1) Acta Cry s l. D50. (i7.)-(i~(i
263
